


EVALUATION OF CHLOROPICRIN AS A TOXIC AIR CONTAMINANT



PART B

Human Health Assessment

DRAFT

Medical Toxicology Branch

Department of Pesticide Regulation

California Environmental Protection Agency

June 1, 2009

1

Contributors and Acknowledgments

2 Principal Author: Carolyn M. Lewis, M.S., D.A.B.T.
3 Associate Toxicologist
4 Health Assessment Section
5 Medical Toxicology Branch

6 Toxicology Reviews: Marilyn H. Silva, Ph.D., D.A.B.T.
7 Staff Toxicologist
8 SB 950 Data Review Section
9 Medical Toxicology Branch

10 Peer Reviewed By: Joyce Gee, Ph.D.
11 Senior Toxicologist
12 Health Assessment Section
13 Medical Toxicology Branch

14 Jay P. Schreider, Ph.D.
15 Primary State Toxicologist
16 Medical Toxicology Branch

17 DPR acknowledges the review of this document by the Pesticide Epidemiology Unit, Office of
18 Environmental Health Hazard Assessment.

TABLE OF CONTENTS

	PAGE
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
	ii
	iii
	1
I.	6
I.A.	6
I.B.	7
II.	8
II.A.	8
II.B.	10
II.C.	22
II.D.	28
II.E.	36
II.F.	38
II.G.	40
III.	43
III.A.	43
III.A.1.	43
III.A.2.	47
III.A.3.	51
III.A.4.	52
III.A.5.	55
III.B.	57
III.B.1.	57
III.B.2.	60
III.B.3.	63
III.C.	63
III.C.1.	64
III.C.2.	66
III.C.3.	67
IV.	69
IV.A.	69
IV.B.	72
IV.C.	75
IV.D.	76
IV.E.	80
V.	83
VI.	85

CHLOROPICRIN**SUMMARY**

Chloropicrin (trichloronitromethane) was first patented for use as an insecticide in 1908. Chloropicrin is a broad-spectrum fumigant with insecticidal, fungicidal, nematicidal and herbicidal properties. Chloropicrin also has a low odor threshold and causes sensory irritation at very low concentrations, so it has been added as a warning agent to other fumigants like methyl bromide and sulfuryl fluoride which are odorless. The Department of Pesticide Regulation (DPR) placed chloropicrin into reevaluation in 2001 based on air monitoring data which found that air concentrations of chloropicrin at some distances from treated fields were greater than established occupational exposure limits (Cortez, 2001). DPR has placed chloropicrin on the high-priority list for risk assessment based on possible adverse effects identified in genotoxicity and developmental toxicity studies submitted under the Birth Defect Prevention Act (SB 950). Chloropicrin is also a high-priority pesticide for risk assessment under the California Toxic Air Contaminant Act (AB 1807). The purpose of this risk assessment is to evaluate the risks for potential human health effects from bystander exposure to chloropicrin.

Toxicity

The pharmacokinetic and toxicology studies were reviewed and presented in the Toxicology Profile section. Included in the Toxicology Profile are guideline studies submitted to the DPR and studies from open literature with the greatest weight generally given to studies that met the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) guidelines. From the treatment-related effects identified in the studies, the highest dose, which did not cause any toxicological effect, known as No-Observed-Effect Level (NOEL), was established for each study. For some studies where a NOEL was not observed, a benchmark dose (BMD) estimate was determined instead. In the Hazard Identification section, the NOELs/BMDs and effects at the Lowest-Observed-Effect Levels (LOELs) from the available toxicity studies were evaluated to determine what would be the most appropriate NOEL/BMD, referred to as a critical NOEL, to evaluate particular exposure scenarios. The toxicity studies can be categorized as acute (< 7 days), subchronic (> 7 days to < 6 months), and chronic (1 or more years) in duration. To evaluate acute exposure, 1-hr, 8-hr and 24-hr NOELs were selected.

The primary effects observed with short and long-term exposure to chloropicrin are sensory and respiratory irritation. The mechanism of action for chloropicrin is not well understood, but may involve reaction with thiol groups of certain proteins, such as glutathione and hemoglobin. A sensory irritation study was conducted using human subjects with exposures up to one hour. Eye irritation was the most sensitive endpoint. A NOEL was not observed with the 1-hr exposure. A BMD estimate of 26 ppb was selected for evaluating 1-hr exposures to chloropicrin. Animal studies were used to evaluate longer-term exposures. The lowest acute NOEL in an animal study was seen in an inhalation developmental toxicity study in rabbits based on mortalities, nasal discharge, reduced body weights and food consumption and red discoloration in lungs. This NOEL was selected for evaluating 8-hr and 24-hr exposures. The 8-hr and 24-hr NOELs estimated from this study were 300 and 100 ppb, respectively. The respective human equivalent concentrations (HECs) were 270 and 90 ppb for children. BMD analysis was also used to determine the most sensitive endpoint and species with seasonal and

1 chronic inhalation exposure to chloropicrin. The lowest BMDL₀₅ with subchronic inhalation
 2 exposure was rhinitis in female rats after adjusting for species differences in breathing rates.
 3 The subchronic BMDL₀₅ for this endpoint was 120 ppb (HEC = 35 ppb for children). The lowest
 4 BMDL₀₅ with chronic inhalation exposure was bronchiectasis in female mice after adjusting for
 5 breathing rate. The chronic BMDL₀₅ for this endpoint was 59 ppb (HEC = 32 ppb for children).

6 A slight increase in adenomas and carcinomas was seen female mice that was significant
 7 by trend analysis and pair-wise comparison when survival was taken into consideration. There
 8 was also an increase in the multiplicity of these tumors and a shortening of the time-to-tumor
 9 with dose. A number of the genotoxicity studies were positive for chloropicrin, most notably all
 10 eight reverse mutation assays with *Salmonella typhimurium*. Therefore, DPR concluded the
 11 weight of evidence was sufficient to do a quantitative assessment of the carcinogenic risk using a
 12 linear approach. The cancer potency was estimated to range from 1.3 (mg/kg/day)⁻¹ for the
 13 maximum likelihood estimate to 2.2 (mg/kg/day)⁻¹ for the 95th percent upper bound.

14 The following table summarizes the critical endpoints used for evaluating chloropicrin
 15 exposure along with their respective reference concentrations:

Exposure Scenario	NOEL	Effects on LOEL	RfC	
			Children	Adults
Acute - 1 hr	26 ppb	Ocular irritation in humans	8.7 ppb (58 µg/m ³) UF ^a = 3	8.7 ppb (58 µg/m ³) UF = 3
Acute - 8 hr & 24 hr	400 ppb (270 µg/m ³)	Mortalities (days 2-4), nasal discharge (onset day 0), ↓ body weights & food consumption (days 0-6), red discoloration in lungs of pregnant rabbits.	<u>8-hr</u> 2.7 ppb (18 µg/m ³) <u>24-hr</u> 0.92 ppb (6.1 µg/m ³) UF = 100	<u>8-hr</u> 5.8 ppb (39 µg/m ³) <u>24-hr</u> 1.9 ppb (13 µg/m ³) UF = 100
Seasonal	120 ppb (807 µg/m ³)	Rhinitis in female rats	0.35 ppb (2.3 µg/m ³) UF = 100	0.73 ppb (4.9 µg/m ³) UF = 100
Chronic	59 ppb (216 µg/m ³)	Bronchiectasis in female mice	0.32 ppb (2.2 µg/m ³) UF = 100	0.68 ppb (4.6 µg/m ³) UF = 100
Lifetime	Potency = 2.2 (mg/kg/day) ⁻¹	Lung tumors in female mice	-----	0.24 ppt ^b (1.6 ng/m ³)
<p>^a UF = Uncertainty factor used to derive RfC. For eye irritation in humans, the intraspecies uncertainty factor was reduced to 3 since toxicokinetic variation among individuals was not anticipated.</p> <p>^b RfC for cancer is the air concentration corresponding to a negligible risk level (i.e., one in a million excess cancer cases)</p>				

1 Several developmental and reproductive effects were seen in studies including reduced
2 number of implantation sites, increased pre- and post-implantation losses, late-term abortions,
3 and visceral and skeletal variations in fetuses. The NOELs for fetal or pup effects were equal to
4 or higher than the maternal or parental NOELs, suggesting there is no increased pre- or post-
5 natal sensitivity to chloropicrin. Direct exposure to neonates, however, was not evaluated.

6 Exposure

7 *Soil Fumigation*

8 The California Air Resources Board (ARB) monitored off-site air concentrations of
9 chloropicrin in Monterey (1986 and 2001), Santa Cruz (2003), and Santa Barbara (2005)
10 Counties in California following soil fumigation. In addition, off-site monitoring studies were
11 conducted by registrants following soil fumigation in Washington, Florida, Arizona and
12 California. The registrants also collected on-site flux data in their studies which DPR used to
13 model off-site exposures since the off-site monitoring from the various studies may not have
14 represented the worse-case scenario as far as weather and sampler location. The modeling
15 estimated downwind centerline exposure estimates at 1.2 m above ground (breathing zone) and 3
16 m from the edge of a 40-acre square field treated at the maximum application rate which were
17 considered reasonable worse-case estimates. From the modeling, 1-hr, 8-hr and 24-hr exposure
18 estimates were generated for the different application methods used in these studies. Broadcast
19 non-tarped application had the highest 1-hr and 8-hr exposure estimates, 16,000 ppb (110,000
20 $\mu\text{g}/\text{m}^3$) and 6,500 ppb (44,000 $\mu\text{g}/\text{m}^3$), respectively. Bedded tarped application had the highest
21 24-hr exposure estimates, 1,100 ppb (7,400 $\mu\text{g}/\text{m}^3$). Seasonal exposure was estimated from the
22 24-hr average flux over 2 weeks, adjusting for time using the peak-to-mean method. The bedded
23 tarped application had the highest estimate, 73 ppb (490 $\mu\text{g}/\text{m}^3$). Annual exposure was estimated
24 by amortizing the seasonal exposure over a year assuming a 4-month use season. The highest
25 annual exposure was 24 ppb (160 $\mu\text{g}/\text{m}^3$) for the bedded tarped application. Lifetime exposure
26 for residential bystanders was the same as the annual exposure, except it was converted to
27 mg/kg/day for ease of calculation of the cancer risk. The lifetime exposure estimate for
28 residential bystanders for bedded tarped application was 20 $\mu\text{g}/\text{kg}/\text{day}$. The lifetime exposure
29 for occupational bystanders assumed exposure was limited to 40 years of a 70-year lifespan.
30 The estimated lifetime exposure for bedded tarped application was 11 $\mu\text{g}/\text{kg}/\text{day}$.

31 Ambient air monitoring studies were also conducted by ARB in Monterey (1986 and
32 2001), Santa Cruz (2001), Santa Barbara (2000) and Kern (2001) Counties. Exposure estimates
33 were not calculated from these studies since the air concentrations were lower than at the
34 application site as would be expected and it was assumed that any mitigation needed for
35 bystander exposure near application sites would mitigate any concerns regarding air
36 concentrations in ambient air.

37 *Structural Fumigation*

38 ARB also monitored off-site air concentrations following structural fumigation with
39 sulfuryl fluoride where chloropicrin was added as a warning agent in Sacramento (2002),
40 Nevada (2004) and Placer (2004) Counties. Modeling was not possible with this use, so
41 exposure estimates were based the actual air concentrations after correcting for recovery. The

1 highest off-site air concentration of chloropicrin associated with structural fumigation was found
2 in the house in Nevada County which had the largest fumigation volume (81,000 ft³). The
3 highest concentrations were seen at 1.5 m northwest of the house during mechanical ventilation.
4 The corrected 1-hr, 8-hr and 24-hr air concentrations at this location were 11, 2.4 and 0.92 ppb
5 (73, 16 and 6.2 µg/m³), respectively. These air concentrations were used to evaluate bystander
6 exposure for structural fumigation. No seasonal and annual exposure estimates were calculated
7 for bystanders following structural fumigation since multiple structural fumigations are not
8 anticipated in the same area.

9 Indoor air concentrations following structural fumigation with chloropicrin were also
10 monitored by ARB in the studies conducted in Sacramento and Nevada counties. The highest
11 indoor air concentrations were seen in the house with the largest fumigation volume. After
12 adjusting for recovery and application rate, the highest indoor air concentration was 21 ppb (140
13 µg/m³) in the first 24 hours after aeration was completed. Indoor air samples were only collected
14 for 24-hr intervals, so 1-hr and 8-hr exposure estimates were not calculated.

15 *Enclosed Space Fumigation*

16 One chloropicrin product includes directions for its use as an active ingredient in
17 fumigating empty potato storages and empty grain bins. Therefore, exposure estimates were
18 calculated for bystanders following enclosed space fumigation. The ARB air monitoring data
19 following structural fumigation was used to estimate bystander exposure for this use adjusting
20 for maximum application rate and building size. Following enclosed space fumigation, the 1-hr,
21 8-hr and 24-hr bystander exposures were estimated to be 360, 100 and 31 ppb (2400, 680 and
22 210 µg/m³), respectively. The annual exposure was estimated to be 0.18 ppb (1.2 µg/m³)
23 assuming only 2 days of exposure per year. The estimate lifetime exposure for bystanders from
24 enclosed space fumigation was 0.14 µg/kg/day.

25 **Risk Characterization**

26 The risk for non-carcinogenic health effects is expressed as a margin of exposure (MOE)
27 which is the ratio of the NOEL from the animal study to the human exposure dosage. Generally,
28 an MOE of at least 100 is desirable when the NOEL is derived from an animal study assuming
29 that humans are 10 times more sensitive than animals and that there is a 10-fold variation in the
30 sensitivity between the lower distribution of the overall human population and the sensitive
31 subgroup. When the NOEL is derived from a human study, a MOE of at least 10 is desirable,
32 assuming a 10-fold variation in the sensitivity of the human population. Since sensory irritation
33 involves a direct-acting mechanism of toxicity where toxicokinetic variation among individuals
34 is not anticipated, a MOE of 3 may be adequate. The negligible risk level for cancer is one in a
35 million or 10⁻⁶. California regulations state that if the air concentrations of a pesticide are not
36 10-fold below the reference concentration that is considered protective of human health, it meets
37 the criteria to be listed as a toxic air contaminant. This is equivalent to the MOEs being less than
38 100 when a human NOEL is used or 1,000 when an animal NOEL is used. For cancer, if the risk
39 is greater than one in 10 million or 10⁻⁷ it would meet the listing criteria.

1 *Soil Fumigation*

2 The potential health risks from bystander exposure to chloropicrin following soil
3 fumigation are of concern since all of the MOEs were less than 100 for both children and adults.
4 The acute MOEs for soil fumigation are clearly of concern since they are all less than 1. With
5 the 1-hr exposure, the MOEs are orders of magnitude lower than the target MOE of 3. The
6 seasonal and chronic MOEs for soil fumigation were greater than 1 (except for seasonal
7 exposure with bedded tarped application), but still less than 100 which is the target MOE. The
8 cancer risk estimates for residential and occupational bystanders ranged between one in 1,000
9 (10^{-3}) to one in 100 (10^{-2}).

10 *Structural Fumigation*

11
12 The off-site air concentrations of chloropicrin following structural fumigation are lower
13 than following soil fumigation, but the 1-hr exposures are still of concern (i.e., MOEs are
14 slightly less than 3). Although the 8-hr and 24-hr MOEs are greater than 100, they are less than
15 1,000. The indoor air concentrations are also of concern since the 24-hr MOEs are less than 100.
16 The 1-hr and 8-hr air concentrations would be higher presumably if samples had been collected
17 for these intervals.

18 *Enclosed Space Fumigation*

19 The acute MOEs for bystander exposure following enclosed space fumigation were of
20 concern since they were all significantly less than their target MOEs. The annual MOEs were
21 greater than their target MOE of 100 for both children and adults and, therefore, were not of
22 concern. The carcinogenic risk estimates were greater than the negligible risk level, ranging
23 from two to three cases in 10,000 (10^{-4}).

24 **Conclusions**

25 The potential health risks from bystander exposure to chloropicrin following soil
26 fumigation are of concern, especially for acute exposure since they were orders of magnitude
27 below the target MOE. The cancer risk estimates were also orders of magnitude greater than the
28 negligible risk level and, therefore, are of concern. The potential health risks for bystanders
29 from acute exposure to chloropicrin after structural fumigation are significantly lower.
30 However, there is some concern regarding the 1-hr exposure since the MOEs were slightly less
31 than the target MOE. The acute and lifetime exposure estimates for bystanders near enclosed
32 space fumigation were also of concern since they were less than their target MOEs or greater
33 than negligible risk level for cancer. The off-site air concentrations of chloropicrin following
34 soil fumigation, structural fumigation and enclosed space fumigation were high enough to meet
35 the criteria for listing chloropicrin as a toxic air contaminant.

1

I. INTRODUCTION

2 IA. REGULATORY BACKGROUND

3 Chloropicrin (trichloronitromethane) was first patented for use as an insecticide in 1908
4 (Gehring *et al.*, 1991). During World War I chloropicrin was used as a war gas because of its
5 strong lacrimatory and respiratory irritant properties. In 1926, chloropicrin was first used as a
6 fumigant in flour mills (Clemson Univ., 2006). Since then it has also been used as a preplant
7 soil fumigant, as a warning agent with other odorless fumigants, and as a wood preservative.

8 The American Conference of Governmental Industrial Hygienists (ACGIH) has long
9 recommended a time-weighted average threshold limit value (TWA-TLV) for chloropicrin of 0.1
10 ppm which appears to be based on reports of painful eye irritation at concentrations between 0.3
11 and 0.37 ppm after exposure of 3-30 seconds (ACGIH, 1997). OSHA's Permissible Exposure
12 Limit (PEL) and NIOSH's Recommended Exposure Limit (REL) are also established at 0.1
13 ppm. NIOSH's Immediately Dangerous to Life or Health (IDLH) value was initially set at 4
14 ppm for chloropicrin, but in 1996 it was reduced to 2 ppm (NIOSH, 1996). The Office of
15 Environmental Health Hazard Assessment (OEHHA) in the California Environmental Protection
16 Agency (Cal/EPA) established an acute 1-hour Reference Exposure Level (REL) for
17 chloropicrin of 4.4 ppb (29 $\mu\text{g}/\text{m}^3$) (OEHHA, 1999). OEHHA also established a chronic REL
18 for chloropicrin of 0.05 ppb (0.4 $\mu\text{g}/\text{m}^3$) (OEHHA, 2001). More recently, U.S. EPA completed
19 a risk assessment for chloropicrin which addressed both occupational and bystander exposure
20 (Reeves and Smith, 2008). Although Reference Concentrations (RfCs) were not identified in
21 this risk assessment, they could be estimated by dividing the selected human concentration (HC)
22 or human equivalent concentration (HEC) by the recommended uncertainty factor (UF). Their
23 RfC for acute bystander and worker exposure was 73 ppb using the HC from the human study
24 and dividing by their recommended UF of 1. Their RfCs for short- and intermediate-term
25 exposure for bystanders and workers would be 0.27 and 1.17 ppb, respectively, by dividing their
26 HECs from the 13-week mouse inhalation study by their recommended UF of 30. Their RfCs
27 for long-term exposure for bystanders and workers would be 0.13 and 0.50 ppb, respectively, by
28 dividing their HECs from the 78-week mouse inhalation study by their recommended UF of 30.
29 Buffer zones were needed for most soil fumigation when chloropicrin concentrations were
30 greater than 2%. Buffer zones may also be needed for greenhouse fumigation depending on size
31 of the greenhouse and the percent released. Risks were not a concern for bystanders near
32 residential structural fumigation. U.S. EPA also found the air concentrations of chloropicrin
33 were not of concern for residential bystanders from non-point sources (i.e., ambient air). U.S.
34 EPA did find that the handler exposures exceeded their level of concern for many scenarios, but
35 these exposures could be mitigated by use of a PF 10 respirator.

36 The Department of Pesticide Regulation (DPR) placed chloropicrin into reevaluation in
37 2001 (Cortez, 2001). The basis for this decision was that air monitoring data submitted by the
38 Chloropicrin Manufacturers Task Force (CMTF) indicated that air concentrations at some
39 distances from treated greenhouses exceeded NIOSH's REL of 0.1 ppm. DPR requested that
40 the chloropicrin registrants conduct and submit worker exposure and air monitoring studies
41 associated with field and greenhouse applications of chloropicrin. DPR placed chloropicrin on
42 the high-priority list for risk assessment based on possible adverse effects identified in

1 genotoxicity and developmental toxicity studies submitted under the Birth Defect Prevention Act
2 (SB 950). Chloropicrin is also a high-priority pesticide for risk assessment under the California
3 Toxic Air Contaminant Act (AB 1807) which is based on a combination of its toxicity and
4 physical/chemical properties. The purpose of this risk assessment is to evaluate the risks for
5 potential human health effects from bystander exposure to chloropicrin. A separate risk
6 assessment to follow will address occupational exposure to chloropicrin.

7 **I.B. CHEMICAL IDENTIFICATION**

8 Chloropicrin is a broad-spectrum fumigant that rapidly diffuses through soil and kills
9 common root destroying fungi, nematodes, soil insects and other plant pests (Wilhelm, 1996).
10 Chloropicrin does not have the broader herbicidal properties of methyl bromide and metam
11 sodium or the broader nematicidal properties of 1,3-dichloropropene, so it is usually used in
12 combination with these other fumigants. Chloropicrin has a low odor threshold and causes
13 sensory irritation at very low concentrations, so it has been added as a warning agent to other
14 fumigants like methyl bromide and sulfuryl fluoride which are odorless. Chloropicrin's
15 mechanism of action is not well understood, but it may be related to its reaction with thiol
16 groups in proteins like glutathione and hemoglobin (Sparks *et al.*, 1997). Chloropicrin also
17 inhibits pyruvate and succinate dehydrogenase (Sparks *et al.*, 2000). The inhibition of these
18 enzymes has been correlated to the lethality of various halonitromethanes, quinones, fungicides
19 and other thiol-reactive chemicals. Today, its greatest use in California is on strawberries,
20 usually in combination with methyl bromide. Due to the eventual phase out of methyl bromide
21 because of its ozone-depleting properties, the amount of chloropicrin in these formulations has
22 increased.

1 II. TOXICOLOGY PROFILE


2 All the available toxicity studies for chloropicrin are summarized in the Toxicology
3 Profile including studies from the open literature and studies submitted to DPR for registration
4 of pesticide products in California as required by the Birth Defects Prevention Act (SB-950).
5 DPR reviews the studies submitted to fill data requirements for SB-950 and determines the
6 acceptability of these toxicology studies based on study guidelines as required under the Federal
7 Insecticide, Fungicide and Rodenticide Act (FIFRA) (U.S. EPA, 2006). For SB-950, literature
8 studies are generally considered supplemental because they do not follow FIFRA guideline
9 protocols and/or do not provide sufficient detail in their reports to determine if they were
10 conducted properly. In the risk assessment, greater weight is given to guideline studies,
11 especially if they are found acceptable based on FIFRA guidelines. However, literature studies
12 are useful in the selection of the critical NOEL in the Hazard Identification section to support
13 effects seen in the guideline studies and can be used for the critical NOEL if they evaluate an
14 endpoint not examined in the guideline studies and they appear to be scientifically valid studies.
15 Except for the Pharmacokinetics and Acute Toxicity sections, the studies are generally organized
16 within each section by route and species with the older studies discussed first. When
17 mechanistic studies are available, they are discussed after the guideline studies under the
18 appropriate route and species. The Pharmacokinetics section is organized by different phases in
19 the disposition of xenobiotics in the body. The Acute Toxicity section is separated into data for
20 the technical grade material and the various formulations.

21 II.A. PHARMACOKINETICS

22 There were no FIFRA guideline pharmacokinetics/metabolism studies for chloropicrin
23 and very limited pharmacokinetic data available in the open literature. Sparks *et al.* (1997)
24 administered ¹⁴C-chloropicrin to male Swiss Webster mice intraperitoneally and orally at 1-3
25 mg/kg with triethylene glycol monomethyl ether as the vehicle. They monitored the radioactivity
26 in the urine, feces and expired air for 48 hours. The urine was the major route of excretion with
27 43-47% excreted in the first 24 hours. Another 8-8.5% was excreted in the urine between 24 and
28 48 hours. The metabolites in urine were analyzed by TLC. None were identified, but they
29 appeared to be polar and nonvolatile. The other major route of excretion was expired air with
30 6.5-15% excreted as CO₂ in 48 hours. Only 2.5-9% of the applied dose was excreted in the feces
31 in the 48 hours following dosing. Tissue levels of radioactivity were measured at 1 hour (i.p.)
32 and 48 hours (i.p. and oral) after dosing. At 1 hour and 48 hours, the liver had the highest level
33 of radioactivity, followed by the kidney, lung, blood, fat and skin.

34 Sparks *et al.* (1997) also investigated the reaction of chloropicrin with biological thiols *in*
35 *vitro*. Chloropicrin reacted quickly with various biological thiols including glutathione (GSH),
36 cysteine, N-acetylcysteine, coenzyme A and reduced lipoic acid. These reactions resulted in the
37 conversion of chloropicrin to dichloronitromethane and the formation of the corresponding
38 disulfide of the thiol. The initial adduct with GSH and chloropicrin was unstable since attempts
39 to isolate it were unsuccessful. Nitric oxide was an unlikely metabolite since S-nitroso-GSH was
40 not found. Chloropicrin also reacted with several protein thiols *in vitro* including hemoglobin
41 (Hb) and alcohol dehydrogenase. The change in the UV profile implied formation of internal


1 and cross-linked disulfide bonds. The Hb adduct formation is more stable than GSH adduct, but
 2 it readily dissociates in buffer. The proposed pathways for reaction of chloropicrin with GSH
 3 and Hb are shown in Figure 1.



4 **Figure 1.** Proposed pathways for reaction of chloropicrin with glutathione and hemoglobin
 5 (Sparks *et al.*, 1997)

6 In a subsequent study, Sparks *et al.* (2000) administered chloropicrin intraperitoneally to
 7 male Swiss-Webster mice at 5 mg/kg with DMSO as the vehicle and kept them in metabolic
 8 chambers for 24 hours. They were able to identify raphanusamic acid (also known as 2-
 9 thioxothiazolidine-4-carboxylic acid, TTCA) in the urine that was equivalent to about 1% of the
 10 administered dose of chloropicrin. Based on this finding, these investigators proposed a
 11 metabolic pathway that involved the initial reaction of chloropicrin with glutathione to form the
 12 $\text{GS-CCl}_2\text{NO}_2$ metabolite which can either react further with glutathione to the form dichloro and
 13 monochloro metabolites or react with cysteine and then be cleaved by cysteine β -lyase to form
 14 raphanusamic acid via thiophosgene (Figure 2).

15 Sparks *et al.* (2000) showed that methemoglobin is not important in the toxicity of
 16 chloropicrin, but oxyhemoglobin accumulated in the liver of mice treated with chloropicrin. The
 17 toxicological significance of this finding is uncertain since oxyhemoglobin is the normal form of
 18 hemoglobin when oxygen is bound to it. They proposed that the enzymes, pyruvate and
 19 succinate dehydrogenase (PDH and SDH), were possible targets for the lacrimatory effects of
 20 chloropicrin because of thiol groups in their active sites. Sparks *et al.* observed that chloropicrin
 21 was an inhibitor of these enzymes *in vitro* with moderate potency (IC_{50} values of 4 and 13 μM
 22 for PDH and SDH, respectively). They found that the dichloro and monochloro metabolites of
 23 chloropicrin were much less potent with IC_{50} values of 60-182 μM . They correlated the
 24 inhibition of PDH and SDH with the lethality of various halonitromethanes, quinones, fungicides
 25 and other thiol-reactive chemicals. The inhibition of PDH correlated most closely with the
 26 lethality of these chemicals. Sparks *et al.* (2000) concluded that the acute toxicity of
 27 chloropicrin is due to the parent compound or metabolites other than the dehalogenated
 28 metabolites and may be associated with the inhibition of PDH and elevated oxyhemoglobin.



2 **Figure 2.** Proposed metabolism of chloropicrin in mice by dechlorination and conversion to
 3 raphanusamic acid via thiophosgene (Sparks *et al.*, 2000).

4 II.B. ACUTE TOXICITY

5 **Summary:** The acute toxicity of chloropicrin was first characterized around 1920 in
 6 studies with dogs. More recently, several LC₅₀ studies were conducted with rats. The reported
 7 LC₅₀ values ranged from 6.6 to 25.5 ppm (44 to 171 mg/m³) depending on the duration of
 8 exposure and whether it was a whole body or nose only exposure. The LC₅₀ values also varied
 9 depending on how long the observation period was after dosing. Deaths occurred in two phases,
 10 either within 24 hours or after 8 to 10 days. The later deaths were attributed to respiratory
 11 infection. The clinical signs were primarily respiratory, although eye irritation, lacrimation and
 12 eye closure were also noted. Numerous gross and histopathological lesions were observed
 13 throughout the respiratory tract. In comparing chloropicrin to other lethal war gases like
 14 chlorine gas and phosgene, early investigators described the respiratory effects to be
 15 intermediate in onset and primarily affecting small to medium bronchi. The ability of
 16 chloropicrin to cause respiratory depression in mice was also evaluated in two studies as an
 17 indication of sensory irritation in man. The RD₅₀ (concentration that caused a 50% reduction in
 18 respiratory rate) values ranged from 2.34 ppm (15.7 mg/m³; HEC_{1hr} - 3.57 ppm) for a 30 minute
 19 exposure to 7.98 ppm (53.7 mg/m³; HEC_{1hr} - 4.06 ppm) for a 10 minute exposure. The RD₅₀ was
 20 proposed as an intolerable concentration to man. More recently a human sensory irritation study
 21 was conducted which consisted of three phases. The first phase identified the median odor
 22 threshold for chloropicrin at 700 ppb. The median threshold for eye irritation was 900 ppb. The
 23 median threshold for nasal irritation was greater than 1200 ppb, the highest level tested. In
 24 phase 2, a NOEL for ocular irritation was established at 50 ppb with a 20-minute exposure in a

1 walk-in chamber. No nasal or throat irritation was observed up to 150 ppb. In phase 3, the
2 NOEL for ocular irritation appears to be less than 100 ppb after a 1-hour exposure in a walk-in
3 chamber. No nasal or throat irritation was reported in this phase, but increased production of
4 nitric oxide (NO) and decreased nasal airflow at 100 and 150 ppb suggests some subtle upper
5 respiratory changes.

6 **II.B.1. Animal Studies**

7 Underhill (1920) exposed 219 dogs to chloropicrin for 30 minutes at air concentrations
8 ranging from 0.36 to 1.25 mg/L (49 to 172 ppm). An LC₅₀ value was not calculated, but 53% of
9 dogs were killed when exposed to chloropicrin at 0.81 to 0.95 mg/L (111-131 ppm). The
10 majority of the dogs died within 24 hours after exposure. However, several delayed deaths were
11 seen. The clinical signs observed after exposure to chloropicrin were not reported, but the
12 respiration, pulse, temperature, and composition of the urine and blood were examined in the
13 dogs. There was an immediate lowering of the respiratory rate that returned to normal within 2-
14 3 hours after exposure except in dogs that died. The respiratory passages became clogged with
15 excessive mucus and the animals began mouth breathing with a gasping reflex. The pulse
16 initially dropped to less than half the normal rate after being exposed to chloropicrin, followed
17 by a return to normal or above normal in more severely affected dogs. A drop in body
18 temperature was seen in most dogs after exposure to chloropicrin and continued to fall (up to
19 4°C) in animals that died. There was an increase in urinary total nitrogen, ammonia nitrogen,
20 creatine nitrogen, phosphate and chloride levels after exposure. An increase in total blood
21 solids, red blood cell count and hemoglobin concentration were seen in dogs after exposure.
22 These values remained elevated in animals that died.

23 Lambert and Jackson (1920) examined 120 dogs that were exposed to chloropicrin gas in
24 studies conducted by Underhill. Dogs that died within in a few days of exposure had extreme
25 edema and congestion of the lungs, necrosis of the bronchial epithelium and bronchiolar walls,
26 dilation of the heart, and passive congestion of the abdominal viscera. The investigators
27 concluded that the edema was not the cause of death because the severity was no greater in
28 animals that died than those that survived. Instead, they proposed that the cause of death was
29 due to the accumulation of fibrin in the pulmonary septa forming a barrier to blood flow through
30 the lungs. There were a number of delayed deaths which were attributed to respiratory infection
31 in most cases. The investigators compared the damage seen with chloropicrin to other lethal war
32 gases, chlorine and phosgene. Chlorine acts very rapidly and affects primarily the upper
33 respiratory tract (trachea, large and medium bronchi) where it first comes in contact. Phosgene,
34 on the other hand, has a delayed action and primarily affects the lower respiratory tract (smaller
35 bronchi, bronchioles and alveoli) presumably due to its metabolism to hydrogen chloride.
36 Chloropicrin is intermediate in its onset and primarily affects the medium and small bronchi.

37 The U.S. Department of Transportation reported a one-hour LC₅₀ (whole body) of 25.5
38 ppm (analytical; 171 mg/m³; HEC_{1hr}¹ - 41.5 ppm) for chloropicrin in rats (Harton and Rawl,
39 1976) (Table 1). The animals exhibited gagging response and irritation to the eyes and mucous

1 HEC (Human Equivalent Concentration) = ppm x RR_a/RR_h x E_a/E_h. RR_a = respiratory rate in animals which was assumed to be 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = respiratory rate in humans which was assumed to be 0.59 m³/kg/day for a child (DPR, 2000). E_a = exposure duration for animals which was 1 hour/day. E_h = exposure duration for humans which was set at 1 hour/day.

Table 1. The Acute Toxicity of Technical Grade Chloropicrin

Species	Sex	Results	References ^a
Acute Inhalation LC₅₀			
Rat	M/F	25.5 ppm (1 hr, whole body) (I)	1
Rat	M	11.9 ppm (4-hr, whole body) (I)	2
Rat	M	14.4 ppm (4-hr, whole body) (I)	3
Rat	M	6.6 ppm (4-hr, nose only) (I)	
Rat	M	16.7 ppm (4-hr, whole body) (I)	4
	F	20.1 ppm (4-hr, whole body) (I)	
Acute RD₅₀			
Mice	M/F	7.98ppm (10 min, head only)	5
	M	2.34 ppm (30 min., head only)	6
Acute Intraperitoneal LD₅₀			
Mice	M/F	8 mg/kg	7
Acute Oral LD₅₀			
Rat	M/F	37.5 mg/kg (I)	1
Acute Dermal LD₅₀			
Rabbit	M/F	100 mg/kg (I)	1
Primary Dermal Irritation			
Rabbit	M/F	Corrosive (I)	1

a References: 1. Harton and Rawl, 1976; 2. Yoshida *et al.*, 1987a; 3. Yoshida *et al.*, 1991; 4. Hoffman, 1999a; 5. Kane *et al.*, 1979; 6. Hoffman, 1999b; 7. Sparks *et al.*, 1997.

membranes during exposure (dose response not indicated). This study had major deficiencies in that there were no data reported on clinical signs or necropsy findings.

Yoshida *et al.* (1987a) conducted a 4-hr LC₅₀ study in which rats were exposed (whole body) to chloropicrin vapors at 0, 8.8, 11.0, 11.4, 12.1, 13.6 or 16.0 ppm (analytical; 0, 59, 74, 77, 81, 91 or 108 mg/m³; HEC_{8hr}² - 0, 7.16, 8.95, 9.27, 9.84, 11.1 or 13.0 ppm). The 4-hr LC₅₀ was estimated to be 11.9 ppm (analytical; 80 mg/m³; HEC_{8hr} - 9.68 ppm). During exposure, eyelid closure, reduced activity, labored breathing, salivation, lacrimation, and rhinorrhea were seen. All but the labored breathing and lacrimation disappeared within a few hours after removal from the exposure chambers. Deaths were biphasic, occurring either within 24 hours or after 8 to 10 days. Animals that died exhibited gasping and cyanosis before dying. At necropsy, they had reduced body weights, increased absolute and relative (to body or brain) lung weights, diffuse pulmonary edema and emphysema, hydrothorax, scattered dark red patches in the lungs, and gastric gaseous distension. Survivors had similar gross pathological lesions at the study termination (day 14), except no hydrothorax. These investigators also exposed rats to chloropicrin for 30 minutes at 21.7 and 45.5 ppm (analytical; 146 and 306 mg/m³; HEC_{1hr} - 17.7 and 37.0 ppm). They were unable to establish an exact LC₅₀ for this exposure duration, but it appears to be between these two dose levels. A no-observed-effect level (NOEL) could not be established for either the 4-hour or the 30-minute exposure period.

² HEC = ppm x RR_a/RR_n x E_a/E_n. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_n = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 4 hours/day. E_n = 8 hours/day.

1 An acute LC₅₀ study in rats was also submitted to DPR by the Chloropicrin
2 Manufacturers Task Force (Hoffman, 1999a). Five Sprague Dawley rats/sex/dose were exposed
3 (whole body) to chloropicrin (purity > 99%) at 0, 10.5, 18.0 or 23.5 ppm (analytical; 0, 71, 121
4 or 158 mg/m³; HEC_{8hr}³ - 0, 8.54, 14.6 or 19.1 ppm) for 4 hours. Deaths occurred at 18.0 ppm (3
5 males, 1 female) and 23.5 ppm (5 males and 4 females) during the 2-day observation period.
6 The clinical signs observed during exposure included labored breathing and/or gasping,
7 decreased activity and closed eyes. After exposure, lacrimation, nasal discharge, salivation,
8 dried brown material on face, labored breathing and/or gasping, and moist rales were observed.
9 Significant decreases in the terminal body weights were seen at 10.5 and 18.0 ppm. Gross
10 pathological findings included red lungs and fluid in the trachea and lungs. Numerous
11 histopathological changes were seen in the respiratory tract at all treatment levels with little or
12 no dose-related differences in the incidence or severity. Luminal fibrin admixed with
13 inflammatory cells, epithelial and/or mucosal necrosis, erosions, edema and inflammation were
14 seen throughout the respiratory tract. Congestion of respiratory mucosa was observed in the
15 nasoturbinates. Thin mucosal epithelium was seen in the nasopharynx and trachea. Vascular
16 congestion was observed in the larynx and lungs. The lungs had bronchiolar and peribronchiolar
17 chronic active inflammation and focal hemorrhages. No NOEL was established for clinical
18 signs or pathological lesions. The estimated LC₅₀ was 16.7 ppm (112 mg/m³; HEC_{8hr} - 13.6 ppm)
19 and 20.1 ppm (135 mg/m³; HEC_{8hr} - 16.4 ppm) in males and females, respectively. This study
20 did not meet FIFRA guidelines due to the short observation period. The LC₅₀ values from this
21 study are slightly higher than those reported by Yoshida, probably due to the delayed deaths that
22 were seen in the Yoshida study 8 to 10 days after exposure.

23 Yoshida *et al.* (1991) compared the acute toxicity of chloropicrin vapors with whole
24 body, nose only and dermal exposure in rats for 4 hours. The LC₅₀ values with whole body and
25 nose only were 14.4 and 6.6 ppm (actual; 96.8 and 44.4 mg/m³; HEC_{8hr}⁴ - 11.7 and 5.37 ppm),
26 respectively. No deaths or toxic signs were observed at the one dose level, 25 ppm (actual: 168
27 mg/m³; HEC_{8hr} - 20.3 ppm), tested with dermal exposure. Most of the deaths occurred within 24
28 hours. Clinical signs and pathological lesions similar to those in their previous study were seen
29 in this study. Insufficient information was provided to establish a NOEL from this study, except
30 with dermal exposure.

31 Sensory irritation is caused by the stimulation of unspecialized free nerve endings of the
32 afferent trigeminal nerve located in the corneal, nasal and oral mucosa (Kane *et al.*, 1979).
33 Stimulation of the trigeminal nerve results in a burning or pungent sensation and numerous
34 physiological reflex responses, including a reduction in respiratory rate. Based on earlier
35 research by these investigators, they were able to show that a reduction in respiratory rate of
36 mice was a good predictor of sensory irritation in man which shows a concentration-response
37 relationship. The concentration which caused a 50% reduction in the respiratory rate (RD₅₀) of
38 mice is used to compare the relative potency of various irritants. They proposed that the RD₅₀
39 would be an intolerable concentration in man. Kane *et al.* (1979) determined the RD₅₀ of

3 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 4 hours/day. E_h = 8 hours/day.

4 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 4 hours/day. E_h = 8 hours/day.

1 chloropicrin was 7.98 ppm (53.7 mg/m³; HEC_{1hr}⁵ - 4.06 ppm) with a 10-minute exposure. The
2 Chloropicrin Manufacturers Task Force also submitted a sensory irritation study in mice
3 (Hoffman, 1999b). Four Swiss-Webster male mice/dose were exposed (head only) to
4 chloropicrin (purity > 99%) at 0.99, 3.20, 4.20, 7.25, 10.0 or 14.5 ppm (analytical: 6.7, 21.5,
5 28.2, 48.7, 67.2 or 97.5 mg/m³; HEC_{1hr}⁶ - 1.51, 4.88, 6.41, 11.1, 15.3 or 22.1 ppm) for 30
6 minutes. No mortalities or clinical signs were seen. The respiratory rate was decreased from
7 pre-exposure level by 30, 55, 65, 72, 73, and 77% at the respective dose levels. The estimated
8 RD₅₀ was 2.34 ppm (15.7 mg/m³; HEC_{1hr} - 3.57 ppm). Buckley *et al.* (1984) reported that mice
9 exposed to chloropicrin at 7.98 ppm (10-min RD₅₀) for 6 hrs/day for 5 days (HEC_{8hr}⁷ = 18.3 ppm)
10 exhibited body weight reductions, nasal discharge, and gaseous distention of the abdomen.
11 When examined histopathologically, the mice had inflammation, exfoliation, erosion, ulceration
12 and necrosis of the upper respiratory epithelium and ulceration and necrosis of the olfactory
13 epithelium. Lesions were also seen in the lower respiratory tract including severe fibrosing
14 peribronchitis and peribronchiolitis. It is unclear from the data presented if any deaths occurred
15 at 7.98 ppm. None of these studies were FIFRA guideline-type studies, but the study by
16 Hoffman (1999b) was conducted in accordance with Good Laboratory Practice regulations.
17

18 The Department of Transportation also reported oral and dermal LD₅₀ values for
19 chloropicrin (Harton and Rawl, 1976). The oral LD₅₀ in rats was 37.5 mg/kg. No other details
20 were reported on clinical signs or necropsy findings. The dermal LD₅₀ in rabbits was 100 mg/kg.
21 Moderate edema was seen during the first 48 hours after exposure. Discoloration and necrosis
22 were also reported. No details were reported on other clinical signs or necropsy findings. In a
23 standard dermal irritation test in rabbits, they determined that chloropicrin was corrosive based
24 on necrosis at 72 hours. Sparks *et al.* (1997) determined the LD₅₀ for chloropicrin in mice to be
25 8 mg/kg after intraperitoneal injection. They also estimated the LD₅₀ for the metabolites,
26 CHCl₂NO₂, CH₂ClNO₂ and CH₃NO₂. Their respective LD₅₀ values were 70, 56 and > 200
27 mg/kg. The signs of toxicity were similar to chloropicrin in that they were primarily
28 neurological with tremors and seizures before death. No other details of clinical signs, body
29 weights, food consumption or necropsy findings were reported.

30 II.B.2. Human Studies

31 II.B.2.a. Case Reports

32 During World War I, chloropicrin was used primarily in high explosive gas shells mixed
33 with other gases due to its high boiling point and was rarely used alone (Underhill, 1920).
34 Chloropicrin was not as poisonous as some of the other war gases, but it penetrated gas masks
35 more rapidly and produced nausea and vomiting. This forced the soldiers to remove their masks,
36 exposing them to the more poisonous gases with which it had been mixed. Berghoff (1919)
37 examined 2,000 cases of soldiers that survived gas attacks during World War I and only 38 cases

5 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 1.8 m³/kg/day for the mouse (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 10 minutes/day. E_h = 60 minutes/day.

6 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 1.8 m³/kg/day for the mouse (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 30 minutes/day. E_h = 60 minutes/day.

7 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 1.8 m³/kg/day for the mouse (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day. E_h = 8 hours/day.

1 involved chloropicrin exposure alone. Another 515 cases involved exposure to a mixture of
2 gases, of which chloropicrin may have been one. Generally, the symptoms with chloropicrin
3 were less severe than with other gases based on the percentage with coughs, other physical
4 findings, and the average time in the hospital. No details were provided about the physical
5 findings with chloropicrin. Since chloropicrin was usually used in combination with other gases,
6 it was difficult to distinguish the effects due to chloropicrin from other war gases. However,
7 accidents in gas manufacturing plants have been useful in identifying effects (Lambert and
8 Jackson, 1920). In humans, inhalation of chloropicrin results in immediate cough, nausea and
9 vomiting. With higher or prolonged exposure, dyspnea, cyanosis, and weakness develop. Death
10 usually occurs within a few hours. Even if initial symptoms are not severe, death may occur 3 or
11 4 days later due to respiratory infection. Other complications reported included nephritis. Fries
12 and West (1921) reported that the eye is very sensitive to chloropicrin, causing essentially
13 involuntary closing of the eye. Concentrations above 25 ppm caused the eye to close so rapidly
14 after exposure that it was impossible to measure the time elapsed. Between 2 and 25 ppm, the
15 eye closed within 3 to 30 seconds. Below 1 to 2 ppm, the eye did not close, but considerable
16 blinking sometimes occurred. Prentiss (1937) reported that exposure to chloropicrin at 2 mg/L
17 (297 ppm) or 0.8 mg/L (119 ppm) was lethal after 10 or 30 minutes, respectively. A
18 concentration of 50 µg/L (7.4 ppm) was intolerable and concentrations as low as 2 µg/L (0.3
19 ppm) caused lacrimation. However, it is unclear if these are original observations or are based
20 on research by others.

21 There are several case reports of effects in humans after accidental exposure to
22 chloropicrin. In one case, the owner of a house released chloropicrin in the basement to get rid
23 of bats 3 to 4 weeks before the new owners moved in (TeSlaa *et al.*, 1986). In the week
24 following the arrival at their new house, the family members (2 adults and 2 children)
25 experienced runny noses, lacrimation and coughing. The father who was a smoker developed
26 the most severe symptoms including a dry cough and red, edematous nasal and pharyngeal
27 mucosa. He was diagnosed with bronchitis and sinusitis. A month later he developed a heart
28 murmur and showed some thickening of the aortic valve with slight left ventricular dilatation.
29 However, the cardiologist and consulting toxicologist concluded it was not related to
30 chloropicrin exposure. The family dog, which was kept in the basement at night, developed
31 lacrimation, dyspnea, and repeated coughing. It was diagnosed with bronchitis and pneumonia.
32 Chloropicrin residues measured at 6, 18 and 38 weeks after application were 30, 2 and 2 ppb,
33 respectively.

34 In October of 1984, the fumigation of a strawberry field (pre-plant) near Ceres,
35 California, with methyl bromide and chloropicrin resulted in 32 people being seen at an
36 emergency room with symptoms such as eye irritation, sore throat, headache, shortness of breath
37 and cough (Goldman *et al.*, 1987). No air samples were taken at the time of the incident, but air
38 samples taken the next day were negative (minimum detection limit was 1 ppb). Several days
39 later, a community survey was conducted to determine the extent of the exposure and nature of
40 symptoms experienced. Among 94 people reporting new illnesses after the incident, 32 adults
41 and 4 children had symptoms consistent with exposure to either methyl bromide or chloropicrin.
42 The vast majority (31 adults and 4 children) had symptoms that were attributed to chloropicrin
43 poisoning. The most common symptoms attributed to chloropicrin exposure were eye irritation
44 (65%), headache (48%), throat irritation (45%) and unusual odors (39%). The reporting of

1 symptoms was related to the distance from the field with 30% of the people living or working
2 within 1 kilometer of the field.

3 In an unusual incident in Japan, an 18-year-old woman and 21-year-old man were
4 sprayed with chloropicrin by an assailant while parked in a car on a farm road (Gonmori *et al.*,
5 1987). The woman was transferred to a hospital 75 minutes after the incident, but died 3 hours
6 later. Dark purple discoloration of the skin and pulmonary edema were the main findings at
7 autopsy. Chemical analysis of lung tissue and wiped samples from the car confirmed the
8 presence of chloropicrin. The male survivor of the incident recovered after spending 30 days in
9 the hospital. No details were reported of his symptoms.

10 In an incident in Belgium, a farmer accidentally fumigated a greenhouse with a mixture
11 of chloropicrin and metam-sodium due to a mislabeling of a bottle containing pure chloropicrin
12 as metam-sodium (Selala *et al.*, 1989). The fumes escaped through the vents of the greenhouse
13 and dissipated into neighboring areas. A number of animals (2,500 turkeys, numerous
14 ducklings, 4 sheep, and a goat) adjacent to the greenhouse died as a result of exposure to the
15 fumes. No human fatalities were reported, but residents within a 200 to 600 meter radius of the
16 greenhouse reported various complaints including eye irritation, lacrimation, coughing, runny
17 nose, nausea, sore throat, headache, dyspnea, and skin irritations. Thirty-five people including
18 some rescue workers were admitted to an emergency room. Seven of these 35 people had
19 elevated methemoglobin levels. Based on the complaints, the investigators estimated that the air
20 concentration of chloropicrin was between 0.05 and 0.1 mg/L (7.5 and 15 ppm, approximately).

21 Three workers from a freight transportation company were briefly exposed to
22 chloropicrin while unloading palettes of canisters containing methyl bromide or chloropicrin
23 from a trailer truck (Prudhomme *et al.*, 1999). Apparently several of the chloropicrin canisters
24 were overfilled at the factory and residue had evaporated from the outside of the canister. One
25 worker was initially exposed for approximately a minute before severe eye irritation and burning
26 chest pain forced him to leave the truck. A co-worker was exposed for about 30 seconds before
27 eye irritation caused him to leave. The third person, a supervisor, held his breath during the 15
28 seconds while he was inside. The first worker had the most severe symptoms including unusual
29 taste or odor, eye, nose and throat irritation, runny nose, headache, nausea, dizziness, lethargy,
30 burning in chest, shortness of breath, stomach/abdominal and generalized muscle cramping, rash,
31 pleuritic chest pain, dysphagia, dysuria, anxiety, fatigue, and peripheral numbness. Laboratory
32 results showed a marked elevation in his serum creatine phosphokinase activity. After his
33 discharge from the hospital 4 days later, he continued to experience headaches and diffuse
34 muscular pain in his upper extremities, chest and abdomen. He remained off work for several
35 months due to lethargy, musculoskeletal pain and poor tolerance to exertion. The second worker
36 experienced less severe symptoms (eye irritation, nausea, shortness of breath, abdominal and
37 stomach cramping, fatigue) and slightly elevated serum creatine phosphokinase activity. He was
38 released from the hospital after 2 days and returned to light-duty work 11 days after the incident.
39 The supervisor had the mildest symptoms (headache, nausea, lethargy, chest pain, and stomach
40 cramping). He was discharged after being seen in the emergency room.

41 From 1992 to 2007, there were a total of 1,015 cases with health effects definitely,
42 probably, or possibly related to chloropicrin exposure reported to the California Pesticide Illness
43 Surveillance Program (Beauvais, 2009). Of these, 571 cases were associated with six incidents

1 where chloropicrin was the sole active ingredient. Two major incidents were responsible for
2 most of these illness reports. One incident in Kern County in 2003 was associated with 165
3 cases following the application of 100% chloropicrin over a 2-day period to fallow land with a
4 buffer zone of 18 m. The chloropicrin was injected in the soil and applicators attempted to
5 confine the fumigant by dragging a weighted board behind the tractor, but they did not compact
6 the soil. Complaints of eye and throat irritation were reported each evening after the
7 applications, but the source of the irritation was not located until the second evening. In 2005,
8 another 324 cases were associated with an application of 94% chloropicrin in Monterey County.
9 The fumigant was applied to a tarped bedded field through a drip irrigation system which
10 apparently was not flushed with an adequate amount of water. Complaints occurred up to 3
11 miles from the application site and mostly involved odor and eye irritation. Another 204 cases
12 were associated with 61 incidents where chloropicrin was used as an active ingredient in
13 combination with other fumigants, all involving soil fumigation. In 230 cases, chloropicrin was
14 used as a warning agent with other fumigants which involved 164 incidents. Most of these cases
15 (176 cases) were related to its use as a warning agent in structural fumigation.

16 Systemic effects as well as local effects to the eye, respiratory tract and skin were
17 reported. Eye irritation was seen in 96% of the cases where chloropicrin was used alone, but
18 was seen in only 72% of the cases where it was used as an active ingredient in combination with
19 another fumigant and in only 46% of the cases where it was used as a warning agent in
20 combination with another fumigant. Systemic effects showed the opposite trend with the highest
21 percentage of cases (64%) with systemic effects associated with the use of chloropicrin as a
22 warning agent and the lowest percentage of cases (32%) associated with its use as an active
23 ingredient alone. The incidence of respiratory effects also tended to be greater with the warning
24 agent use (22%) and in combination with other fumigants (17%) compared to chloropicrin alone
25 (2.5%).

26 **II.B.2.b. Controlled Study**


27 The sensory irritation potential of chloropicrin vapors was evaluated in human subjects
28 by Cain (2004). Young adults were used for this study because it has been observed that
29 olfactory and trigeminal nerve sensitivity declines with age (Cain *et al.*, 1995; Hummel *et al.*,
30 2003; Kjaergaard *et al.*, 1992; Shusterman *et al.* 2003; Wysocki *et al.*, 2003). Subjects
31 underwent a physical examination to ensure that subjects were healthy, nonsmokers free from
32 exposure to chloropicrin, mood-altering drugs and medications that could interfere with the
33 conduct of the study and the female subjects were not pregnant. Potential subjects underwent a
34 brief odor identification test to ensure their sense of smell was normal. The study was divided
35 into three phases. Some subjects participated in more than one phase of the study. In phase 1,
36 the odor, nasal and ocular sensitivity was evaluated in subjects who were asked if they could
37 detect the presence of chloropicrin by odor, ocular “feel” or nasal “feel” after brief exposures (5
38 seconds for odor and nasal localization and 25 seconds for ocular) to increasing concentrations at
39 356, 533, 800 and 1200 ppb. Each subject was exposed to the 4 different levels in 30 rounds.
40 The subjects were blinded to their exposure by randomly exposing them through one of 3 cones
41 at a station, which varied from trial to trial. With ocular detection, the subjects wore nose clips.
42 For nasal localization, tubes from separate cones were directed to the left and right nostrils. For
43 odor detection, 62 subjects (32 males, 30 females) were tested. The median level of detection
44 for odor was 700 ppb (males - 590 ppb; females - 810 ppb). The ocular detection was tested in

1 63 subjects (32 males, 31 females). The median level of detection by eye irritation was 900 ppb
2 (males - 790 ppb males; females - 1010 ppb). Nasal localization was only tested in 20 subjects.
3 Due to their inability to localize nasal irritation, no additional subjects were tested.

4 In phase 2, 30 male and 30 female subjects were exposed to chloropicrin in a walk-in
5 chamber in the following order at 0 ppm for 30 minutes, 50 ppb for 30 minutes, 75 ppb for 20
6 minutes, 100 ppb for 20 minutes and 150 ppb for 20 minutes with 30 minute blank exposures or
7 a break in between exposures to chloropicrin. The subjects were asked to report the “feel” in the
8 eyes, nose and throat during exposures and the certainty of their detection (on a scale of 1-6).
9 The detection of the chloropicrin in the eyes was greater than in the nose and throat and
10 increased with concentration and duration of exposure (Figure 3). The detection in the nose and
11 throat diverged only slightly from the blank and the average ratings of confidence were
12 approximately 2 or lower. For ocular detection, the average ratings at 50, 75, 100 and 150 ppb
13 diverged from the blank after the first 20, 5, 3 and 2 minutes, respectively. However, only
14 exposures at 100 and 150 ppb reached a point where the average rating crossed over into the yes
15 zone (i.e., the average confidence score was greater than 3.5). The average rating of confidence
16 at 75 ppb clearly diverged from the blank, but the highest average rating was just over 2.5. At 50
17 ppb, the average rating of confidence was similar to the controls until after 20 minutes and even
18 at 30 minutes was only slightly over 2. The clear divergence of the average rating of confidence
19 in the ocular detection of chloropicrin from the blank at 75 ppb suggests some detected it even if
20 they were not certain. There was no significant difference between sexes in the eye irritation
21 scores. Therefore, the NOEL appears to be 50 ppb with a 20 minute exposure in phase 2.


22 In phase 3, subjects (15 males and 17 females) were exposed to chloropicrin at 0, 100 or
23 150 ppb in a walk-in chamber for 1 hour/day for 4 consecutive days. The 4-day exposure
24 represented one cycle. Subjects were exposed to all concentrations in three different cycles with
25 one week separating each cycle. Subjects were asked to rate their symptoms with a scale of 0 to
26 3 for severity. Clinical examination of the eyes, nose and throat was also performed on the
27 subjects before and after each exposure. The mean rating for ocular symptoms was
28 approximately 1 (mild with minimal awareness; easily tolerated) at 150 ppb which reached a
29 plateau after 15 minutes (Figure 4, Table 2). The mean rating for ocular symptoms at 100 ppb
30 was approximately 0.5 with a maximal rating after 30 minutes. Average scores are shown for
31 the entire exposure and for just the plateau (minutes 31-55 of exposure). The mean ratings for
32 nasal and throat symptoms were similar between the treated and blank exposures. Nasal air flow
33 and pulmonary function was evaluated based on the forced vital capacity (FVC) and forced
34 expiratory volume in 1 second (FEV₁) before and after each exposure. There was no treatment-
35 related effect on FVC or FEV₁; however, the post-exposure nasal flow rates were significantly
36 lower (~10%) at 150 ppb than the pre-exposure flow rates. The amount of nitric oxide (NO) in
37 the exhaled air of subjects was measured for the lungs and nose before and after each exposure
38 as an indicator of respiratory inflammation. The NO in expired nasal air was significantly
39 elevated at both 100 and 150 ppb, although the dose response was relatively flat (Table 2). The
40 investigators suggested that the reduced air flow at 150 ppb was due to some engorgement which
41 may have impeded the diffusion of NO from the tissue resulting in the flat dose response. There
42 were no significant gender-related differences in ocular irritation or upper respiratory effects
43 during in this phase. There was also no residual effect from one day to the next in either ocular
44 irritation or upper respiratory effects (Figure 5). The NOEL in phase 3 appears to be less than
45 100 ppb based on ocular irritation and subtle upper respiratory changes in NO production and

1



2 **Figure 3 (from Cain, 2004).** Average ratings of confidence for detection on transformed scale
 3 of 1-6 in phase 2 of the human sensory irritation study for chloropicrin (n = 60, males and
 4 females combined). Omitted for clarity, the SEM equaled approximately 0.3. Numbers below
 5 the midpoint of the y-axis (3.5) represent judgments of “no” with one or another level of
 6 confidence whereas ratings above it reflect “yes” judgements.

1



2 **Figure 4 (from Cain, 2004).** Average rated severity of symptoms during 1-hour exposures in
3 the chamber during phase 3 in the human sensory irritation study for chloropicrin (n = 32, males
4 and females combined). Omitted for clarity, the SEM equaled approximately 0.03, 0.06 and 0.09
5 for ocular symptoms at 0, 100 and 150 ppb, respectively, during the plateau.

Table 2. Ocular and Nasal Irritation in Human Subjects after 1-Hour Exposures for 4 Consecutive Days to Chloropicrin^a

	Dose Level (ppm)		
	0	100	150
Ocular Irritation			
Average score, overall ^b	0.10±0.19 ^c	0.39±0.39	0.76±0.71
Average score, plateau ^c	0.12±0.22	0.54±0.51	0.90±0.86
Nasal Irritation			
Average difference in NO in expired nasal air ^d	1.6±15.6	12.0±11.9	12.7±16.6

^a Cain, 2004.
^b The average score for ocular irritation overall is the average of the reported severity score for every minute of the 1 hour exposure for all four days of exposure. The severity score had a four point scale from 0 (no symptom) to 3 (severe; symptom hard to tolerate and can interfere with activities of daily living or sleeping).
^c mean±standard deviation. n = 32, males and females combined since no significant gender-related differences.
^d The average difference in the nitric oxide (NO) concentration (ppb) in expired nasal air is the average of the difference in the pre- and post-exposure levels in expired nasal air for an each individual for all four days of exposure. Increased NO production is an indication of inflammation. Individual increases of greater than 25% are considered clinically significant.




Figure 5 (from Cain, 2004). Ratings of ocular symptoms in the chamber by day of exposure in phase 3. Each point represents the average of five minutes of exposure (n = 32, males and females combined). Blank air shown by unfilled circles, 100 ppb by filled circles and 150 ppb by unfilled squares.

1 airflow. See the Risk Assessment section (Section III.A.1) and the Risk Appraisal section
2 (Section IV.A) of this document for a discussion of the benchmark dose analysis of this study.
3 Although there currently are no FIFRA guidelines for conducting human studies, this study was
4 conducted in accordance with Good Laboratory Practice regulations and was approved by the
5 Internal Review Board of the University of California, San Diego, which reviewed the protocol
6 and informed consent forms signed by subjects. In addition, the study protocol was reviewed
7 prior to the study start by a biostatistician, Dr. Robert Sielken, to ensure there was sufficient
8 statistical power.

9 **II.B.3. Formulations**

10 All of the currently registered formulations containing chloropicrin are labeled as
11 Category I pesticides and as such, are not required to submit acute toxicity data to DPR to
12 register them in California. Consequently, DPR has no acute toxicity data on file for the
13 formulations containing methyl bromide or 1,3-dichloropropene, except for one 1,3-
14 dichloropropene/chloropicrin formulation which is not currently registered.

15 **II.C. SUBCHRONIC TOXICITY**

16 **Summary:** Four subacute/subchronic toxicity studies in rats were available for
17 chloropicrin, two inhalation toxicity studies and two oral toxicity studies (one 10-day and one
18 90-day study). In addition, one subchronic inhalation toxicity study in mice was conducted.
19 Three of the studies are published reports and two others were conducted by registrants in
20 accordance with FIFRA guidelines. It is uncertain if the published studies were conducted
21 according to FIFRA guidelines. The effects seen in the inhalation studies included eye closure,
22 reddened eyes, labored respiration, reduced activity, reduced body weights and food
23 consumption, changes in hematological and clinical chemistry values, increased lung weights
24 and various histopathological lesions in the nasal cavity and lungs. A NOEL of 0.3 ppm (2.20
25 mg/m³) was established in both rats (HEC - 0.088 ppm) and mice (HEC - 0.16 ppm). The effects
26 seen with oral administration in rats included reduced body weights, changes in thymus, liver
27 and spleen weights, changes in hematological and clinical chemistry values, and
28 histopathological lesions in the forestomach (nonglandular stomach). The NOEL in the 90-day
29 oral gavage study appears to be 8 mg/kg/day based on body weight reduction, hematological
30 changes and histological changes in the forestomach.

31 **II.C.1. Inhalation-Mouse**

32 CD-1® mice (10 mice/sex/dose) were exposed (whole body) to chloropicrin vapors
33 (99.6% purity) at 0, 0.3, 1.03 or 2.89 ppm (actual; 0, 2.02, 6.93 or 19.4 mg/m³; HEC⁸ - 0, 0.16,
34 0.56 or 1.57 ppm) for 6 hours/day, 5 days/week for 13 weeks (Chun and Kintigh, 1993). One
35 male at 1.03 ppm was found dead and one control female was sacrificed in extremis, but these
36 deaths were not considered treatment-related. The only clinical sign observed during exposure
37 were blepharospasm (tonic spasm of the orbicularis oculi muscle, producing more or less
38 complete closure of the eye) at 2.89 ppm. After exposure, dehydration was observed in mice at

8 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 1.8 m³/kg/day for the mouse (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 5 days/week. E_h = 24 hours/day, 7 days/week.

1 2.89 ppm during the first 2 weeks of exposure. Male mice had significantly reduced body
2 weights (1.03 ppm – 7%; 2.89 ppm - 17%) and body weight gains (1.03 ppm – 44%; 2.89 ppm –
3 95%). Female mice at 2.89 ppm also had significantly reduced body weights (8%) and body
4 weight gain (58%). The food consumption was significantly reduced in both sexes at 1.03 ppm
5 (M: 9-12%; F: 13-25%) and 2.89 ppm (M: 17-38%; F: 17-44%). Male mice had significant
6 increases in red blood cell (RBC) and eosinophil counts and significant decreases of the mean
7 cell volume (MCV) and mean corpuscular hemoglobin (MCH). Female mice only had a
8 significant decrease in monocytes at 1.03 ppm. Total serum protein, albumin and calcium were
9 significantly elevated in male mice at 2.89 ppm. Blood urea nitrogen (BUN) was significantly
10 reduced at 0.3 and 2.89 ppm, but did not show a clear dose response relationship. Only globulin
11 levels were significantly elevated in females at 2.89 ppm. The toxicological significance of the
12 hematological and clinical chemistry changes is uncertain. Significant reductions in organ
13 weights were seen in both sexes at 2.89 ppm including liver (absolute: M&F), kidneys (absolute:
14 M; relative to brain: M) and spleen (absolute: M&F; relative to body: M; relative to brain:
15 M&F). A significant reduction was seen in spleen weights of males at 0.3 ppm (absolute,
16 relative body and relative to brain) and in liver weights of females at 1.03 ppm (absolute and
17 relative to brain). Lung weights were significantly elevated at 1.03 and 2.89 ppm in both sexes
18 (absolute, relative body and relative brain) (Tables 3 and 4). Significant increases in
19 histopathological lesions were seen in the nasal cavity of both sexes at 2.89 ppm including
20 epithelial hyaline inclusions, respiratory epithelial hyperplasia/dysplasia, rhinitis and mucosal
21 ulceration (Tables 3 and 4). Females at 1.03 ppm also had a significant increase in epithelial
22 hyaline inclusions in the nasal cavity. Numerous histopathological lesions were found in the
23 lungs of both sexes at 2.89 ppm including alveolar histiocytosis, bronchitis/bronchiolitis,
24 perivascular infiltrates, interstitial pneumonitis, peribronchial/peribronchiolar fibrosis,
25 bronchial/bronchiolar epithelial hyperplasia and peribronchial/peribronchiolar muscle
26 hyperplasia (Tables 3 and 4). Alveolar histiocytosis and bronchial/bronchiolar epithelial
27 hyperplasia were also significantly elevated at 1.03 ppm in females. The increases in lung
28 weights were probably related to the histopathological lesions found in the lung. The
29 toxicological significance of the reduction in the other organ weights is uncertain, but may be
30 related to the reduced body weights. The NOEL appears to be 0.3 ppm (2.02 mg/m³; HEC - 0.16
31 ppm) based on reduced body weights in males, reduced food consumption in both sexes,
32 increased lung weights in both sexes and lesions in the nasal cavity and lungs of females at 1.03
33 ppm. This study was found acceptable to DPR toxicologists based on the FIFRA guidelines.

34 II.C.2. Inhalation-Rat

35 Five male Fischer 344 rats/dose were exposed (whole body) to chloropicrin vapor (99.7%
36 purity) at 0, 0.37, 0.67, 1.58 or 2.93 ppm (actual; 0, 2.5, 4.5, 10.6 or 19.7 mg/m³; HEC⁹ - 0, 0.11,
37 0.19, 0.46 or 0.85 ppm) for 6 hours/day, 5 days/week for 13 weeks (Yoshida et al., 1987b). No
38 mortalities were seen at any dose level. During exposure, eyelid closure and decreased motor
39 activity was observed at all dose levels. The mean body weights were significantly lower than
40 controls at 1.58 ppm (8-11%) and 2.93 ppm (16-30%) throughout the study. Food consumption
41 and food efficiency were also significantly reduced at 2.93 ppm during the week 1 and 2. There
42 was a significant increase in red blood cell count values at 1.58 ppm (2.9%) and 2.93 ppm
43 (4.4%). Hemoglobin values were significantly elevated at 0.67 ppm (3.2%) and 2.93 ppm

⁹ HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 5 days/week. E_h = 24 hours/day, 7 days/week.

Table 3. Respiratory Effects Observed in Male Mice Exposed to Chloropicrin Vapors for 90 Days^a

Effects Observed	Dose Level (ppm)			
	0	0.3	1.03	2.89
Body Weight (g) - wk 13	39.5±2.01	37.1±2.86	36.8±3.13*	32.4±3.42**
Lung Weight – Absolute (g)	0.23±0.02 ^b	0.22±0.02	0.25±0.02*	0.32±0.04**
Relative to Body Weight (%)	0.57±0.04	0.59±0.04	0.67±0.06**	0.96±0.12**
Relative to Brain Weight (%)	45.6±3.1	45.6±3.7	50.5±3.9**	66.1±8.0**
Nasal Cavity				
Epithelial Hyalin Inclusions	0/10 (0%)	0/10 (0%)	3/9 (33%)	10/10** (100%)
Respiratory Epithelial Hyperplasia/Dysplasia	0/10 (0%)	0/10 (0%)	1/9 (11%)	7/10** (70%)
Rhinitis	0/10 (0%)	1/10 (10%)	1/9 (11%)	10/10** (100%)
Mucosal Ulceration	0/10 (0%)	0/10 (0%)	1/9 (11%)	7/10** (70%)
Lung				
Alveolar Histiocytosis	2/10 (20%)	1/10 (10%)	5/9 (56%)	9/10** (90%)
Bronchitis/Bronchiolitis	0/10 (0%)	0/10 (0%)	1/9 (11%)	5/10* (50%)
Perivascular Infiltrates	0/10 (0%)	0/10 (0%)	3/9 (33%)	4/10 (40%)
Interstitial Pneumonitis	1/10 (10%)	0/10 (0%)	0/9 (0%)	4/10 (40%)
Peribronchial/Peribronchiolar Fibrosis	0/10 (0%)	0/10 (0%)	1/9 (11%)	6/10* (60%)
Bronchial/Bronchiolar Epithelial Hyperplasia	0/10 (0%)	0/10 (0%)	1/9 (11%)	8/10** (80%)
Peribronchial/Peribronchiolar Muscle Hyperplasia	0/10 (0%)	0/10 (0%)	3/9 (33%)	6/10* (60%)
^a Chun and Kintigh, 1993. ^b Mean ± standard deviation *,** Significantly different from controls based on pair-wise comparisons using a pooled t-test for continuous data and Fisher's exact test for quantal data.				

(4.5%). Hematocrit values were only significantly higher at 2.93 ppm (3.3%). Several significant changes in clinical chemistry values were seen at 2.93 ppm including a decrease in total cholesterol (16%), an increase in BUN (9.5%) and an increase in alkaline phosphatase (ALP) (7.3%). There was no treatment-related effect on ophthalmology or gross pathology.

The absolute and relative lung weights were significantly higher at 2.93 ppm. Rats at 1.58 ppm had only a significant increase in relative lung weights. Significant increases in the relative brain, adrenal and testes weight were also seen at 2.93 ppm, but the investigators suggested these increases were due partly to the severe growth depression at this dose level. Histopathological lesions were seen in the respiratory tract at 1.58 and 2.93 ppm. These lesions

Table 4. Respiratory Effects Observed in Female Mice Exposed to Chloropicrin Vapors for 90 Days^a

Effects Observed	Dose Level (ppm)			
	0	0.3	1.03	2.89
Body Weight (g) - wk 13	27.7±1.58	27.9±1.93	27.4±1.28	25.6±2.31*
Lung Weight – Absolute (g)	0.20±0.01 ^b	0.20±0.02	0.23±0.02**	0.28±0.03**
Relative to Body Weight (%)	0.70±0.05	0.72±0.03	0.85±0.09**	1.11±0.13**
Relative to Brain Weight (%)	41.2±4.7	42.9±2.7	48.6±4.7**	61.5±5.8**
Nasal Cavity				
Epithelial Hyalin Inclusions	0/9 (0%)	2/10 (20%)	6/10* (60%)	10/10** (100%)
Respiratory Epithelial Hyperplasia/Dysplasia	0/9 (0%)	0/10 (0%)	0/10 (0%)	8/10** (80%)
Rhinitis	1/9 (11%)	0/10 (0%)	4/10 (40%)	9/10** (90%)
Mucosal Ulceration	0/9 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
Lung				
Alveolar Histiocytosis	1/9 (11%)	2/10 (20%)	8/10** (80%)	10/10** (100%)
Bronchitis/Bronchiolitis	0/9 (0%)	0/10 (0%)	2/10 (11%)	4/10 (40%)
Perivascular Infiltrates	0/9 (0%)	1/10 (10%)	2/10 (20%)	3/10 (30%)
Interstitial Pneumonitis	0/9 (0%)	0/10 (0%)	0/10 (0%)	4/10 (40%)
Peribronchial/Peribronchiolar Fibrosis	0/9 (0%)	0/10 (0%)	1/10 (10%)	8/10** (80%)
Bronchial/Bronchiolar Epithelial Hyperplasia	0/9 (0%)	0/10 (0%)	1/10 (10%)	8/10** (80%)
Peribronchial/Peribronchiolar Muscle Hyperplasia	0/9 (0%)	0/10 (0%)	0/10 (0%)	9/10** (90%)
^a Chun and Kintigh, 1993. ^b Mean ± standard deviation **, * Significantly different from controls based on pair-wise comparisons using a pooled t-test for continuous data and Fisher's exact test for quantal data.				

included catarrhal inflammation of the nasal mucosa, thickening of the epithelial layer in the larynx, epithelial hypertrophy in the trachea, bronchus and bronchiole, epithelial degeneration/necrosis/desquamation in the bronchus and bronchiole, epithelial hypertrophy of bronchial gland in the bronchus, and thickening of the bronchial wall in the bronchus and bronchiole. The NOEL for this study appears to be less than 0.37 ppm (2.5 mg/m³; HEC - 0.60 ppm) based on the eye closure and reduced activity during exposure. It was reported that this study was conducted in accordance with U.S. EPA guidelines; however, there was insufficient documentation to verify this.

1 In a second study, groups of 10 CD® rats/sex/dose were exposed (whole body) to
2 chloropicrin vapors (99.6% purity) at 0 (filtered air), 0.3, 1.03 or 2.89 ppm (actual; 0, 2.02, 6.93
3 or 19.4 mg/m³; HEC¹⁰ - 0, 0.088, 0.30 or 0.84 ppm) for 6 hours/day, 5 days/week for 13 weeks
4 (Chun and Kintigh, 1993). Three male rats at 2.89 ppm were sacrificed *in extremis* with signs of
5 emaciation, dehydration, urogenital stains and wetness, hunched posture, labored respiration and
6 reddened eyes. The only clinical sign observed during exposure was blepharospasm at 2.89
7 ppm. After exposure, discoloration of fur was observed on the face, neck and front limbs of rats
8 during most of the study. There was a significant reduction in terminal body weights (M: 17%)
9 and overall body weight gains (M: 41%; F: 15%) in rats at 2.89 ppm. Male rats at 2.89 ppm also
10 have significantly reduced food consumption (9-29%) during most weeks throughout the study.
11 A significant increase in the hemoglobin level was seen in male rats at 2.89 ppm, although the
12 toxicological significance of this change is uncertain. There were significant reductions in
13 several organ weights at 2.89 ppm including liver (absolute: M&F; relative to brain: M&F),
14 kidneys (absolute: M&F; relative to brain: F) and spleen (absolute: M; relative to brain: M).
15 There were also significant increases in lung weights at 1.03 ppm (absolute: M&F; relative to
16 body: M) and 2.89 ppm (absolute: M&F; relative to body: M&F) (Tables 5 and 6). There were
17 significant increases in several histopathological lesions in the nasal cavity of males and/or
18 females at 2.89 ppm, including the following lesions: rhinitis, respiratory epithelial
19 hyperplasia/dysplasia, and goblet cell hyperplasia (females only) (Tables 5 and 6). Females also
20 had a significant increase in goblet cell hyperplasia at 0.3 and 1.03 ppm, although the
21 investigator suggested that this was a sign of irritation, but was not toxicologically significant.
22 The following histopathological lesions were significantly increased in the lungs of both sexes at
23 2.89 ppm: peribronchial/peribronchiolar muscle hyperplasia, bronchitis/ bronchiolitis (males
24 only), peribronchial/peribronchiolar fibrosis, and bronchial/bronchiolar epithelial hyperplasia
25 (Tables 5 and 6). There was also a significant increase in peribronchial/peribronchiolar muscle
26 hyperplasia and bronchial/bronchiolar epithelial hyperplasia in females at 1.03 ppm. DPR
27 considered the increases in lung weights related to the lung lesions observed. The NOEL
28 appears to be 0.3 ppm (2.02 mg/m³; HEC - 0.088 ppm) based on the increase in weights and
29 histopathological lesions in the lung at 1.03 ppm. DPR toxicologists found this study to be
30 acceptable based on FIFRA guidelines.

31 II.C.3. Oral-Rat

32 Chloropicrin (98.3% pure) was administered by oral gavage to 10 Sprague-Dawley
33 rats/sex/dose at 0 (corn oil), 10, 20, 40 and 80 mg/kg/day for 10 consecutive days (Condie *et al.*,
34 1994). Two males at 80 mg/kg/day and 6 females at 20, 40 and 80 mg/kg/day died and were
35 considered treatment-related by the investigators. No clinical signs were reported. The mean
36 terminal body weight was significantly reduced at 40 (M: 9%) and 80 mg/kg/day (M: 25%; F:
37 8%). Significant reductions in the absolute and relative (to body) mean organ weights were seen
38 at 40 and 80 mg/kg including a reduction in thymus weight (males and females) and an increase
39 in liver and spleen weights (females only). Hematological changes were also noted at 40 and/or
40 80 mg/kg/day including an increase in white blood cell (WBC) counts and reticulocytes and a
41 reduction in red blood cell (RBC) counts, hemoglobin levels and hematocrits. Changes in
42 several clinical chemistry values were noted including a reduction in the aspartate
43 aminotransaminase (AST) values in both sexes at 40 and 80 mg/kg and an increase in phosphate

10 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h =
0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 5 days/week. E_h = 24 hours/day, 7 days/week.

Table 5. Respiratory Effects Observed in Male Rats Exposed to Chloropicrin Vapors for 90 Days^a

Effects Observed	Dose Level (ppm)			
	0	0.3	1.03	2.89
Body Weight (g) - wk 13	488±33.9	489±39.4	499±62.6	403.4±34.5**
Lung Weight – Absolute (g)	1.54±0.13 ^b	1.63±0.11	1.78±0.10**	1.94±0.29**
Relative to Body Weight (%)	0.31±0.03	0.33±0.02	0.36±0.04*	0.49±0.10**
Nasal Cavity				
Rhinitis	2/10 (20%)	2/10 (20%)	4/10 (40%)	10/10** (100%)
Respiratory Epithelial Hyperplasia/Dysplasia	1/10 (10%)	0/10 (0%)	2/10 (20%)	10/10** (100%)
Goblet Cell Hyperplasia	7/10 (70%)	7/10 (70%)	8/10 (80%)	9/10 (90%)
Lung				
Peribronchial/Peribronchiolar Muscle Hyperplasia	0/10 (0%)	0/10 (0%)	3/10 (30%)	8/10** (80%)
Bronchitis/Bronchiolitis	0/10 (0%)	0/10 (0%)	0/10 (0%)	7/10** (70%)
Peribronchial/Peribronchiolar Fibrosis	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10** (90%)
Bronchial/Bronchiolar Epithelial Hyperplasia	0/10 (0%)	0/10 (0%)	4/10 (40%)	9/10** (90%)
^a Chun and Kintigh, 1993. ^b Mean ± standard deviation *,** Significantly different from controls based on pair-wise comparisons using a pooled t-test for continuous data and Fisher's exact test for quantal data.				

levels at 20, 40 and 80 mg/kg/day in both sexes. Histopathological changes in the forestomach (nonglandular stomach) were reported at all dose levels including inflammation, necrosis, acantholysis, hyperkeratosis, epithelial hyperplasia, and ulceration. The severity was dose-related with the changes generally minimal at the lowest dose level and marked at the highest dose level. The NOEL appears to be less than 10 mg/kg/day based on the histological lesions in the forestomach. This subacute study was a non-guideline type study.

Condie et al. (1994) also administered chloropicrin by oral gavage to 10 Sprague-Dawley rats/sex/dose at 0 (corn oil), 2, 8, or 32 mg/kg/day for 90 days. Sixty percent of males and 80% of females at 32 mg/kg/day died. Most of the deaths were due to pulmonary complications that the investigators suggested were probably due to aspiration of chloropicrin. Wheezing and dyspnea were the main clinical signs observed. Significant body weight reductions were observed at the study termination in males at 32 mg/kg/day (21%). The reduction in the terminal body weights for females at 32 mg/kg/day was not statistically significant, but was greater than 10% (18%). Slight changes in hematological values were noted at 32 mg/kg/day including a reduction in hemoglobin and hematocrit values in males and an increase in red blood cell counts in females. A significant decrease in WBC counts was seen in females at 8 mg/kg/day. The only organ weight change was a significant reduction in the absolute thymus weight at 8 (M: 25%) and 32 mg/kg/day (F: 12%). The investigators suggested that the reduced thymus weight and

Table 6. Respiratory Effects Observed in Female Rats Exposed to Chloropicrin Vapors for 90 Days^a

Effects Observed	Dose Level (ppm)			
	0	0.3	1.03	2.89
Body Weight (g) - wk 13	325±24.9	330±30.4	316±19.9	306±21.1
Lung Weight – Absolute (g)	1.31±0.08 ^b	1.33±0.08	1.39±0.10	1.57±0.12 ^{**}
Relative to Body Weight (%)	0.40±0.03	0.40±0.02	0.44±0.04 [*]	0.51±0.05 ^{**}
Nasal Cavity				
Rhinitis	1/10 (10%)	1/10 (10%)	7/10 [*] (70%)	8/10 ^{**} (80%)
Respiratory Epithelial Hyperplasia/Dysplasia	0/10 (0%)	0/10 (0%)	0/10 (0%)	9/10 ^{**} (90%)
Goblet Cell Hyperplasia	0/10 (0%)	6/10 [*] (60%)	7/10 ^{**} (70%)	5/10 [*] (50%)
Lung				
Peribronchial/Peribronchiolar Muscle Hyperplasia	0/10 (0%)	0/10 (0%)	6/10 [*] (60%)	7/10 ^{**} (70%)
Bronchitis/Bronchiolitis	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
Peribronchial/Peribronchiolar Fibrosis	0/10 (0%)	0/10 (0%)	0/10 (0%)	8/10 ^{**} (80%)
Bronchial/Bronchiolar Epithelial Hyperplasia	0/10 (0%)	0/10 (0%)	5/10 [*] (50%)	7/10 ^{**} (70%)
^a Chun and Kintigh, 1993. ^b Mean ± standard deviation [*] , ^{**} Significantly different from controls based on pair-wise comparisons using a pooled t-test for continuous data and Fisher's exact test for quantal data.				

WBC counts suggests an adverse effect on the immune system. However, the reduction in the WBC count in females at 8 mg/kg/day does not correlate with a reduction in thymus weight nor does the reduction in thymus weights in males at 8 mg/kg/day correlate with a reduction in WBC counts. Histopathological changes in the forestomach were observed at 32 mg/kg/day including chronic inflammation, acantholysis and hyperkeratosis. In animals that died, chronic pulmonary inflammation and congestion were seen. The NOEL for this study appears to be 8 mg/kg/day based on body weight reduction, hematological changes and histological changes in the forestomach. There was insufficient information in this published report to determine if this study met FIFRA guidelines.

II.D. CHRONIC TOXICITY/CARCINOGENICITY

Summary: Six chronic toxicity/carcinogenicity studies were available for chloropicrin. Two studies were mouse carcinogenicity studies (one oral, one inhalation). Three studies were rat chronic toxicity/carcinogenicity studies (two oral, one inhalation). One oral chronic toxicity study was conducted in dogs. Four of these studies met FIFRA guidelines. The effects observed with oral exposure included reduced survival, ptyalism, emesis, diarrhea, hunched posture, squinted or reddened eyes, reddened ears, urogenital stains, reduced body weights,

1 hematological and clinical chemistry changes, nonneoplastic lesions in the forestomach/
2 nonglandular stomach and liver, and neoplastic lesions in the mammary gland and stomach. The
3 lowest NOEL with oral exposure was 0.1 mg/kg/day based on reduced body weights and
4 periportal hepatocyte vacuolation in rats. The effects seen with inhalation exposure included
5 reduced survival, reduced body weights and food consumption, increased lung weights, and
6 nonneoplastic and neoplastic lesions in the respiratory tract. The lowest NOEL with inhalation
7 exposure was 0.1 ppm (0.67 mg/m³) in both rats (HEC = 0.029 ppm) and mice (HEC = 0.054
8 ppm).

9 II.D.1. Inhalation-Mouse

10 Fifty CD-1 mice/sex/dose were exposed (whole body) to chloropicrin (99.6% pure)
11 vapors at 0, 0.1, 0.5 or 1.0 ppm (analytical; 0, 0.67, 3.36 or 6.72 mg/m³; HEC¹¹ - 0.054, 0.27 or
12 0.54 ppm) for 6 hours/day, 5 days/week for at least 78 weeks (Burleigh-Flayer *et al.*, 1995).
13 Surviving animals were sacrificed at week 82. There was no treatment-related effect on
14 mortality or clinical signs. Significant decreases in the mean body weights (M: 3 and 7%; F: 4
15 and 10% at week 53) and the mean body weight gains (M: 8 and 24%; F: 15 and 35% at week
16 53) were seen at 0.5 and 1.0 ppm, respectively, throughout the study. Decreases in the mean
17 food consumption corresponded with the body weight changes in males at 1.0 ppm and in
18 females at 0.5 and 1.0 ppm. No treatment-related changes in hematological values were seen.
19 Significant increases in absolute and/or relative lung weights (to body or brain) were seen in
20 both sexes at 0.5 ppm (absolute – M: 14%) and 1.0 ppm (absolute – M: 16%; F: 36%). There
21 was also a significant decrease in the absolute brain weight in females at 1.0 ppm (4%), but there
22 were no microscopic findings in this tissue so the toxicological significance of this finding is
23 uncertain. Macroscopic pathological changes were seen in the lung (color change,
24 hyperinflation, nodules and/or masses) and kidney (cysts, size decrease and color change),
25 primarily at 1.0 ppm. Significant increases in numerous microscopic lesions in the respiratory
26 tract were seen in both sexes at 0.5 and 1.0 ppm (Tables 7 and 8). These microscopic lesions
27 involved both the nasal cavity (serous exudate, hyaline epithelial inclusions, rhinitis, olfactory
28 epithelial atrophy) and the lungs (alveolar protein deposits – females only, alveolar histiocytosis,
29 peribronchial lymphocytic infiltrates, bronchiectasis, bronchial submucosal fibrosis,
30 bronchioalveolar cell hyperplasia – females only, peribronchial smooth muscle hyperplasia –
31 females only). The slight increase in adenomas and carcinomas in the lungs was significant by
32 trend analysis but was not significant by Fisher's exact test even when combined although the p
33 value was 0.053. Consequently, the combined incidence of adenomas and carcinomas in females
34 was further analyzed using the Poly-3 trend test that takes survival into consideration. It also
35 contains a pairwise comparison test. With this test, the trend was not only significant, but the
36 combined incidence at the high dose was significant (p = 0.021). Also noteworthy is an increase
37 in the number of animals with multiple lung adenomas and/or carcinomas in males (4/49, 0/49,
38 6/45 and 10/50) and females (3/48, 3/48, 6/47 and 9/49), although these increases were only
39 significant by trend analysis in males and not significant in either sex by Fisher's exact. The
40 average time to tumor did not show a dose-related decrease in males (562, 540, 546 and 549
41 days at 0, 100, 500 and 1,000 ppb, respectively), but was shorter in the high dose females (554,
42 562, 564 and 543 days at 0, 100, 500 and 1,000 ppb, respectively). However, the shorter time to
43 tumor in the high dose females appears to be primarily due to two deaths that occurred within the

11 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 1.8 m³/kg/day for the mouse (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 5 days/week. E_h = 24 hours/day, 7 days/week.

Table 7. Microscopic Lesions in the Respiratory Tract of Male Mice Exposed to Chloropicrin Vapors for 78 Weeks^a

Lesion	Treatment Level (ppm)			
	0	0.1	0.5	1.0
Nasal Cavity				
Serous Exudate	4/50 ⁺⁺⁺ (8%)	7/50 (14%)	18/50 ^{**} (36%)	38/50 ^{**} (76%)
Hyaline Epithelial Inclusion	3/50 ⁺⁺⁺ (6%)	6/50 (12%)	7/50 (14%)	16/50 ^{**} (32%)
Rhinitis	6/50 ⁺⁺⁺ (12%)	7/50 (14%)	17/50 ^{**} (34%)	35/50 ^{**} (70%)
Olfactory Epithelial Atrophy	5/50 ⁺⁺⁺ (10%)	6/50 (12%)	8/50 (16%)	40/50 ^{**} (80%)
Lungs				
Alveolar Histiocytosis	18/50 ⁺⁺ (36%)	17/50 (34%)	22/50 (44%)	29/50 [*] (58%)
Peribronchial Lymphocytic Infiltrates	1/50 ⁺⁺ (2%)	6/50 (12%)	10/50 ^{**} (20%)	12/50 ^{**} (24%)
Bronchiectasis	0/50 ⁺⁺⁺ (0%)	3/50 (6%)	28/50 ^{**} (56%)	41/50 ^{**} (82%)
Bronchial Submucosal Fibrosis	0/50 ⁺⁺⁺ (0%)	0/50 (0%)	16/50 ^{**} (32%)	19/50 ^{**} (38%)
Adenoma ^c	16/49 (33%)	14/49 (29%)	18/45 (40%)	18/50 (36%)
Carcinoma	1/49 (2%)	0/49 (0%)	5/45 (11%)	2/50 (4%)
Combined Adenoma and Carcinoma	17/49 ^b (35%)	14/49 (29%)	22/45 (49%)	20/50 (40%)
<p>a Burleigh-Flayer <i>et al.</i>, 1995. b The denominator is the number of animals at risk which are animals that survived up to the day the first tumor was observed, 253 days. c Historical control data published by Charles River for this strain for studies conducted between 1987 and 1996 had an average incidence of 14% (0-28%) and 8.7% (0-27%) for adenomas in males (46 studies) and females (48 studies), respectively (Giknis and Clifford, 2000) ⁺⁺,⁺⁺⁺ Significant trend based on the Armitage-Cochran trend test at $p < 0.01$ and 0.001, respectively (Gart <i>et al.</i>, 1986). [*],^{**} Significantly different from the control group based on the Fisher's exact test at $p < 0.05$ and 0.01, respectively.</p>				

first year that were unrelated to the tumors (both had adenomas, not carcinomas; trauma in one case and undetermined cause of death in another). No historical control data were available for this laboratory, but historical control data published by Charles River for this strain for studies conducted between 1987 and 1996 had an average incidence of 14% (0-28%) and 8.7% (0-27%) for adenomas in males (46 studies) and females (48 studies), respectively (Giknis and Clifford, 2000). The incidence of these tumors was above the average for the historical control data for all groups and outside the historical control range for most groups including the control group of the males. Other possible treatment-related increases in microscopic lesions included auditory sebaceous gland adenitis (7/50, -, -, 17/50^{*}) in males at 1.0 ppm, liver Ito cell hyperplasia (29/50, 23/50, 31/50, 43/50^{**}) and endocervical metaplasia (0/50, 0/50, 2/50, 5/50^{*}) in females

Table 8. Microscopic Lesions in the Respiratory Tract of Female Mice Exposed to Chloropicrin Vapors for 78 Weeks^a

Lesion	Treatment Level (ppm)			
	0	0.1	0.5	1.0
Nasal Cavity				
Serous Exudate	4/50 ⁺⁺⁺ (8%)	3/50 (6%)	36/50 ^{**} (72%)	46/50 ^{**} (92%)
Hyaline Epithelial Inclusion	10/50 ⁺⁺⁺ (20%)	11/50 (22%)	24/50 ^{**} (48%)	37/50 ^{**} (74%)
Rhinitis	3/50 ⁺⁺⁺ (6%)	6/50 (12%)	18/50 ^{**} (36%)	32/50 ^{**} (64%)
Olfactory Epithelial Atrophy	13/50 ⁺⁺⁺ (26%)	14/50 (28%)	39/50 ^{**} (78%)	36/50 ^{**} (72%)
Lungs				
Alveolar Protein Deposits	0/50 ⁺⁺⁺ (0%)	1/50 (2%)	1/50 (2%)	9/50 ^{**} (18%)
Alveolar Histiocytosis	14/50 ⁺⁺⁺ (28%)	14/50 (28%)	19/50 (38%)	35/50 ^{**} (70%)
Peribronchial Lymphocytic Infiltrates	5/50 ⁺⁺⁺ (10%)	10/50 (20%)	17/50 ^{**} (34%)	28/50 ^{**} (56%)
Bronchiectasis	0/50 ⁺⁺⁺ (0%)	5/50 (10%)	28/50 ^{**} (56%)	44/50 ^{**} (88%)
Bronchial Submucosal Fibrosis	0/50 ⁺⁺⁺ (0%)	0/50 (0%)	13/50 ^{**} (26%)	22/50 ^{**} (44%)
Peribronchial Smooth Muscle Hyperplasia	0/50 ⁺⁺⁺ (0%)	0/50 (0%)	0/50 (0%)	5/50 [*] (10%)
Adenoma	13/48 ^{++b} (27%)	9/48 (19%)	17/47 (36%)	19/49 (39%)
Carcinoma	0/48 ^b (0%)	4/48 (8%)	3/47 (6%)	4/49 (8%)
Combined Adenoma and Carcinoma	13/48 ^{++b} (27%)	12/48 (25%)	20/47 (43%)	22/49 (45%)
Combined Adenoma and Carcinoma - Adjusted	13/42 ^{++d} (31%)	12/41 (29%)	20/43 (46%)	22/42 [*] (53%)
<p>a Burleigh-Flayer <i>et al.</i>, 1995. b The denominator is the number of animals at risk which are animals that survived up to the day the first tumor was observed, 253 days. c Historical control data published by Charles River for this strain for studies conducted between 1987 and 1996 had an average incidence of 14% (0-28%) and 8.7% (0-27%) for adenomas in males (46 studies) and females (48 studies), respectively (Giknis and Clifford, 2000). d The animals at risk was determined in the Poly-3 trend test by weighting the animals without tumors based on their time of death. The Poly-3 trend test is utilized by the National Toxicology Program (Portier and Bailer, 1989). ^{+,++,+++} Significant trend based on the Armitage-Cochran trend test at $p < 0.05$, 0.01 and 0.001, respectively (Gart <i>et al.</i>, 1986). ^{*,**} Significantly different from the control group based on the Fisher's exact test at $p < 0.05$ and 0.01, respectively.</p>				

at 1.0 ppm, and kidney cysts (5/50, 10/50, 14/50*, 13/50) in females at 0.5 ppm. In addition, at week 82 there was a significant increase in corneal mineralization (2/34, 2/34, 2/31, 9/32*) and vascularization (0/34, 2/34, 3/31, 4/32*) in the eyes of females at 1.0 ppm. No other treatment-related increases in tumors were observed. The NOEL for this study was 0.1 ppm (0.67 mg/m³;

1 HEC - 0.054 ppm) based on the reduction in body weights and food consumption, increased lung
2 weights and microscopic lesions in the nasal cavity and lungs. DPR found this study acceptable
3 based on FIFRA guidelines.

4 **II.D.2. Oral-Mouse**

5 Groups of 50 B653F1 mice/sex/dose were administered chloropicrin (98% purity) by oral
6 gavage in corn oil at 25 and 50 mg/kg/day during weeks 1 through 13 and 35 and 70 mg/kg/day,
7 respectively, during weeks 14 to 78 weeks followed by an observation period of 13 weeks (NCI,
8 1978). The respective time-weighted average dosages were 33 and 66 mg/kg/day. Twenty
9 mice/sex were assigned to untreated and vehicle (corn oil) control groups. A significant
10 reduction in survival was seen in both sexes at 66 mg/kg/day. There was a progressive
11 depression of body weights in female mice at both 33 and 66 mg/kg/day. No consistent
12 difference in male body weight gains was seen. After the first 6 months of the study, there was a
13 higher frequency of hunched or bloated appearance in treated animals compared to controls. An
14 increased incidence of acanthosis and hyperkeratosis in the stomach was seen in both sexes at 33
15 and 66 mg/kg/day, especially the females. Two squamous cell carcinomas were seen the
16 stomach of males at 66 mg/kg/day and one papilloma in the stomach of a female at 33
17 mg/kg/day. However, the incidence of neither of these lesions was statistically significant. The
18 NOEL appears to be less than 33 mg/kg/day based on the acanthosis and hyperkeratosis in the
19 forestomach in both sexes and the body weight depression in females. The study had major
20 deficiencies including an inadequate number of dose groups and control animals. The report
21 also lacks data on the analysis of dosing solution, individual body weights, food consumption
22 and clinical data.

23 **II.D.3. Inhalation-Rat**

24 In a rat inhalation carcinogenicity study, groups of 50 CD[®] rats/sex/dose were exposed
25 (whole body) to chloropicrin (99.6% purity) vapors at 0 (air), 0.1, 0.5 and 1.0 ppm (analytical; 0,
26 0.67, 3.36 or 6.72 mg/m³; HEC¹² - 0, 0.029, 0.15 or 0.29 ppm) for 6 hours/day, 5 days/week for
27 at least 107 weeks (Burleigh-Flayer and Benson, 1995). A significant reduction in the survival
28 rate of males at 0.5 and 1.0 ppm were observed (Table 9). The incidence of a few clinical signs
29 were elevated at 1.0 ppm, including hypoactivity, prostration, cold extremities, urogenital
30 wetness, blepharospasm, and periocular encrustation. There was no significant difference in
31 absolute body weights, but the body weight gains were significantly reduced during the first few
32 weeks of exposure at 0.5 and 1.0 ppm (M: 8-28%; F: 9-25%) in both sexes. Female rats at 0.1
33 ppm also had significant reductions in body weight gains (6-10%) during this time; however,
34 these minor reductions in body weight gain were of uncertain toxicological significance. There
35 was no treatment-related effect on food consumption, palpable masses or hematology. A few
36 significant differences in the absolute liver and kidney weights were seen in females at 0.1 and
37 0.5 ppm which the investigators suggested was due to the lower terminal body weights in these
38 groups and not treatment-related. The increases in the absolute and relative (to body and brain)
39 lung weights at 1.0 ppm were considered treatment-related by the investigators, although not
40 statistically significant. There appeared to be a treatment-related increase in spleen weight
41 and/or in the incidence of increased spleen size especially in males, but the differences were not

12. HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 5 days/week. E_h = 24 hours/day, 7 days/week.

Table 9. Possible Treatment-Related Effects in Rats Exposed to Chloropicrin Vapors for 107 Weeks^a

Lesion	Treatment Level (ppm)			
	0	0.1	0.5	1.0
MALES				
Mean survival, days	696±97 ^b	669±118	672±99*	647±110**
Mortality rate	42%	58%	66%	70%
Body weight gains, wk 0-1	31.2±4.2	30.1±4.0	28.6±2.9**	22.6±4.6**
Liver weights, grams	14.4±2.6	14.3±3.2	12.4±2.5*	14.7±2.7
Kidney weights, grams	4.90±1.52	4.54±0.71	4.98±1.02	5.35±1.18
Spleen weights, grams	1.03±0.26	1.16±0.30	1.40±0.96	1.23±0.46
Lung weights, grams	2.09±0.65	2.09±0.22	2.20±0.32	2.45±0.78
Lung weights, relative (% brain)	95.9±31.0	94.4±11.1	100.6±14.8	112.5±35.0
Hyperinflated lung	2/50 ^c (4%)	6/50 (12%)	5/50 (10%)	6/50 (12%)
Nasal cavity Rhinitis	20/50 ⁺⁺ (40%)	24/50 (48%)	21/50 (42%)	35/50** (70%)
Mammary gland Fibroadenoma	1/16 (6%)	0/10 (0%)	0/15 (0%)	1/15 (7%)
FEMALES				
Mean survival, days	690±97	673±99	666±102	661±128
Mortality rate	48%	64%	56%	56%
Body weight gains, wk 0-1	15.8±3.6	14.3±3.7	13.4±3.6**	11.9±3.4**
Liver weights, grams	14.4±2.6	14.3±3.2	12.4±2.5*	14.8±2.7
Kidney weights, grams	3.25±0.57	2.93±0.30*	2.90±0.36*	3.00±0.52
Spleen weights, grams	0.79±0.27	0.89±0.54	0.69±0.16	0.90±0.46
Lung weights, grams	1.57±0.29	1.46±0.14	1.46±0.12	1.63±0.35
Lung weights, relative (% brain)	79.9±16.1	75.0±7.37	74.2±6.50	89.1±37.7
Hyperinflated lung	3/50 (6%)	4/50 (8%)	3/50 (6%)	2/50 (4%)
Nasal cavity Rhinitis	18/50 (36%)	17/50 (34%)	26/50 (52%)	23/50 (46%)
Mammary gland Fibroadenoma	10/49 (20%)	16/50 (32%)	14/50 (28%)	16/47 (34%)
<p>a Burleigh-Flayer and Benson, 1995.</p> <p>b Mean ± standard deviation</p> <p>c Denominator represents the number examined except for mammary gland fibroadenomas in females in which case the denominator is the number of animals at risk (i.e., animals that survived > 365 days).</p> <p>++ Significant trend based on the Armitage-Cochran trend test at p < 0.01 (Gart <i>et al.</i>, 1986).</p> <p>*,** Significantly different from the control group based on product-limit survival analysis for survival, Dunnett's test for weights and the Fisher's exact for lesions at p < 0.05 and 0.01, respectively.</p>				

statistically significant in either sex. Males also appeared to have an increased incidence of hyperinflated lung that was observed macroscopically, but the increase was not statistically significant. No other treatment-related macroscopic pathological lesions were observed. The only significant increase in microscopic lesions was rhinitis in the anterior nasal cavities in male rats at 1.0 ppm. The rhinitis was characterized by sporadic lymphocytic or neutrophilic mucosal/submucosal infiltrates and occasionally by purulent exudate. There was no treatment-

1 related increase in tumor incidence, except for the incidence in fibroadenomas in females.
2 However, this incidence was not statistically significant and within the reported historical control
3 range for this strain from this laboratory (11-47%). The NOEL for this study was 0.1 ppm (0.67
4 mg/m³; HEC - 0.029 ppm) based on the reduced survival rate in males and reduced body weight
5 gain in both sexes. DPR found this study acceptable based on FIFRA guidelines.

6 **II.D.4. Oral-Rat**

7 In an NCI study, 50 Osborne-Mendel rats that were administered chloropicrin (95% pure)
8 by oral gavage 5 days per week at two dose levels (NCI, 1978). Rats of both sexes initially
9 received 23 and 46 mg/kg/day at the low and high-dose level during the first 4 weeks. Starting
10 at week 5, the dose levels for males were increased to 28 and 56 mg/kg/day for the low and high
11 dose-groups while the dose levels for females remained the same. After week 17, the dosing was
12 stopped for the high dose animals for 13 weeks, but was continued for low dose animals. At
13 week 31, high-dose animals resumed dosing at the same dose level as the low dose animals.
14 Beginning with week 34, a cyclic pattern of dosing was started with all the treated animals
15 beginning with one week of no dosing, followed by 4 weeks of dosing. This continued through
16 week 78 of the study followed by a 32-week observation period before the study was terminated.
17 This dosing regimen resulted in a time-weighted average of 25 and 26 for the low- and high-
18 dose males, respectively, and 20 and 22 mg/kg/day for the low- and high-dose females,
19 respectively, during the 78-week dosing period. The vehicle control group consisted of 20
20 rats/sex which were administered corn oil by gavage during weeks 1 through 78. The untreated
21 control group consisted of 20 rats/sex that were not gavaged. There was a high incidence of
22 mortality in the treated rats. Fifty percent of the male rats were dead after 54 and 48 weeks at
23 the low- and high-dose levels, respectively. The same percent of female rats were dead after 59
24 and 70 weeks at the low- and high-dose levels, respectively. By contrast, over 50% of the
25 control animals survived past week 89 for males and week 108 for females. No dose-related
26 increases in tumors were seen; however, it is unlikely that treated rats survived long enough to
27 develop late-appearing tumors. The only other effects reported were reduced body weights and
28 clinical signs. The clinical signs included hunched or thin appearance, squinted or reddened
29 eyes, reddened ears, and urogenital stains. The NOEL appears to be less than 20 mg/kg/day
30 based on the increased mortalities, reduced body weights and clinical signs. This study had
31 major deficiencies including an inadequate number of control animals, inadequate number of
32 dose levels, frequent dose-level changes, no hematology data, and no individual data.

33 Chloropicrin (99% pure) was administered at 0 (corn oil), 0.1, 1 and 10 mg/kg/day by
34 oral gavage to 30 Sprague-Dawley derived rats (CrI:CD[®]BR, VAF/Plus)/sex/dose for 2 years
35 (Slauter, 1995). There was no treatment-related effect on survival. Increased salivation was
36 observed at 10 mg/kg/day in both sexes throughout the study after dosing for about 15 to 30
37 minutes. At study termination, male body weights were reduced 11.6% from controls at both 1.0
38 and 10 mg/kg/day. No treatment-related differences in food consumption, ophthalmology, and
39 hematology were observed. Increases in serum calcium and phosphorus levels were seen in
40 females at 10 mg/kg/day, but were of uncertain toxicological significance since they were not
41 associated with any histopathological changes. Subcutis skin masses were observed in females
42 that exhibited an apparent dose-response relationship. Microscopic examination of these masses
43 confirmed the presence of mammary fibroadenomas and was statistically significant at 10
44 mg/kg/day by pair-wise comparison with controls (Table 10). The toxicological significance of

Table 10. Microscopic Lesions in Rats Administered Chloropicrin by Oral Gavage for 2 Years^a

Lesion	Treatment Level (mg/kg/day)			
	0	0.1	1.0	10.0
MALES				
Liver				
Periportal hepatocyte vacuolation	2/30 (7%)	8/30 (27%)	3/30 (10%)	6/30 (20%)
Nonglandular Stomach				
Hyperkeratosis	7/30 ⁺⁺⁺ (23%)	9/30 (30%)	11/30 (37%)	20/30 ^{**} (67%)
Epithelial Hyperplasia	3/30 ⁺⁺⁺ (10%)	5/30 (17%)	4/30 (13%)	18/30 ^{**} (60%)
FEMALES				
Liver				
Periportal hepatocyte vacuolation	2/30 ⁺⁺ (7%)	6/30 (20%)	10/30* (33%)	13/30 ^{**} (43%)
Nonglandular Stomach				
Hyperkeratosis	6/30 ⁺⁺⁺ (20%)	5/30 (17%)	11/30 (37%)	24/30 ^{**} (80%)
Epithelial Hyperplasia	6/30 ⁺⁺⁺ (20%)	5/30 (17%)	6/30 (20%)	14/30* (47%)
Mammary Gland				
Fibroadenoma	6/30 ⁺⁺⁺ (20%)	9/30 (30%)	12/30 (40%)	14/30* (47%)
^a Slaughter, 1995. ⁺⁺ , ⁺⁺⁺ Significant trend based on the Armitage-Cochran trend test at p < 0.01 and 0.001, respectively (Gart <i>et al.</i> , 1986). [*] , ^{**} Significantly different from the control group based on the Fisher's exact test at p < 0.05 and 0.01, respectively.				

this dose-related increase is uncertain since the incidence was within the historical control range for this strain from this laboratory (up to 55%) and from other facilities (up to 49%). Other dose-related increases in microscopic lesions were seen including periportal hepatocyte vacuolation in the liver and hyperkeratosis and epithelial hyperplasia of the nonglandular stomach. The historical control range for hepatocyte vacuolation from this laboratory was reported to be 12-41% and 6-35% in males and females, respectively. The distribution of the vacuolation within the lobule was generally not specified, but in one other study, the incidence of periportal hepatocyte vacuolation was 7 and 13% in males and females, respectively. The historical control range for hyperkeratosis of the nonglandular stomach was reported to be 0-28% and 0-24% in males and females, respectively. The historical control range for hyperplasia/acanthosis was 0-30% in males and 0-9% in females. A papilloma in the nonglandular stomach was observed microscopically in one male rat at 10 mg/kg/day that could have been treatment-related based on the increase in hyperplasia and hyperkeratosis in this tissue. However, the incidence was not statistically significant and was reported to be within the historical control range for this laboratory (data not provided). The NOEL for this study was 0.1 mg/kg/day based on the reduction in male body weights and periportal hepatocyte vacuolation in females at 1.0 mg/kg/day. This study was considered acceptable by DPR based on the FIFRA guidelines.

1 II.D.5. Oral-Dog

2 Four beagle dogs/sex/dose were administered chloropicrin (99% pure) in capsules at 0
3 (corn oil), 0.1, 1.0 and 5.0 mg/kg for 1 year (Wisler, 1994). There was no treatment-related
4 effect on mortality, food consumption, ophthalmology, urology, gross pathology or
5 histopathology. There was an increase in ptyalism, food-like or frothy emesis, and soft
6 stool/diarrhea in dogs at 5.0 mg/kg/day. Discolored feces were observed in half the animals of
7 both sexes during the last 13 weeks of the study. Food-like emesis was also observed with
8 increased frequency at 1.0 mg/kg/day. The mean body weights of males at 5.0 mg/kg/day were
9 reduced (~10%) throughout the study compared to controls. There was a significant decrease in
10 the mean corpuscular volume and mean corpuscular hemoglobin in both sexes at 5.0 mg/kg/day
11 throughout the study. A decrease in aspartate aminotransferase, total protein and albumin were
12 also seen in both sexes at 5.0 mg/kg/day throughout the study. In addition, the calcium levels
13 were reduced during the last 6 months of the study. The investigators suggested that the
14 diarrhea/soft stools, and reduced body weights in conjunction with the clinical pathological
15 changes at 5.0 mg/kg /day were indicative of an enterogenous malabsorption condition. The
16 NOEL was 1.0 mg/kg/day based on the clinical signs, reduced body weights (males) and clinical
17 pathology changes. This study was considered acceptable to DPR based on FIFRA guidelines.

18 II. E. GENOTOXICITY

19 **Summary:** Chloropicrin tested positive in eight reverse mutation assays with
20 *Salmonella typhimurium* strains with and without activation; however, only one of these studies
21 met FIFRA guidelines. One study found that the addition of GSH alone also converted
22 chloropicrin to a mutagenic metabolite either through reductive dechlorination or through the
23 formation of a reactive intermediate GSH conjugate, such as $GSCCl_2NO_2$ or $GSCHCINO_2$. In
24 addition, chloropicrin tested positive in a reverse mutation assay with *Escherichia coli* WP2 *hcr*.
25 Chloropicrin was negative in a mouse lymphoma assay which met FIFRA guidelines. Results
26 from the sex-linked recessive lethal assay were mixed. One study reported it was weakly
27 mutagenic, but another reported it was negative. It is unclear if either of these published studies
28 met FIFRA guidelines. Results from chromosomal aberrations assays were mixed. One study,
29 which met FIFRA guidelines, reported that chloropicrin induced chromosomal aberrations in
30 Chinese hamster ovary cells without S-9. In a published report, no increase in chromosomal
31 aberrations was seen in human lymphocytes with or without S-9; however, an increase in sister
32 chromatid exchanges was observed with and without S-9. No increase in micronuclei was seen
33 in the peripheral blood erythrocytes of newt larvae exposed to chloropicrin for 12-days. There
34 was also no increase in unscheduled DNA synthesis in rat primary hepatocytes. This study met
35 FIFRA guidelines. However, in a published report, an increase in primary DNA damage was
36 observed in *E. coli* with S-9 in a SOS chromotest.

37 II.E.1. Gene Mutation

38 Chloropicrin (99.5%) was tested in a reverse mutation assay with *S. typhimurium* strains
39 TA98, TA100, TA1535, TA1537 and TA1538 with and without S-9 up to 1,000 µg/plate in the
40 initial assay and up to 500 µg/plate in the confirmatory assay (San and Wagner, 1990). An
41 increase in revertant colonies with seen in strain TA98 with S-9. TA 1537 and TA1538 were

1 also positive without S-9. DPR found this study acceptable based on FIFRA guidelines. Moriya
2 *et al* (1983) reported that chloropicrin (purity not stated) was mutagenic using the reverse
3 mutation assay *S. typhimurium* TA98 (no S-9) and TA 100 (with S-9) and *E. coli* WP2 *hcr*.
4 Doses were reported to be tested up to 5,000 µg/plate, unless toxic to bacteria. Insufficient
5 information was provided in this published report to determine if this study was conducted in
6 accordance with FIFRA guidelines. There were other published reports of positive responses in
7 the reverse mutation assay with *S. typhimurium*. Shirasu *et al.* (1982) reported an increase in
8 mutation frequency with TA100, but only with S-9. Haworth *et al.* (1983) also reported an
9 increase in mutation frequency with TA100 both with and without S-9. Kawai *et al.* (1987)
10 observed an increase in mutation frequency with *S. typhimurium* TA100 and 98 strains (+ S9
11 only) and *E. coli* WP2uvrA/pKM101 strain (+/- S9). In a modified Ames assay with *S.*
12 *typhimurium* strains TA98 and TA1538, Sariaslani and Stahl (1990) found an increase in
13 mutation frequency after activation with *Streptomyces griseus* cells. In an another adaptation of
14 the reverse mutation assay with *S. typhimurium* TA100 in liquid medium, Giller *et al.* (1995)
15 observed a significant increase in wells containing prototrophic revertants with S-9. Schneider
16 *et al.* (1999) reported that chloropicrin was toxic to *S. typhimurium* TA100 at 500 nmol/plate, but
17 not mutagenic. Chloropicrin became mutagenic, but not toxic at this concentration with the
18 addition of S-9 or 1-2 molar equivalents of glutathione (GSH). The dechlorination products,
19 CHCl_2NO_2 and CH_2ClNO_2 , were also mutagenic with and without GSH. The investigators
20 suggested that the mutagenicity of chloropicrin may be due to its reductive dechlorination or
21 from a reactive intermediate GSH conjugate, such as $\text{GSCCl}_2\text{NO}_2$ or GSCHClNO_2 .

22 A forward mutation assay was conducted in which L5178Y TK +/- mouse lymphoma
23 cells were incubated with chloropicrin (99.5% pure) up to 0.5 nl/ml without S-9 and up to 21
24 nl/ml with S-9 in the initial trial (San and Sigler, 1990). In the confirmatory assay, chloropicrin
25 was tested up to 0.75 nl/ml without S-9 and up to 16 nl/ml with S-9. No increase in forward
26 mutation frequency was reported. This study was acceptable to DPR based on FIFRA
27 guidelines.

28 A sex-linked recessive lethal assay was conducted in which *Drosophila melanogaster*
29 Canton-S wild-type males were fed chloropicrin (91% pure) at 0 and 150 ppm for 4 hours or
30 injected at 0 and 100 ppm (Valencia *et al.*, 1985). Males were then mated with 3 harems of *Basc*
31 virgin females to produce 3 broods of 3, 2, and 2, days. To reduce the chances of recovering
32 several lethals from the same male, no more than 40 F₁ females were mated individually from
33 each brood of each male. Therefore, no more than 120 chromosomes were tested from each P₁
34 male. F₂ cultures were scored as lethal if the number of wild-type males recovered was less than
35 5% of the number of *Basc* males (or *Basc*/+ females). Chloropicrin was negative when
36 administered by injection, but gave equivocal results when administered in the feed. Insufficient
37 information was provided in this published report to determine if this study was conducted in
38 accordance with FIFRA guidelines.

39 Auerbach (1950) evaluated both mustard gas and chloropicrin for their ability to induce
40 sex-linked recessive lethality in *Drosophila melanogaster* to confirm that the mutagenicity of
41 mustard gas is not related to its ability to react with -SH groups. Chloropicrin is also an
42 effective blocker of -SH groups. A series of three tests were conducted. In the first test, young
43 males were exposed to chloropicrin vapor (purity and dose level not reported) for as long as they
44 could tolerate (2-3 minutes). Survivors were then tested for sex-linked lethals. Only 1 lethal

1 was found out of 1318 X chromosomes. Since exposure may have been too short to ensure
2 penetration to the germ cells, chloropicrin was mixed with liquid paraffin in the second test. The
3 tolerance threshold was shifted by altering the proportion of the two fluids. Only 2 lethals out of
4 463 X chromosomes were found after exposure for 6 to 9 minutes in the second test. The males
5 were exposed 5 to 7 minutes to a mixture of chloropicrin and liquid paraffin in a third test and
6 then mated with a succession of virgin females every 3-4 days. Only 7 out of 4454 X
7 chromosomes were lethals. The incidence of lethals was no greater than usually found in
8 untreated controls. Therefore, it was concluded that the blockage of -SH groups is not
9 associated with its mutagenic activity.

10 II.E.2. Chromosome Aberrations

11 A chromosome aberration assay was conducted in which Chinese hamster ovary (CHO)
12 cells were exposed to chloropicrin (99.5% pure) at concentrations up to 0.003 $\mu\text{l/ml}$ without S-9
13 and up to 0.006 $\mu\text{l/ml}$ with S-9 in the initial assay (Putman and Morris, 1990). In the first
14 confirmatory assay, concentrations up to 0.002 $\mu\text{l/ml}$ without S-9 and 0.006 $\mu\text{l/ml}$ with S-9 were
15 tested. A second confirmatory assay was conducted to confirm the positive findings without
16 activation at concentrations up to 0.001 $\mu\text{l/ml}$. A significant increase in chromosomal aberrations
17 was seen in both confirmatory assays without S-9 in the presence of some cytotoxicity as
18 determined by a decrease in the mitotic index. A significant increase in chromosomal
19 aberrations was also seen in the initial assay with S-9, but the increase was not dose-responsive
20 or reproducible. This study was found acceptable to DPR based on the FIFRA guidelines. Garry
21 *et al.* (1990) reported no increase in chromosome aberrations in cultured human lymphocytes
22 with or without S-9 using an unusual protocol where the cells were exposed to chloropicrin $\frac{1}{2}$
23 hour before stimulation with PHA rather than after stimulation. However, they did report an
24 increase in sister chromatid exchanges with or without S-9. There was insufficient information
25 available in this published report to determine if the study met FIFRA guidelines. Giller *et al.*
26 (1995) conducted an *in vivo* micronucleus assay using *Pleurodeles waltl* newt larvae. After a 12-
27 day exposure peripheral blood erythrocytes were evaluated for clastogenic or spindle poison
28 activity. No increase in micronuclei was observed with this assay. This was a non-guideline
29 type study.

30 II.E.3. Other Genotoxic Effects

31 Chloropicrin (99.5% pure) was tested in an unscheduled DNA synthesis (UDS) assay
32 with rat primary hepatocytes at concentrations up to 0.009 $\mu\text{l/ml}$ (Curren, 1990). No increase in
33 UDS was observed in either the initial assay or the confirmatory assay. DPR found this study
34 acceptable based on FIFRA guidelines. Giller *et al.* (1995) also conducted a SOS chromotest
35 which is an *in vitro* assay which detects primary DNA damage in *Escherichia coli*. Chloropicrin
36 was tested positive with S-9 in this assay. There are no FIFRA guidelines for this type of study.

37 II.F. REPRODUCTIVE TOXICITY

38 **Summary:** One range-finding and one main study were conducted to evaluate the
39 reproductive toxicity of chloropicrin. In the range-finding study, only one generation was
40 exposed to chloropicrin vapors while the main study exposed 2 generations to chloropicrin

1 vapors. The main study met FIFRA guidelines. The only reproductive effect seen was in the
2 range finding study in which there was a reduced number of implantation sites at 2 ppm. No
3 adverse effects were seen in pups in either study. The only other adverse effects reported were
4 reductions in body weights and food consumption, and macroscopic and microscopic lesions in
5 the lungs of adults. The reproductive NOEL was equal to or greater than 1.5 ppm (10.09 mg/m³;
6 HEC - 0.61 ppm), the highest dose tested in the main study. The parental NOEL was 0.5 ppm
7 (3.36 mg/m³; HEC - 0.20 ppm) based on body weight reductions and pathological lesions in the
8 lungs in the main study.

9 II.F.1. Inhalation-Rat

10 Groups of 10 CRL:CD® VAF/Plus® rats/sex/dose were exposed (whole body) to
11 chloropicrin (purity >99%) vapors at 0, 0.4, 1.0 or 2.0 ppm (0, 2.69, 6.72 or 13.45 mg/m³; HEC¹³
12 - 0, 0.16, 0.41 or 0.81 ppm) for 6 hrs/day beginning 2 weeks prior to mating and continuing
13 through gestation day 20 (Denny, 1996). There were no deaths or clinical signs. Significant
14 reductions in body weights and food consumption were seen at 2.0 ppm. All the reproductive
15 parameters were normal, except the average litter size was reduced at 2.0 ppm. This appears to
16 be due to a reduced number of implantation sites. The parental NOEL was 1.0 ppm (6.72
17 mg/m³; HEC - 0.41 ppm) based on the reduced body weights and food consumption. The
18 reproductive NOEL was also 1.0 ppm based on the reduced number of implantation sites at 2.0
19 ppm. This range-finding study was considered supplemental by DPR toxicologists.

20 Twenty-six Charles River Crl:CD® VAF/Plus® rats/sex/dose were exposed (whole body)
21 to chloropicrin (99% pure) vapors at 0, 0.5, 1.0 and 1.5 ppm (0, 3.36, 6.72 or 10.09 mg/m³;
22 HEC¹⁴ - 0, 0.20, 0.41 or 0.61 ppm) for 6 hours/day, 7 days/week for 2 generations (Schardein,
23 1994). Dams were not exposed from gestation day 21 to lactation day 4. On lactation days 4-21,
24 only the dams were exposed. The F₁ parental generation was exposed from 28 days of age to a
25 minimum of 83 days prior to mating. In the F₀ generation, one control female, one female at 0.5
26 ppm, two animals (1 M & 1 F) at 1.0 ppm and 4 animals (2 M & 2 F) at 1.5 ppm died prior to
27 scheduled sacrifices, but none of the deaths were considered treatment-related by the study
28 investigator. There were no deaths in the F₁ animals. There was no treatment-related effect on
29 clinical signs in either generation. Transient significant reductions in mean body weights were
30 seen in both sexes of both generations at 1.0 and/or 1.5 ppm. F₁ females at 1.5 ppm had
31 significantly lower food consumption during gestation. There was no treatment-related effect on
32 reproductive parameters including fertility indices, gestation length, and spermatogenesis. No
33 treatment-related effect on pup survival, growth and gross pathological findings. A slight
34 increase in macroscopic pathological lesions was found in the lungs of females (primarily F₀) at
35 1.0 and 1.5 ppm, including red discoloration, tan foci, white foci, nodule and adhesions (Table
36 11). The increase in these lesions was insufficient to reach statistical significance by either trend
37 analysis or pair-wise comparison with controls. There was also a slight dose-related increase in
38 the incidence and severity of acute/subacute inflammation in the lungs of F₀ females; however,
39 this increase also was not statistically significant. Despite the lack of statistical significance,
40 these lesions were considered treatment-related by DPR. Consequently, the parental NOEL for

13 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 7 days/week. E_h = 24 hours/day, 7 days/week.

14 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 7 days/week. E_h = 24 hours/day, 7 days/week.

Table 11. Possible Treatment-Related Pathological Lesions in the Lungs of Female Rats Exposed to Chloropicrin Vapors for Two Generations^a

Lesion	Treatment Level (ppm)			
	0	0.5	1.0	1.5
Macroscopic (F₀)				
Red discoloration	1/26 (4%)	1/26 (4%)	1/26 (4%)	2/26 (8%)
Tan foci	0/26 (0%)	1/26 (4%)	1/26 (4%)	1/26 (4%)
White foci	0/26 (0%)	0/26 (0%)	1/26 (4%)	0/26 (0%)
Nodule	0/26 (0%)	0/26 (0%)	1/26 (4%)	1/26 (4%)
Adhesions	0/26 (0%)	0/26 (0%)	1/26 (4%)	0/26 (0%)
Microscopic (F₀)				
Acute/subacute inflammation	7/16 (44%)	10/21 (48%)	12/24 (50%)	11/18 (61%)
Macroscopic (F₁)				
Yellow foci	1/26 (4%)	0/26 (0%)	2/26 (8%)	3/26 (12%)
Adhesions	0/26 (0%)	0/26 (0%)	0/26 (0%)	1/26 (4%)

^a Schardein, 1994

the study was set at 0.5 ppm (3.36 mg/m³; HEC - 0.20 ppm) based on the body weight changes in both sexes and pathological lesions in the lungs of females. The reproductive NOEL for the study was equal to or greater than 1.5 ppm (10.09 mg/m³; HEC - 0.61 ppm) based on the lack of any reproductive effects in the adults or developmental effects in the pups at any dose level tested. This study was considered acceptable to DPR based on the FIFRA guidelines.

II.G. DEVELOPMENTAL TOXICITY

Summary: Two developmental toxicity studies were available for chloropicrin, one in rats and one in rabbits. Both exposed animals by the inhalation route. Maternal toxicity was observed in both studies including mortalities, clinical signs, reduced body weights and food consumption, and red discoloration and edema of lungs. The lowest maternal NOEL was 0.4 ppm (2.7 mg/m³; HEC_{8hr} - 0.27 ppm) based on mortalities, nasal discharge, reduced body weights and food consumption, and red discoloration of the lungs in rabbits. Developmental effects were seen including miscellaneous visceral and skeletal variations, increased pre-implantation losses, late-term abortions and reduced fetal weights. The lowest developmental NOEL was also 0.4 ppm based on skeletal variations in both rats and rabbits.

1 II.G.1. Inhalation-Rat

2 Schardein (1993) exposed (whole-body) 30 pregnant female rats/dose to chloropicrin
3 (99% pure) vapors at 0, 0.4, 1.2 or 3.5 ppm (analytical; 0, 2.7, 8.1 or 23.5mg/m³; HEC¹⁵ - 0, 0.16,
4 0.49 or 1.42 ppm) for 6 hrs/day from gestation days 6-15. Four deaths were observed at 3.5 ppm
5 between gestation days 14 and 18. At necropsy, these four animals had red discolored lungs. No
6 exposure-related necropsy findings were seen in the survivors. In addition, labored breathing,
7 emaciation, coldness to touch, reduced activity, and red nasal stains were seen at 3.5 ppm
8 primarily after gestation day 12. Emaciation, however, was observed as early as gestation day 8.
9 In addition, animals at 1.2 and 3.5 ppm had significantly reduced mean body weights (-3% and
10 -9%, respectively), body weight changes (-7% and -27%, respectively) and mean food
11 consumption (-16% and -47%, respectively) during gestation days 6-9. Fetal body weights
12 were also reduced (-6%) at 3.5 ppm. There was an increase in several skeletal variations
13 (reduced ossification of skull bone, less than 13 rib pairs, 14th rudimentary ribs, bent ribs,
14 unossified 5th and 6th sternbrae) at 1.2 and 3.5 ppm. However, the difference was only
15 statistically significant at 3.5 ppm when the total number of fetuses with developmental
16 variations was combined. The developmental NOEL was 0.4 ppm (2.7 mg/m³; HEC_{8hr} - 0.49
17 ppm) based on the skeletal variations in fetuses. The maternal NOEL was also 0.4 ppm based on
18 clinical signs, reduced body weight, body weight gains, and food consumption. DPR found this
19 study acceptable based on FIFRA guidelines.

20 II.G.2. Inhalation-Rabbit

21 Twenty pregnant female rabbits/dose were exposed (whole body) to chloropicrin (99%
22 pure) vapors at 0, 0.4, 1.2, or 2.0 ppm (analytical; 0, 2.7, 8.1 or 13.4 mg/m³; HEC¹⁶ - 0, 0.092,
23 0.27 or 0.46 ppm) for 6 hrs/day during gestation days 7 to 20 (York, 1993). Deaths occurred at
24 1.2 ppm (2 deaths on gestation days 9 and 19) and 2.0 ppm (10 deaths on gestation days 9, 10,
25 11, and 19). All of the animals that died had red discoloration of the lungs at necropsy. In
26 addition, 1 animal at 1.2 ppm (died gestation day 19) and 7 animals at 2.0 ppm (died gestation
27 days 9-11, and 19) had edema of the lungs. Various clinical signs indicative of sensory or
28 respiratory irritation were seen at 1.2 and/or 2.0 ppm, including gasping, labored breathing,
29 increased salivation, clear nasal discharge, red area around eyes/eyelids, and excessive
30 lacrimation. The nasal discharge appears to be one of the more sensitive endpoints with an onset
31 between gestation days 7 and 11 in 7 of 18 animals at 1.2 ppm. Animals at 1.2 and 2.0 ppm had
32 reduced body weights (-5% and -8%, respectively) and food consumption (-49% and -79%)
33 from gestation days 7 to 13. One rabbit at 1.2 ppm and 2 rabbits at 2.0 ppm had late-term
34 abortions between gestation days 25-29. There was also an increase in pre- (13%) and post-
35 implantation losses (214%) and a reduction in fetal body weights (8.4%) at 2.0 ppm. The post-
36 implantation losses were within the historical control and, therefore, were not considered
37 treatment related by the study investigators. Several developmental variations were observed in
38 the fetuses including visceral (left carotid artery arising from the innominate artery) and skeletal
39 variations (unossified hyoid body and unossified tail) which were considered toxicologically

15 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 7 days/week. E_h = 24 hours/day, 7 days/week.

16 HEC = ppm x RR_a/RR_h x E_a/E_h. RR_a = 0.54 m³/kg/day for the rabbit (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day, 7 days/week. E_h = 24 hours/day, 7 days/week..

1 significant at 2.0 ppm. The developmental NOEL was 1.2 ppm (2.7 mg/m³; HEC_{8hr} - 0.27 ppm)
2 based on the increased developmental variations, increased pre- and post-implantation losses,
3 late-term abortions and reduced fetal body weights. The maternal NOEL was 0.4 ppm based on
4 mortalities, nasal discharge, reductions in body weights and food consumption, abortions and red
5 discoloration and edema in the lung. This study was acceptable to DPR based on FIFRA
6 guidelines.

1 **III. RISK ASSESSMENT**

2 **III.A. HAZARD IDENTIFICATION**

3 **III.A.1. Acute Toxicity**

4
5 For ease of comparison with other studies and with the exposure dosages, the air
6 concentrations in the Risk Assessment and Risk Appraisal sections are expressed in ppb or
7 $\mu\text{g}/\text{m}^3$. The acute toxicity of chloropicrin was first characterized around 1920 in studies in dogs
8 (Underhill, 1920; Lambert and Jackson, 1920). More recently, several LC_{50} studies were
9 conducted in rats (Harton and Rawl, 1976; Yoshida *et al.*, 1987a & 1991; Hoffman, 1999a). The
10 reported LC_{50} values ranged from 6,600 ppb to 25,500 ppb (44,000 to 171,000 $\mu\text{g}/\text{m}^3$) depending
11 on the duration of exposure and whether it was a whole body or nose only exposure. The LC_{50}
12 values also varied depending on how long the observation period was after dosing. Deaths
13 occurred in two phases, either within 24 hours or after 8 to 10 days. The later deaths were
14 attributed to respiratory infection. The clinical signs were primarily respiratory, although eye
15 irritation, lacrimation and eye closure were also noted. Numerous gross and histopathological
16 lesions were observed throughout the respiratory tract. Two of the 4-hour LC_{50} studies had
17 sufficient information to establish a LOEL, but a NOEL was not observed either study (Table
18 12).

19 Chloropicrin produces sensory irritation of the eyes, nose and throat. Sensory irritation is
20 caused by the stimulation of unspecialized free nerve endings of the afferent trigeminal nerve
21 located in the corneal, nasal and oral mucosa (Kane *et al.*, 1979). Stimulation of the trigeminal
22 nerve results in a burning or pungent sensation and numerous physiological reflex responses,
23 including a reduction in respiratory rate. Based on earlier research by these investigators they
24 were able to show that a reduction in the respiratory rate of mice was a good predictor of sensory
25 irritation in man and shows a concentration-response relationship. The RD_{50} (concentration that
26 caused a 50% reduction in respiratory rate) is used to compare the relative potency of various
27 irritants. They proposed that the RD_{50} would be an intolerable concentration in man. The RD_{50}
28 of chloropicrin was estimated in two studies with mice. The RD_{50} values ranged from 2,340 ppb
29 for a 30 minute exposure (Hoffman, 1999b) to 7,980 ppb for a 10 minute exposure (Kane *et al.*,
30 1979). Due to differences in exposure duration and breathing rates for different species, the dose
31 levels in the various animal studies were also expressed as human equivalent concentrations
32 (HECs) for ease of comparison. DPR converted the dose levels from the animal studies to
33 human equivalent concentrations (HECs) as follows:

34
$$\text{HEC}(\text{ppb}) = \text{Dose}(\text{ppb}) \times \frac{\text{RR}_a (\text{m}^3/\text{kg}/\text{day})}{\text{RR}_h (\text{m}^3/\text{kg}/\text{day})} \times \frac{E_a (\text{hrs}/\text{day})}{E_h (\text{hrs}/\text{day})}$$

35
$$\text{HEC}(\mu\text{g}/\text{m}^3) = \text{HEC}(\text{ppb}) \times \frac{M.\text{Wt.}(164.38\text{g})}{M.\text{Vol.}(24.45\text{L} @ 25^\circ\text{C})}$$

36 where RR_a is the respiratory rate in animals, RR_h is the respiratory rate in humans, E_a is the
37 exposure duration in animals, and E_h is the exposure duration in humans, assuming a default
38 respiratory rate of 0.28, 0.59, 0.54, 0.96 and 1.8 $\text{m}^3/\text{kg}/\text{day}$ for adults, children, rabbits, rats, and
39 mice, respectively. Note that DPR's HEC calculation is different from U.S. EPA's HEC
40 calculation which is discussed in more detail in the Risk Appraisal section (Section IV.A.). The

Table 12. Acute Effects of Chloropicrin and Their Respective NOELs and LOELs

Species	Exposure	Effect	NOEL	LOEL	Ref. ^b
			ppb (HEC ^a)		
Inhalation					
Rat ^e	Single, 4-hr, WB ^f	↓ Body weight, clinical signs, histopathological lesions in respiratory tract, gastric gaseous distention	-----	8,800 (7,160-8 hr) (2,390-24 hr)	1
Rat ^e	Single, 4-hr, WB	↓ Body weight, clinical signs, histopathological lesions in respiratory tract		10,500 (17,100-8 hr) (5,690-24 hr)	2
Mouse ^c	Single, 10 min, HO ^d	50% depression in respiratory rate	-----	7,980 (4,060-1 hr)	3
Mouse ^c	Single, 30 min, HO	30% depression in respiratory rate	-----	990 (1,510-1 hr)	4
Mouse	6 hrs/day, 5 days, WB	↓ Body weight, nasal discharge, gaseous distention of stomach, histopathological lesions in olfactory and respiratory epithelium	-----	7,980 (18,300-8 hr) (6,090-24 hr)	5
Rat ^g	6 hrs/day, 10 days, WB	Maternal: Emaciation (onset day 2), ↓ body weight and food consumption (days 0-3) Fetal: Skeletal variations	400 (490-8 hr) (160-24 hr)	1,200 (1,460-8 hr) (490-24 hr)	6*
Rabbit ^g	6 hrs/day, 14 days, WB	Maternal: Mortalities (days 2-4), nasal discharge (onset day 0), ↓ body weights & food consumption (days 0-6), red discoloration & edema in lungs	400 (270-8 hr) (92-24 hr)	1,200 (820-8 hr) (270-24 hr)	7*
Human	Single, 20 min, WB	Ocular irritation	50 ^h	75	8
	Single, 1 hr, WB	Ocular irritation ↑ NO in expired nasal air	26 ^h 75 ^h	100	

a HEC (Human Equivalent Concentration) = ppb x RR_a/RR_h x E_a/E_h. RR_a = respiratory rate in animals which was assumed to be 1.8, 0.96 and 0.54 m³/kg/day for the mouse, rat and rabbit, respectively (Zielhuis and van der Kreek, 1979). RR_h = respiratory rate in humans which was assumed to be 0.59 m³/kg/day for a child (DPR, 2000). E_a = exposure duration for animals. E_h = exposure duration for humans as indicated.

b References: 1. Yoshida *et al.*, 1987a; 2. Hoffman, 1999a; 3. Kane *et al.*, 1979; 4. Hoffman, 1999b; 5. Buckley *et al.*, 1984; 6. Schardein, 1993; 7. York, 1993; 8. Cain, 2004.

c RD₅₀ study designed to determine the concentration at which the respiratory rate is depressed by 50% as an indication of sensory irritation.

d HO = head only exposure

e LC₅₀ study

f WB = whole body exposure

g Developmental toxicity study: All fetal effects were considered acute effects; however, only maternal effects observed within the first few days of exposure were considered acute exposure.

h The NOEL was set at the BMDL₁₀ using the hybrid approach developed by Crump (1995). The multiplier, k, of the standard deviation was set to 0.61 which corresponded to the P₀ and π set to 0.05 and 0.1, respectively. See the Risk Appraisal section (Section IV.A) of this document for additional discussion of BMD analysis of this study.

* Acceptable study based on FIFRA guidelines

1 RD₅₀ values for these two studies expressed as 1-hr HECs¹⁷ were 3,570 ppb for the Hoffman
2 study and 4,060 ppb for the Kane *et al.* study. A NOEL was not identified in either of these
3 studies due to insufficient information and/or high exposure levels; however, LOELs based on
4 the respiratory depression were included in Table 12. A 30% depression in respiratory rate was
5 observed at the lowest dose level tested, 990 ppb (HEC_{1hr} - 1,510 ppb) by Hoffman (1999b).
6 Buckley *et al.* (1984) evaluated the respiratory tract lesions in mice caused by chloropicrin when
7 exposed at 7,980 ppb (10-min. RD₅₀) for 6 hrs/day for 5 days (HEC_{8hr} - 18,300 ppb). In addition
8 to numerous histopathological lesions in the respiratory and olfactory epithelium, the mice had
9 reduced body weights, nasal discharge and gaseous distension of the abdomen. Since only one
10 concentration was tested in this study, a NOEL was not observed, but the LOEL for this study is
11 included in Table 12.

12 Two developmental toxicity studies submitted to DPR by registrants were useful for
13 identifying acute NOELs for chloropicrin (Table 12). Maternal effects seen within the first few
14 days of exposure and all fetal effects were considered signs of acute toxicity. Death, labored
15 breathing, emaciation, coldness to the touch, reduced activity, red nasal stains, reduced body
16 weights and food consumption were seen in the dams, but most of these effects were not
17 considered acute since they occurred after 6 days of exposure. The NOEL for acute toxicity in
18 pregnant rats was 400 ppb (HEC_{8hr}¹⁸ - 490 ppb) based on emaciation (onset day 2), reduced body
19 weight, body weight gains, and food consumption (days 0-3) (Schardein, 1993). Fetal effects in
20 rats included reduced fetal weights and various skeletal variations (reduced ossification of skull
21 bone, less than 13 rib pairs, 14th rudimentary ribs, bent ribs, unossified 5th and 6th sternbrae).
22 The NOEL for fetal effects in the rat study was also 400 ppb based on skeletal variations.
23 Maternal effects in rabbits included death, red discoloration and edema in lungs of rabbits that
24 died, clinical signs of sensory or respiratory irritation (gasping, labored breathing, increased
25 salivation, clear nasal discharge, red area around eyes/eyelids, excessive lacrimation), reduced
26 body weights and food consumption (York, 1993). The acute NOEL in pregnant rabbits was 400
27 ppb (HEC_{8hr}¹⁹ - 270 ppb) based on mortalities, nasal discharge, reductions in body weights and
28 food consumption, and red discoloration and edema in the lung. Developmental effects in
29 rabbits included increased pre- and post-implantation losses, late-term abortions, reduced fetal
30 body weights, visceral (left carotid arising from the innominate) and skeletal variations
31 (unossified hyoid body and unossified tail). The acute NOEL in rabbit fetuses was 1,200 ppb
32 based on the increased developmental variations. Both of the developmental toxicity studies met
33 FIFRA guidelines.

34 Although chloropicrin was used as a war gas in World War I, it was difficult to
35 distinguish the effects of chloropicrin from other war gases since it was usually mixed with
36 other, more lethal gases (Berghoff, 1919). In comparing chloropicrin to other lethal war gases
37 like chlorine gas and phosgene, early investigators described the respiratory effects of
38 chloropicrin to be intermediate in onset and primarily affecting small to medium bronchi.

17 HEC = ppb x RR_a/RR_h x E_a/E_h. RR_a = 1.8 m³/kg/day for the mouse (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 30 minutes/day. E_h = 60 minutes/day.

18 HEC = ppb x RR_a/RR_h x E_a/E_h. RR_a = 0.96 m³/kg/day for the rat (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day. E_h = 8 hours/day.

19 HEC = ppb x RR_a/RR_h x E_a/E_h. RR_a = 0.54 m³/kg/day for the rabbit (Zielhuis and van der Kreek, 1979). RR_h = 0.59 m³/kg/day for a child (DPR, 2000). E_a = 6 hours/day. E_h = 8 hours/day.

1 Accidents in gas manufacturing plants during World War I were more useful in identifying
2 effects (Lambert and Jackson, 1920). Immediate symptoms included cough, nausea, and
3 vomiting. Higher or prolonged exposures resulted in dyspnea, cyanosis, and weakness. Death
4 usually occurred within a few hours, but even if symptoms were not severe, death could occur 3-
5 4 days later due to respiratory infection. Other complications included nephritis. Chloropicrin
6 was fatal at approximately 300,000 and 120,000 ppb after 10 and 30 minutes of exposure,
7 respectively (Prentiss, 1937). Fries and West (1921) reported the eyes were very sensitive to
8 chloropicrin where concentrations above 25,000 ppb resulted in involuntary closing of the eyes
9 so rapidly the time lapsed could not be measured. Below 1-2,000 ppb, the eye did not close, but
10 considerable blinking occurred. Prentiss (1937) reported that lacrimation occurred as low as
11 300 ppb, but no data supporting this statement were presented. There have been other more
12 recent accidental poisonings involving chloropicrin; however, there was generally inadequate
13 information on the exposure level that produced the signs and/or symptoms which were
14 primarily related to eye and respiratory irritation. Therefore, these reports were not considered
15 very reliable for estimating acceptable exposure levels for chloropicrin in humans.

16 A sensory irritation study was conducted recently with human volunteers which consisted
17 of three phases (Cain, 2004). The first phase identified the median odor threshold for
18 chloropicrin after a 5 second exposure at 700 ppb. The median threshold for detection by eye
19 irritation after a 25 second exposure was 900 ppb. The median threshold for detection by nasal
20 irritation after 5 second exposure was greater than 1200 ppb, the highest level tested. In phase 2,
21 a NOEL for ocular irritation was established at 50 ppb with a 20-minute exposure in a walk-in
22 chamber. No nasal or throat irritation was observed up to 150 ppb. In phase 3, the NOEL for
23 ocular irritation appears to be less than 100 ppb after a 1-hour exposure in a walk-in chamber
24 based on mild irritation observed at the lowest dose level tested. No nasal or throat irritation was
25 reported in this phase, but increased concentration of nitric oxide (NO) in expired nasal air (an
26 indication of inflammation) at 100 and 150 ppb and decreased nasal airflow at 150 ppb suggests
27 some subtle upper respiratory changes. There are no FIFRA guidelines for human studies. This
28 study, however, was conducted in accordance with Good Laboratory Practice regulations and
29 was approved by the Internal Review Board at the University of California, San Diego, which
30 reviewed the protocol and informed consent forms signed by the subjects. In addition, the study
31 protocol was reviewed prior to the study start by a biostatistician, Dr. Robert Sielken, to ensure
32 there was sufficient statistical power.

33 A benchmark dose (BMD) analysis was performed to identify a NOEL for phase 3. Only
34 the average scores for the plateau period (minutes 31-55) were used since this reflected the most
35 severe response during the exposure. U.S. EPA's Bench Mark Dose Software (BMDS, version
36 1.3.2) was used to calculate the lower limit on the BMD at the 10% response level (BMDL₁₀). A
37 10% response level was selected instead of the default 5% response level because the endpoint
38 being considered was mild and, therefore, the level of protection needed was not considered to
39 be as great. A hybrid approach was used in which the benchmark response (BMR) was defined
40 as a change of the mean response at a specified multiplier of the standard deviation (Crump,
41 1995). The multiplier, k , was set to 0.61 which corresponded to a background risk, P_0 , of 0.05
42 and a risk above the background, π , of 0.10. Four models for continuous data were available
43 with the BMDS software. The Hill model could not be run with these data because it required
44 more treatment groups. The Akaike's Information Criterion (AIC) scores were provided for
45 each model which is an indication of fit. In general, the lower the AIC value, the better the

1 model fits the data. However, sometimes models with higher AIC scores have better fits
2 visually, especially around the BMD and BMDL. The two models with the lowest AICs and
3 best fit visually with this data set were the polynomial and power models with identical AIC
4 values. Therefore, the NOEL was set at the average of the BMDLs for these two models, 26 ppb
5 ($170 \mu\text{g}/\text{m}^3$).

6 The same approach was used for estimating BMDLs for the increase in NO in expired
7 nasal air. The difference in the NO in expired nasal air was averaged for the 4 days of exposure.
8 The model with the lowest AIC was the linear model with a corresponding BMDL_{10} of 75 ppb
9 ($500 \mu\text{g}/\text{m}^3$). This BMDL_{10} was selected as the NOEL for this endpoint. The BMD analysis of
10 these two endpoints indicates that the ocular irritation is the more sensitive endpoint; therefore,
11 the BMDL for ocular irritation of 26 ppb was selected as the critical NOEL for evaluating acute
12 1-hr bystander exposure to chloropicrin.

13 There is evidence from this study and in the open literature that Haber's Law ($c \times t = k$)
14 may not apply to sensory irritation. The plateau in the sensory irritation with the 1 hour
15 exposure in the human study for chloropicrin suggests that concentration is more important than
16 time in the severity of the effects observed with exposure. This appears to be true with other
17 sensory irritants and Shusterman *et al.* (2006) suggests that a power equation ($c^n \times t = k$) rather
18 than Haber's Law better defines the severity of the endpoint. They not only noted that the
19 severity of effects plateaued with time, but frequently the severity decreased after awhile. This
20 appeared to be the case with chloropicrin with a slight decrease in the average scores for ocular
21 irritation from minutes 55 to 60. However, there was insufficient information to predict the
22 severity beyond 1 hr. Therefore, rather than estimate an 8-hr or 24-hr NOEL from the 1-hr
23 exposure in humans, the developmental toxicity study in rabbits was selected as the definitive
24 study to evaluate the 8-hr and 24-hr bystander exposure to chloropicrin (York, 1993). The
25 critical NOEL was 400 ppb ($270 \mu\text{g}/\text{m}^3$) based on maternal effects observed within the first few
26 days of exposure including nasal discharge, reduced food consumption and body weights and
27 mortalities associated with red discolored lungs. Since these effects appear to involve more than
28 sensory irritation, Haber's Law was applied. The critical 8-hr and 24-hr NOELs were estimated
29 to be 300 ppb ($2,000 \mu\text{g}/\text{m}^3$) and 100 ppb ($670 \mu\text{g}/\text{m}^3$), respectively. The critical 8-hr HECs were
30 270 ppb ($1,800 \mu\text{g}/\text{m}^3$) and 580 ppb ($3,900 \mu\text{g}/\text{m}^3$) for children and adults, respectively. The
31 critical 24-hr HECs were 92 ppb ($610 \mu\text{g}/\text{m}^3$) for children and 190 ppb ($1,300 \mu\text{g}/\text{m}^3$) for adults.

32 III.A.2. Subchronic Toxicity

33
34 The effects observed in laboratory animals after subchronic exposure to chloropicrin are
35 summarized in Table 13. Clinical signs observed in 13-week inhalation studies included eye
36 closure, reddened eyes, labored respiration, reduced activity, emaciation, dehydration, urogenital
37 stains, and hunched posture. Reductions in body weights and food consumption were also seen.
38 Pathological findings observed with subchronic inhalation exposure included changes in
39 hematological (\uparrow RBCs, Hgb, Hct, eosinophils & monocytes, \downarrow MCV and MCH) and clinical
40 chemistry values (\downarrow cholesterol, \uparrow protein, calcium, BUN, & ALP), increased absolute and
41 relative lung weights, and numerous microscopic lesions in the nasal cavity (epithelial hyaline
42 inclusions, respiratory epithelial hyperplasia/dysplasia, rhinitis, mucosal ulceration, goblet cell
43 hyperplasia and catarrhal inflammation of mucosa) and lungs (thickening of the epithelial layer
44 in the larynx, epithelial hypertrophy in the trachea, bronchus and bronchiole, alveolar

Table 13. Subacute/Subchronic Effects of Chloropicrin and Their Respective NOELs and LOELs

Species	Exposure	Effect	NOEL	LOEL	Ref. ^b
			ppb (HEC ^a)		
Inhalation					
Rat ^c	6 hrs/day, daily for 10 days, WB ^d	Maternal: Clinical signs, ↓ body weights and food consumption	400 (160)	1,200 (490)	1*
Rabbit ^c	6 hrs/day, daily for 14 days, WB	Maternal: Mortalities, clinical signs, ↓ body weights & food consumption, red discoloration and edema in lung	400 (92)	1,200 (270)	2*
Mouse	6 hrs/day, 5 days/wk, 13 weeks, WB	↓ Body weights (M), ↓ food consumption, ↑ lung weights, histopathological lesions in nasal cavity and lungs.	300 (160)	1,030 (560)	3*
Rat	6 hrs/day, 5 days/wk, 13 weeks, WB	Eye closure, ↓ motor activity	370 (110)	670 (190)	4
Rat	6 hrs/day, 5 days/wk, 13 weeks, WB	↑ Lung weights, histopathological lesions in the lung	300 (88)	1,030 (300)	3*
Rat ^e	6 hrs/day, 7 days/wk, 1 generation, WB	Parental: ↓ Body weights, ↓ food consumption, ↓ implantation sites	1,000 (410)	2,000 (81)	5
Rat ^e	6 hrs/day, 7 days/wk, 2 generations, WB	Parental: ↓ Body weights, histopathological lesions in lungs (F)	500 (200)	1,000 (410)	6*
Oral^f					
Rat	Gavage, daily for 10 days	Histopathological lesions in forestomach	---	10	7
Rat	Gavage, daily for 90 days	↓ Body weights, hematological changes, histopathological lesions in forestomach	8	32	7

^a HEC (Human Equivalent Concentration) = ppb x RR_a/RR_h x E_a/E_h. RR_a = respiratory rate in animals which was assumed to be 1.8, 0.96 and 0.54 m³/kg/day for the mouse, rat and rabbit, respectively (Zielhuis and van der Kreek, 1979). RR_h = respiratory rate in humans which was assumed to be 0.59 m³/kg/day for a child (DPR, 2000). E_a = exposure duration for animals. E_h = exposure duration for humans which was set at 24 hours/day, 7 days/week.
^b References: 1. Schardein, 1993; 2. York, 1993; 3. Chun and Kintigh, 1993; 4. Yoshida *et al.*, 1987b; 5. Denny, 1996; 6. Schardein, 1994; 7. Condie *et al.*, 1994.
^c Developmental toxicity study: Only maternal effects observed after the first few days were included.
^d WB = whole body exposure
^e Reproductive toxicity study
^f Oral NOELs and LOELs expressed in mg/kg/day.
* Acceptable study based on FIFRA guidelines

1 histiocytosis, bronchitis/bronchiolitis, perivascular infiltrates, interstitial pneumonitis,
2 peribronchial/peribronchiolar fibrosis and muscle hyperplasia, epithelial degeneration/necrosis/
3 desquamation in the bronchus and bronchiole, epithelial hypertrophy of the bronchial gland in
4 the bronchus, thickening of the bronchial wall in the bronchus and bronchiole). Two of the three
5 13-week inhalation studies met FIFRA guidelines including those in mice and rats conducted by
6 Chun and Kintigh (1993). The lowest NOEL in the subchronic inhalation studies was 300 ppb
7 based on the increased lung weights and histopathological lesions in the lungs of rats and
8 reduced body weights and food consumption, increased lung weights and histopathological
9 lesions in the nasal cavity and lungs of mice (Chun and Kintigh, 1993).

10 No clinical signs were observed with subchronic oral exposure to chloropicrin.
11 Reductions in body weight were seen as well as changes in absolute and relative organ weights
12 (\uparrow thymus, \downarrow liver and spleen weights). Pathological findings with subchronic oral exposure
13 included changes in hematological values (\downarrow RBCs & WBCs, \uparrow reticulocytes, \downarrow Hgb and Hct) and
14 clinical chemistry values (\downarrow AST, \uparrow phosphate) and histopathological lesions in the forestomach
15 (chronic inflammation, necrosis, acantholysis, hyperkeratosis, epithelial hyperplasia and
16 ulceration). Animals that died after subchronic oral exposure to chloropicrin also had pulmonary
17 inflammation and congestion. There was insufficient information in the published report for the
18 90-day oral gavage study to determine if it met FIFRA guidelines. The lowest NOEL in
19 subchronic oral studies was 8 mg/kg/day based on reduced body weight, hematological changes
20 and histopathological lesions in the forestomach of rats (Condie *et al.*, 1994).

21 In addition to the standard subchronic toxicity studies, Table 13 includes two
22 developmental toxicity studies where maternal effects were observed after subacute exposure for
23 1 to 2 weeks. Maternal signs observed with subacute exposure to chloropicrin included death,
24 gasping, labored breathing, clear nasal discharge, red area around eyes/eyelids, excessive
25 lacrimation, red nasal stains, increased salivation, emaciation, coldness to touch, and reduced
26 activity. Reductions in food consumption and maternal body weights were also seen. Red
27 discoloration and edema were seen in the lungs of pregnant rabbits that died. The lowest
28 maternal NOEL in a developmental toxicity study was 400 ppb (HEC - 92 ppb) based on death,
29 clinical signs, \downarrow body weights & food consumption, red discoloration and edema in lung of
30 rabbits (York, 1993).

31 The effects observed in the two reproductive toxicity studies after subchronic inhalation
32 exposure to chloropicrin for one or two generations were also included in Table 13. No clinical
33 signs were observed in either study. The effects observed in the parental generations included
34 reductions in body weight and food consumption and pathological lesions in the lungs (gross:
35 red discoloration, tan foci, white foci, nodule and adhesions; histological: acute/subacute
36 inflammation). There was no treatment-related effect on reproductive parameters, except a
37 reduction in the number of implantation sites in the 1-generation study (Denny, 1996). The
38 lowest parental NOEL was 500 ppb (HEC - 200 ppb) based on the reduced body weights and
39 pathological lesions in the lungs in the two-generation study. The lowest reproductive NOEL
40 was 1,000 ppb (HEC - 410 ppb) based on the reduced number of implantation sites in the one-
41 generation study.

42 The NOELs for the 90-day inhalation studies in rats and mice were identical, although
43 mice appear to be more sensitive than rats based on the severity of endpoints at the LOEL. On

1 the other hand, if breathing rate is taken into consideration, the rats appear to be more sensitive.
 2 Consequently, a benchmark dose analysis was performed on the more sensitive endpoints
 3 observed in these studies, taking into consideration the breathing rate adjustments. The BMDS
 4 software was also used for this analysis, except the models for dichotomous data were used for
 5 the histopathological lesions. Because the histological effects were more frank effects, the
 6 BMDL at the 5% response level was selected as equivalent to a NOEL. Also, because there
 7 appeared to be gender-related differences, the incidences for the males and females were not
 8 combined. As with the models for continuous data, AIC scores were generated. In comparing
 9 the results from the various models, it was noted that even when the AIC scores and visual fit
 10 were similar among the models, the BMDL estimate could vary significantly because of
 11 differences in the way the confidence limits were calculated between the models. This made
 12 selection of the most sensitive endpoint difficult because it could be very model dependent.
 13 Consequently, one model was selected to compare all the endpoints. The probit model was
 14 selected for this purpose because it seemed to have a good fit consistently with tight confidence
 15 limits among the various data sets. Table 14 is a summary of the endpoints examined by BMD
 16 analysis including their BMD and BMDL₀₅ estimates. The BMDL₀₅ estimates were then
 17 converted to HECs to adjust for differences in breathing rate. From this comparison, the rhinitis
 18 in female rats appears to be the most sensitive endpoint with subchronic exposure. Therefore,
 19 the 90-day inhalation study conducted by Chun and Kintigh (1993) was selected as the definitive

20 **Table 14.** Benchmark Dose Analysis of the Most Sensitive Endpoints in the Mouse and Rat
 21 Subchronic Inhalation Studies^a

Species	Endpoint	Sex	BMD (ppb)	BMDL ₀₅ (ppb)	HEC (ppb)
Mouse ^b	Epithelial Hyalin Inclusions	M	840	360	200
		F	180	84	45
	Alveolar Histiocytosis	M	370	140	76
		F	260	81	44
	Rhinitis	M	1,000	650	350
		F	500	210	110
Rat ^c	Rhinitis	M	880	320	170
		F	190	120	34
	Peribronchial/Peribronchiolar Muscle Hyperplasia	M	510	220	64
		F	260	160	46
	Bronchial/Bronchiolar Epithelial Hyperplasia	M	470	200	58
		F	310	180	52

25 a Benchmark dose estimates shown for the probit model only.

26 b Chun and Kintigh, 1993.

27 c Chun and Kintigh, 1993.

1 study for evaluating seasonal exposure to chloropicrin in air based on the incidence of rhinitis in
2 female rats with a critical NOEL of 120 ppb (HEC = 35 ppb).

3 III.A.3. Chronic Toxicity

4 The effects observed in laboratory animals with chronic exposure to chloropicrin are
5 summarized in Table 15. Two chronic inhalation studies were conducted with chloropicrin, one
6 in mice and the other in rats. The effects observed with chronic inhalation exposure included
7 reduced survival, reduced body weights and food consumption, increased lung weights and non-
8 neoplastic and neoplastic changes in the respiratory tract. The non-neoplastic lesions included
9 lesions in the nasal cavity (serous exudate, hyaline epithelial inclusions, rhinitis, olfactory
10 epithelial atrophy) and lungs (alveolar protein deposits, alveolar histiocytosis, peribronchial

11 **Table 15.** Chronic Effects of Chloropicrin and Their Respective NOELs and LOELs

Species	Exposure	Effect	NOEL	LOEL	Ref. ^b
			ppb (HEC ^a)		
Inhalation					
Mouse	6 hrs/day, 5 days/wk, 78 weeks, WB ^c	↓ Body weights & food consumption, ↑ lung weights, histopathological lesions in lungs	100 (54)	500 (270)	1*
Rat	6 hrs/day, 5 days/wk, 107 weeks, WB	↓ Survival (M), ↓ body weight gain	100 (29)	500 (150)	2*
Oral^d					
Mouse	Gavage, daily for 78 weeks	↓ Body weights (F), histopathological lesions in forestomach	---	33	3
Rat	Gavage, 5 days/wk, 78 weeks	↓ Survival, ↓ body weights, clinical signs	---	20	3
Rat	Gavage, daily for 2 years	↓ Body weights, histopathological lesions in liver	0.1	1	4*
Dog	Capsules, daily for 1 year	Clinical signs, ↓ body weights, hematological and clinical chemistry changes	1.0	5.0	5*

21 a HEC (Human Equivalent Concentration) = ppb x RR_a/RR_h x E_a/E_h. RR_a = respiratory rate in animals which was assumed to be 1.8 and 0.96
22 m³/kg/day for the mouse and rat, respectively (Zielhuis and van der Kreek, 1979). RR_h = respiratory rate in humans which was assumed to
23 be 0.59 m³/kg/day for a child (DPR, 2000). E_a = exposure duration for animals. E_h = exposure duration for humans which was set at 24
24 hours/day, 7 days/week.
25 b References: 1. Burleigh-Flayer *et al.*, 1995; 2. Burleigh-Flayer and Benson, 1995; 3. NCI, 1978; 4. Slauter, 1995; 5. Wisler, 1994.
26 c WB = Whole body exposure
27 d Oral NOELs and LOELs expressed in mg/kg/day.
28 * Acceptable study based on FIFRA guidelines

1 lymphocytic infiltrates, bronchiectasis, bronchial submucosal fibrosis, bronchioalveolar cell
2 hyperplasia, peribronchial smooth muscle hyperplasia). The only neoplastic change was a slight
3 increase in adenomas in the lungs of females that was not significant by Fisher's exact test, but
4 did have a significant trend. Both of the inhalation studies met FIFRA guidelines. The lowest
5 NOEL among the chronic inhalation studies was 100 ppb based on the reduced survival and
6 rhinitis in male rats and reduced body weights and food consumption, increased lung weights
7 and histopathological lesions in the lungs of mice (Burleigh-Flyer and Benson, 1995; Burleigh-
8 Flyer *et al.*, 1995).

9 Four chronic oral studies were available for chloropicrin, one in mice, two in rats and one
10 in dogs. In the mouse and both rat studies, chloropicrin was administered by gavage.
11 Chloropicrin was administered in capsules in the dog study. Effects seen in the chronic oral
12 studies for chloropicrin included reduced survival, ptyalism, emesis, diarrhea, hunched posture,
13 squinted or reddened eyes, urogenital stains, reduced body weights, hematological (\downarrow MCV &
14 MCH) and clinical chemistry (\uparrow calcium, \uparrow phosphorus, \downarrow ASAT, total protein, albumin) changes,
15 non-neoplastic changes in the forestomach/nonglandular stomach (acanthosis, hyperkeratosis,
16 epithelial hyperplasia), and neoplastic changes in the mammary glands (fibroadenoma -female
17 rats) and stomach (papilloma - one male rat). One rat study and the dog study met FIFRA
18 guidelines. The lowest NOEL with chronic oral exposure to chloropicrin was 0.1 mg/kg/day
19 based on reduced body weights and histopathological lesions in the liver of rats (Slauter, 1995).

20 As with the subchronic inhalation studies, the NOELs for the chronic inhalation studies
21 in rats and mice were identical, although mice appear to be more sensitive than rats based on the
22 severity of endpoints at the LOEL. On the hand, if the NOELs are adjusted for breathing rate,
23 the NOEL in rats appears to be more sensitive. Consequently, a benchmark dose analysis was
24 performed on the more sensitive endpoints observed in these studies, taking into consideration
25 the breathing rate adjustments. As before, the probit model was used to compare endpoints and
26 the BMDL at the 5% response level was selected as equivalent to a NOEL. Table 16 is a
27 summary of the endpoints examined by BMD analysis including their BMD, BMDL₀₅ and HEC
28 estimates. Based on this comparison, the increase in bronchiectasis in female mice appears to
29 be the most sensitive endpoint with chronic exposure. Therefore, the chronic inhalation study
30 conducted by Burleigh-Flyer *et al.* (1995) was selected as the definitive study for evaluating
31 annual exposure to chloropicrin in air based on the incidence of bronchiectasis in female mice
32 with a critical NOEL of 59 ppb (HEC = 32 ppb).

33 III.A.4. Carcinogenicity - Weight of Evidence

34 The results of the genotoxicity studies for chloropicrin were mixed. Chloropicrin was
35 clearly positive in bacterial systems with positive responses reported in eight reverse mutation
36 assays with *Salmonella typhimurium* and two with *Escherichia coli*, one of which met FIFRA
37 guidelines (San and Wagner, 1990; Moriya *et al.*, 1983; Shirasu *et al.*, 1982; Haworth *et al.*,
38 1983; Kawai *et al.*, 1987; Sariaslani and Stahl, 1990; Giller *et al.*, 1995; Schneider *et al.*, 1999).
39 Other positive tests included an *in vitro* chromosomal aberrations assay with Chinese hamster
40 ovary cells (Putman and Morris, 1990) and a sister chromatid exchange assay with human
41 lymphocytes (Garry *et al.*, 1990). The assay with Chinese hamster ovary cells did meet FIFRA
42 guidelines; however, it was unclear if the sister chromatid exchange assay met FIFRA guidelines
43 due to insufficient information. A SOS chromotest with *E. coli*, which is an *in vitro* assay that

Table 16. Benchmark Dose Analysis of the Most Sensitive Endpoints in the Mouse and Rat Chronic Inhalation Studies^a

Species	Endpoint	Sex	BMD (ppb)	BMDL ₀₅ (ppb)	HEC (ppb)
Mouse ^b	Bronchiectasis	M	93	68	37
		F	76	59	32
	Epithelial Hyalin Inclusions	M	480	290	160
		F	180	100	54
	Rhinitis	M	280	130	70
		F	150	120	65
	Alveolar Histiocytosis	M	300	190	100
		F	370	150	82
Rat ^c	Rhinitis	M	800	230	67

^a Benchmark dose estimates shown for the probit model only.
^b Burleigh-Flayer *et al.*, 1995
^c Burleigh-Flayer and Benson, 1995

detects primary DNA damage, was also positive (Giller *et al.*, 1995). The significance of this positive finding is uncertain since this is not a commonly conducted assay and there are no guidelines for it. There were a number of negative assays including the sex-linked recessive lethal (SLRL) assay in *Drosophila melanogaster* (Auerbach (1950), forward mutation assay with L5178Y TK+/- mouse lymphoma cells (San and Sigler, 1990), another chromosomal aberrations assay in cultured human lymphocytes (Garry *et al.* 1990), an *in vivo* test for chromosomal damage was a micronucleus assay in *Pleurodeles waltl* newt larvae (Giller *et al.*, 1995) and an unscheduled DNA synthesis (UDS) assay with rat primary hepatocytes (Curren, 1990). Only two of these assays met FIFRA guidelines (forward mutation assay and UDS assay). However, negative results in the UDS assay were not very meaningful since this assay has a reputation for not being very sensitive. The other assays did not meet FIFRA guidelines because there was insufficient information or there were no guidelines for that type of assay. One SLRL assay in *Drosophila* had equivocal results (Valencia *et al.*, 1985), but there was also insufficient information to determine if this study met FIFRA guidelines. Based on the positive results, especially in all of the reverse mutation assays, DPR concluded a genotoxic mode of action for tumor formation was possible.

There was also evidence of carcinogenicity in two chronic toxicity studies for chloropicrin. In a 78-week mouse inhalation study, there was a slight increase in adenomas of the lung in females that was significant ($p < 0.05$) by trend analysis, but not by the Fisher's exact test (Burleigh-Flayer *et al.*, 1995). When combined with the carcinomas the trend was significant at $p < 0.01$ and the p-value for Fisher's exact approached statistical significance (0.053). The combined tumor incidence was further examined using the Poly-3 trend test which

1 takes survival into consideration. This test also includes an pair-wise comparison test similar to
2 the Fisher's exact test. Using this test, not only was the increase in combined tumors significant
3 by trend analysis, but the incidence at the high dose was significant by pair-wise comparison (p
4 = 0.021). In addition, the number of animals with multiple lung adenomas and/or carcinomas
5 increased in both sexes, although it was only significant by trend analysis and not by Fisher's
6 exact in either sex. The increase in multiplicity in males, even though the number of animals
7 with tumors was not significantly higher, is interesting, suggesting that chloropicrin may be
8 affecting the progression of the tumors more than the formation of DNA damage. The average
9 time to tumor did not show a dose-related decrease in males (562, 540, 546 and 549 days at 0,
10 100, 500 and 1,000 ppb, respectively), but was shorter in the high dose females (554, 562, 564
11 and 543 days at 0, 100, 500 and 1,000 ppb, respectively). However, the shorter time to tumor in
12 the high dose females appears to be primarily due to two deaths that occurred within the first
13 year that were unrelated to the tumors (both had adenomas, not carcinomas; trauma in one case
14 and undetermined cause of death in another). No historical control data were available from the
15 laboratory where the study was conducted. Historical control data reported by the supplier
16 during a similar time period, however, suggests the incidence in all groups, including the
17 controls, is above the average incidence for this strain and outside the historical control range for
18 most groups including the male controls (Giknis and Clifford, 2000). The apparent high
19 background incidence of these tumors makes it difficult to determine if there was a treatment-
20 related increase. Furthermore, a similar increase was not found in the 107-week inhalation study
21 in rats conducted in the same laboratory, although there was a slight increase in fibroadenomas
22 of the mammary glands in females (Burleigh-Flayer and Benson, 1995). The increase in
23 fibroadenomas, however, was not statistically significant and it was within the historical control
24 range for this laboratory. A few rare tumors (2 squamous cell carcinomas in the stomach of
25 males at 66 mg/kg/day and one papilloma in the stomach of a female at 33 mg/kg/day) were seen
26 in an oral chronic gavage study in mice (NCI, 1978), but no significant increase in tumors were
27 seen in a similar oral gavage study in rats conducted in the same laboratory (NCI, 1978). It is
28 unlikely that treated rats in this study survived long enough to develop late-appearing tumors. In
29 another chronic oral study in rats, a papilloma was seen in one male and there was a slight, but
30 statistically significant increase (by Fisher's exact and trend analysis) in fibroadenomas in
31 females at the high-dose (Slauter, 1995). The toxicological significance of this increase is
32 uncertain since the incidence was within the historical control range for this strain from this
33 laboratory. While this evidence of carcinogenicity was limited to one sex in one species, DPR
34 concluded that the increase in the lung tumors with inhalation exposure was sufficient to warrant
35 a quantitative assessment of carcinogenicity due to the positive genotoxicity studies, especially
36 the reverse mutation assays.

37 **III.A.4.a. Quantitative Assessment of Carcinogenic Effects**

38 There was a dose-related increase in the combined incidence of pulmonary adenomas and
39 carcinomas in female mice exposed to chloropicrin by the inhalation route which was significant
40 by trend analysis and pair-wise comparison when survival was taken into consideration
41 (Burleigh-Flayer *et al.* 1995). The increase in these tumors was not statistically significant in
42 male mice or rats of either sex by either trend analysis or pair-wise comparison. However, there
43 was an increase in the multiplicity of these tumors in both sexes of mice and a shortening of time
44 to tumor in female mice. There was also a statistically significant (by trend analysis and Fisher's
45 exact test) increase in fibroadenomas in female rats with oral exposure to chloropicrin.

1 Furthermore, a number of the genotoxicity tests were positive, the most significant being the
2 eight reverse mutation assays with *S. typhimurium* and *E. coli*. Although there was insufficient
3 information to determine the mode of action for the carcinogenicity, the positive results with the
4 reverse mutation assays suggest a direct DNA interaction. If a genotoxic mode of action is
5 involved a linear dose response is assumed to estimate the carcinogenic potential. But even
6 when there is insufficient data on the mode of action, as is the case with chloropicrin, the U.S.
7 EPA Guidelines for Carcinogen Risk Assessment recommends that a linear approach be used as
8 a default (U.S. EPA, 2005). Consequently, a linear dose response was assumed in evaluating the
9 carcinogenic potential of chloropicrin.

10 The combined incidence of lung adenomas and carcinomas in female mice in the
11 carcinogenicity study conducted by Burleigh-Flayer *et al.* (1995) was used to estimate
12 carcinogenic potency. The adjusted incidence from the Poly-3 trend test was used to estimate
13 potency with the Multistage Cancer model in the BMDS software. The air concentrations from
14 the mouse study were first converted to mg/kg/day ($\text{mg/kg/day} = \text{ppm} \times \text{M.Wt./M.Vol.} \times \text{RR}_a \times 6$
15 $\text{hrs/24 hrs} \times 5 \text{ days/7days}$) and then converted to human equivalent dose by multiplying by an
16 interspecies scaling factor of body weight to the 3/4 power [$(\text{BWt}_A/\text{BWt}_H)^{0.25} = (0.030 \text{ kg}/70$
17 $\text{kg})^{0.25} = 0.144$] (U.S. EPA, 2005). The resulting adjusted dosages were 0, 0.031, 0.155 and
18 0.311 mg/kg/day. The estimated carcinogenic potency for chloropicrin ranged from 1.3
19 $(\text{mg/kg/day})^{-1}$ (maximum likelihood estimate or MLE) to 2.2 $(\text{mg/kg/day})^{-1}$ (95% upper bound or
20 95% UB).

21 The estimated carcinogenic potency for chloropicrin expressed as unit risk is shown in
22 Table 17 relative to other chemicals for which there are carcinogenic potency estimates that have
23 been approved by the Scientific Review Panel (SRP) for Toxic Air Contaminants (TACs). The
24 unit risk estimate for chloropicrin was $6.3 \times 10^{-4} (\mu\text{g}/\text{m}^3)^{-1}$ at the 95% UB.

25 III.A.5. Reference Concentrations

26 The reference concentration (RfC) is the air concentration at which no adverse effects are
27 expected to occur in humans. RfCs were calculated for chloropicrin for acute, seasonal and
28 chronic exposures. Generally, the RfCs are calculated by dividing the NOEL (after conversion
29 to a HEC) by a default uncertainty factor of 100 when the NOEL is from an animal study to
30 account for interspecies and intraspecies variation in sensitivity. When the NOEL is from a
31 human study the NOEL was divided by a default uncertainty factor of 10 for intraspecies
32 variation. A BMDL₁₀ of 26 ppb ($170 \mu\text{g}/\text{m}^3$) was selected as the NOEL for evaluating acute 1-hr
33 exposures to chloropicrin based on eye irritation in humans after a 1-hour exposure (Cain, 2004).

34 Due to the uncertainty about the application of Haber's Law to sensory irritation, 8-hr and 24-hr
35 NOELs were derived from a developmental toxicity study in rabbits in which the does were
36 exposed for 6 hours/day (York, 1993). The acute maternal effects observed at the LOEL in this
37 study included nasal discharge, reduced food consumption and body weights and mortalities
38 associated with red discolored lungs during the first few days of exposure. Since these effects
39 appear to involve more than sensory irritation, Haber's Law was used to estimate 8-hr and 24-hr
40 NOELs. The 8-hr and 24-hr NOELs were estimated to be 300 ppb ($2,000 \mu\text{g}/\text{m}^3$) and 100 ppb
41 ($670 \mu\text{g}/\text{m}^3$), respectively. The 8-hr HECs were 270 ppb ($1,800 \mu\text{g}/\text{m}^3$) and 580 ppb ($3,900$
42 $\mu\text{g}/\text{m}^3$) for children and adults, respectively. The 24-hr HECs were 92 ppb ($610 \mu\text{g}/\text{m}^3$) and 190
43 ppb ($1,300 \mu\text{g}/\text{m}^3$) for children and adults, respectively. The 90-day inhalation study in rats was

1 **Table 17. Carcinogenic Potency for Chloropicrin Relative to Other Carcinogenic Potencies**
 2 **Approved by the Scientific Review Panel for Toxic Air Contaminants^a**

3 Compound	Unit Risk ($\mu\text{g}/\text{m}^3$)⁻¹	Potency ($\text{mg}/\text{kg}/\text{day}$)⁻¹
4 Dioxins	3.8×10^1 to 3.8×10^0	1.3×10^4 to 1.3×10^5
5 Chromium IV	1.5×10^{-1}	5.1×10^2
6 Asbestos	6.3×10^{-2}	2.2×10^2
7 Dibenzo[a,h]pyrene	1.1×10^{-2}	3.9×10^1
8 1,6-Dinitropyrene	1.1×10^{-2}	3.9×10^1
9 6-Nitrochrysene	1.1×10^{-2}	3.9×10^1
10 Cadmium	4.2×10^{-3}	1.5×10^1
11 Inorganic Arsenic	3.3×10^{-3}	1.2×10^1
12 Benzo[a]pyrene	1.1×10^{-3}	3.9×10^0
13 Dibenzo[a,e]pyrene	1.1×10^{-3}	3.9×10^0
14 7H-Dibenzo[c,g]carbazole	1.1×10^{-3}	3.9×10^0
15 1,8-Dinitropyrene	1.1×10^{-3}	3.9×10^0
16 5-Methylchrysene	1.1×10^{-3}	3.9×10^0
17 Chloropicrin	6.3×10^{-4}	2.2×10^0
18 Diesel Exhaust	3×10^{-4}	1.1×10^0
19 Nickel	2.6×10^{-4}	9.1×10^{-1}
20 1,3-Butadiene	1.7×10^{-4}	6.0×10^{-1}
21 Benz[a]anthracene	1.1×10^{-4}	3.9×10^{-1}
22 Benz[b]fluoranthrene	1.1×10^{-4}	3.9×10^{-1}
23 Indeno[1,2,3-cd]pyrene	1.1×10^{-4}	3.9×10^{-1}
24 Dibenzo[a,h]acridine	1.1×10^{-4}	3.9×10^{-1}
25 1-Nitropyrene	1.1×10^{-4}	3.9×10^{-1}
26 4-Nitropyrene	1.1×10^{-4}	3.9×10^{-1}
27 Ethylene Oxide	8.8×10^{-5}	3.1×10^{-1}
28 Vinyl Chloride	7.8×10^{-5}	2.7×10^{-1}
29 Ethylene Dibromide	7.1×10^{-5}	2.5×10^{-1}
30 Carbon Tetrachloride	4.2×10^{-5}	1.5×10^{-1}
31 Naphthalene	3.4×10^{-5}	1.2×10^{-1}
32 Benzene	2.9×10^{-5}	1.0×10^{-1}
33 Ethylene Dichloride	2.1×10^{-5}	7.2×10^{-2}
34 Inorganic Lead	1.2×10^{-5}	4.2×10^{-2}
35 Chrysene	1.1×10^{-5}	3.9×10^{-2}
36 2-Nitrofluorene	1.1×10^{-5}	3.9×10^{-2}
37 Perchloroethylene	5.9×10^{-6}	2.1×10^{-2}
38 Formaldehyde	6.0×10^{-6}	2.1×10^{-2}
39 Chloroform	5.3×10^{-6}	1.9×10^{-2}
40 Acetaldehyde	2.7×10^{-6}	1.0×10^{-2}
41 Trichloroethylene	2.0×10^{-6}	7.0×10^{-3}
42 Methylene Chloride	1.0×10^{-6}	3.5×10^{-3}
43 Methyl <i>tert</i> -butyl ether (MTBE)	2.6×10^{-7}	1.8×10^{-3}
44 a Unit risk values from OEHHA (2005).		

1 selected as the definitive study for evaluating seasonal inhalation exposure with a critical NOEL
 2 of 120 ppb (807 $\mu\text{g}/\text{m}^3$) based on the BMDL_{05} for rhinitis in females (Chun and Kintigh, 1993).
 3 The subchronic HECs were 35 ppb (230 $\mu\text{g}/\text{m}^3$) for children and 73 ppb (490 $\mu\text{g}/\text{m}^3$) for adults.
 4 The 78-wk inhalation study in mice was selected as the definitive study for evaluating chronic
 5 inhalation exposure to chloropicrin with a critical NOEL of 59 ppb (216 $\mu\text{g}/\text{m}^3$) based on the
 6 BMDL_{05} for bronchiectasis in females (Burleigh-Flayer *et al.*, 1995). The chronic HECs were
 7 32 ppb (220 $\mu\text{g}/\text{m}^3$) for children and 68 ppb (460 $\mu\text{g}/\text{m}^3$) for adults.

8 Reference concentrations were then calculated from the HECs by an dividing uncertainty
 9 factor.

$$10 \quad RfC(ppb) = \frac{HEC(ppb)}{\text{uncertainty factor (e.g., 100)}}$$

$$11 \quad RfC(\mu\text{g}/\text{m}^3) = RfC(ppb) \times \frac{M. Wt. (164.38 g)}{M. Vol. (24.45L @ 25^\circ C)}$$

12 An uncertainty factor of 3 was applied to the NOEL for sensory irritation in the human study,
 13 assuming toxicokinetic variation among individuals is minimal (see Risk Characterization
 14 section under the Risk Appraisal section for further discussion). The 1-hr RfC for chloropicrin is
 15 8.7 ppb (58 $\mu\text{g}/\text{m}^3$) for both children and adults. No adjustment is needed for differences in
 16 breathing rate with this endpoint since it did not involve the respiratory system. An uncertainty
 17 factor of 100 was applied to the HECs from the animal studies to allow for interspecies and
 18 intraspecies variation in sensitivity. The 8-hr RfCs are 2.7 ppb (18 $\mu\text{g}/\text{m}^3$) and 5.8 ppb (39
 19 $\mu\text{g}/\text{m}^3$) for children and adults, respectively. The 24-hr RfCs are 0.92 ppb (6.1 $\mu\text{g}/\text{m}^3$) and 1.9
 20 ppb (13 $\mu\text{g}/\text{m}^3$) for children and adults, respectively. The subchronic RfCs are 0.35 ppb (2.3
 21 $\mu\text{g}/\text{m}^3$) and 0.73 ppb (4.9 $\mu\text{g}/\text{m}^3$) for children and adults, respectively. The chronic RfCs are 0.32
 22 ppb (2.2 $\mu\text{g}/\text{m}^3$) and 0.68 ppb (4.6 $\mu\text{g}/\text{m}^3$) for children and adults, respectively. The reference
 23 concentrations for chloropicrin are summarized in Table 18.

24 Generally, RfDs/RfCs are not calculated for carcinogenicity since it is assumed there is
 25 no threshold for this endpoint. However, it is possible to calculate a dose or air concentration at
 26 which the carcinogenic risk is negligible. To do this, the negligible risk level (1×10^{-6}) is
 27 divided by the 95% UB estimate of carcinogenic potency ($2.2 \text{ (mg/kg/day)}^{-1}$). For chloropicrin,
 28 the exposure dosage or RfD corresponding to a negligible carcinogenic risk is 0.45 ng/kg/day.
 29 The exposure dosage was converted to an air concentration by dividing by the estimated
 30 breathing rate for an adult male ($0.28 \text{ m}^3/\text{kg/day}$). The air concentration below which there
 31 would be no regulatory concern for carcinogenic effects is 0.24 ppt (1.6 ng/m^3).

32 III.B. EXPOSURE ASSESSMENT

33 III.B.1. Soil Fumigation

34 III.B.1.a. Bystander Exposure

35 Individuals might be exposed to chloropicrin if they are working or standing adjacent to
 36 fields that are being treated or have recently been treated (i.e., bystander exposure). Two types

Table 18. DPR Critical NOELs and Reference Concentrations for Chloropicrin

Exposure Scenario	NOEL	Effects on LOEL	RfC	
			Children	Adults
Acute - 1 hr	26 ppb	Ocular irritation in humans	8.7 ppb (58 µg/m ³) UF ^a = 3	8.7 ppb (58 µg/m ³) UF = 3
Acute - 8 hr & 24 hr	400 ppb (270 µg/m ³)	Mortalities (days 2-4), nasal discharge (onset day 0), ↓ body weights & food consumption (days 0-6), red discoloration in lungs of pregnant rabbits.	<u>8-hr</u> 2.7 ppb (18 µg/m ³) <u>24-hr</u> 0.92 ppb (6.1 µg/m ³) UF = 100	<u>8-hr</u> 5.8 ppb (39 µg/m ³) <u>24-hr</u> 1.9 ppb (13 µg/m ³) UF = 100
Seasonal	120 ppb (807 µg/m ³)	Rhinitis in female rats	0.35 ppb (2.3 µg/m ³) UF = 100	0.73 ppb (4.9 µg/m ³) UF = 100
Chronic	59 ppb (216 µg/m ³)	Bronchiectasis in female mice	0.32 ppb (2.2 µg/m ³) UF = 100	0.68 ppb (4.6 µg/m ³) UF = 100
Lifetime	Potency = 2.2 (mg/kg/day) ⁻¹	Lung tumors in female mice	-----	0.24 ppt ^b (1.6 ng/m ³)
<p>^a UF = Uncertainty factor used to derive RfC. For eye irritation in humans, the intraspecies uncertainty factor was reduced to 3 since toxicokinetic variation among individuals was not anticipated.</p> <p>^b RfC for cancer is the air concentration corresponding to a negligible risk level (i.e., one in a million excess cancer cases)</p>				

of air monitoring studies were conducted following soil fumigation with chloropicrin where air samples were collected either on-site for direct estimation of field volatility or flux or off-site (See Barry (2008) and Beauvais (2009) for detailed description of these studies). Preliminary studies of off-site air concentrations were conducted by DPR in 1982 and 1983 in Orange County (Maddy *et al.*, 1983 & 1984). However, the application rate and percentage of chloropicrin in the methyl bromide/chloropicrin mixture were not reported, so these studies were not used. Off-site monitoring was conducted by the Air Resources Board (ARB) in 1986, 2001, 2003 and 2005. The 1986 study monitored off-site air concentrations following a tarped broadcast application in Monterey County (ARB, 1987). However, the methyl bromide/-chloropicrin formulation, field size and application rate were not reported. Due to insufficient information, this study was not used in analyzing the off-site air concentrations for chloropicrin. The ARB monitoring in 2001 was conducted in Monterey County following a shank tarped bed application of a methyl bromide/chloropicrin 50:50 mixture (ARB, 2003c). In 2003, ARB monitored off-site air concentrations in Santa Cruz County after a shallow shank tarped bed application of a methyl bromide/chloropicrin 50:50 mixture (ARB, 2004). In 2005, off-site air concentrations were monitored by ARB in Santa Barbara County following a drip tarped bed application of 94% chloropicrin (ARB, 2006). Two off-site monitoring studies were also

1 conducted by registrants (Beard *et al.*, 1996; Rotondaro, 2004). Beard *et al.* (1996) monitored
2 off-site air concentrations in Washington (broadcast tarped application), Florida (broadcast
3 tarped application) and Phoenix, Arizona (broadcast tarped, broadcast non-tarped, bedded tarped
4 and bedded non-tarped applications) following the application of 99.4% chloropicrin. Rotondaro
5 (2004) monitored off-site air concentrations after field and greenhouse surface drip applications
6 of 99.1% chloropicrin in California.

7 The two off-site air monitoring studies conducted by the registrants also characterized the
8 flux for chloropicrin on-site following the soil fumigation (Beard *et al.*, 1996; Rotondaro, 2004).
9 Flux (expressed as $\mu\text{g}/\text{m}^2/\text{sec}$) is the rate at which a chemical moves out from the ground into the
10 air. Direct measurement of flux measures air concentrations on a mast in the center of the field.
11 Since off-site air concentrations were dependent on environmental conditions, it is unlikely that
12 the highest possible air concentrations were encountered during a particular study. Therefore,
13 the flux data along with air modeling were used to estimate off-site air concentrations for a
14 worse case scenario. The flux following the applications in Washington and Florida was lower
15 than that following the applications in Arizona in the study conducted by Beard *et al.* (1996) and,
16 therefore, was not further considered in the exposure assessment. From the on-site monitoring,
17 DPR estimated the maximum 6-hour and 24-hour time-weighted average (TWA) chloropicrin
18 flux (Barry, 2008). From these maximum 6-hr and 24-hr flux estimates, DPR then calculated
19 rate adjusted air concentrations for 1.2 m (4 ft) above ground (breathing zone) and 3 m (10 ft)
20 from the edge of a 40-acre square field using the Industrial Source Complex Short Term model,
21 Version 3 (ISCT3). The model generated downwind centerline estimates of reasonable worst-
22 case air concentrations for the different application methods at the maximum application rate for
23 6-hours and 24-hours (TWA). Table 19 summarizes highest exposure estimates for bystanders
24 using the different application methods based on the reasonable worst case air concentrations
25 from modeling. The highest day or night 6-hr air concentration with each application method
26 was used for their respective 1-hr and 8-hr exposure estimates. Since 6 hours was the shortest
27 monitoring interval for flux, 1-hr exposure estimates were calculated using a peak-to-mean ratio
28 as described in Barry (2008). The 1-hr exposure estimates ranged from 11,000 to 110,000 $\mu\text{g}/\text{m}^3$
29 (1,600 to 16,000 ppb)²⁰. The 6-hr air concentrations were not adjusted for time for the 8-hr
30 exposure estimates. The 8-hr exposure estimates were between 4,700 and 44,000 $\mu\text{g}/\text{m}^3$ (700 to
31 6,500 ppb). The 24-hr exposure estimates ranged from 1,100 to 7,400 $\mu\text{g}/\text{m}^3$ (164 to 1,100 ppb).
32 For periods of 24 hours or less, it was assumed a bystander was located downwind throughout
33 the entire exposure period. For the subchronic and chronic exposure, this assumption was
34 unrealistic since wind direction would change. Therefore, the seasonal exposure was estimated
35 from 2-week TWA air concentrations which were calculated by first taking a 24-hr average flux
36 over 2 weeks and then adjusting with a time-scaling factor using the peak-to-mean theory. In
37 addition, the air concentrations were adjusted for the typical application rate instead of the
38 maximum application rate. The seasonal exposure estimates were between 54 and 490 $\mu\text{g}/\text{m}^3$
39 (8.0 to 73 ppb). The annual exposure was estimated from the 2-week average air concentration
40 assuming it was used 4 months out of the year. The annual exposure estimates ranged from 18
41 to 160 $\mu\text{g}/\text{m}^3$ (2.7 and 24 ppb). The highest estimates for 1-hr and 8-hr exposure were for
42 broadcast, non-tarped application. Bedded, tarped application had the highest 24-hour, seasonal,
43 and annual exposure estimates.

20 The exposure estimates were rounded to two significant figures for both $\mu\text{g}/\text{m}^3$ and ppb.

1 For ease in calculation of cancer risk, the reasonable worst case lifetime exposure
2 estimates for bystanders was calculated from annual exposures in $\mu\text{g}/\text{m}^3$ from Table 19 and
3 converted to $\mu\text{g}/\text{kg}/\text{day}$ by multiplying by the breathing rate for adult humans (Table 20). The
4 lifetime exposure for residential bystanders was assumed to be the same as their annual exposure
5 except using the 50th percentile for the application rate (i.e., 150 lb A.I./acre) instead of the
6 typical rate that was used for seasonal and annual exposure. The lifetime exposure for
7 occupational bystanders was the same as residential bystanders except that it was assumed they
8 were only exposed for 40 years in a 70-year life span. The lifetime exposure estimates for
9 residential bystanders ranged from 2.2 to 20 $\mu\text{g}/\text{kg}/\text{day}$. The lifetime exposure estimates for
10 occupational bystanders ranged from 1.2 to 11 $\mu\text{g}/\text{kg}/\text{day}$. The lifetime exposure estimates were
11 highest for bedded tarped applications for both residential and occupational bystanders.

12 **III.B.1.b. Ambient Air Exposure**

13 Ambient air monitoring was conducted by ARB in four counties (Monterey, Santa Cruz,
14 Santa Barbara and Kern County) in four studies (ARB, 1987, 2003a & b; Wofford *et al.*, 2003).
15 These studies confirm that exposure to chloropicrin can occur through ambient air in individuals
16 living in communities near where there is high use, but who do not actually live or work next to
17 an application site. The highest air concentration, 14.3 $\mu\text{g}/\text{m}^3$, was observed at the La Joya
18 Elementary School site in Salinas (Monterey County) during monitoring conducted from early
19 September to early November of 2001 which was a time when high chloropicrin use was
20 anticipated (Pan-Huang, 2003b). DPR's Pesticide Use data for this county showed that
21 September and October were the two highest use months in Monterey county (Beauvais, 2009).
22 These monitoring studies support the assumption that exposures to chloropicrin in ambient air
23 are equal to or less than bystander exposures near the application site. Therefore, the bystander
24 exposure estimates for application site air were assumed to be health protective estimates for
25 ambient air, also, and no separate exposure estimates were calculated for ambient air.

26 **III.B.2. Structural Fumigation**

27 **III.B.2.a. Bystander Exposure**

28 ARB also monitored off-site air concentrations of chloropicrin following structural
29 fumigations with sulfuryl fluoride in which chloropicrin was used as a warning agent (ARB,
30 2003d, 2005 a&b). One study was conducted in Sacramento County during a fumigation of a
31 single-story home with an estimated fumigation volume of 22,000 ft^3 . A second study was
32 conducted in Nevada county during a fumigation of a two-story house with a fumigation volume
33 of 81,000 ft^3 . The third study was conducted in Placer County during a fumigation of another
34 two-story house with a fumigation volume of 45,000 ft^3 . As might be expected, the highest off-
35 site air concentrations were found in the second study with the house that had the highest
36 fumigation volume (ARB, 2005a). The highest air concentrations occurred at 1.5 m northwest of
37 the house during the mechanical ventilation. The off-site air concentration from this location
38 was used for estimating bystander exposure for structural fumigation after adjusting for recovery
39 and the maximum application rate. The air sample at 1.6 hours was used for the 1-hour
40 exposure. The 8-hour exposure was the time-weighted average of the consecutive 1.6 and 4.9
41 hour concentrations. The 24-hour exposure was an average of the consecutive 12-hour
42 concentrations. Table 21 summarizes the highest exposure estimates for bystanders near

Table 19. Estimated Exposure for Bystanders to Chloropicrin Following Soil Fumigation^a

Exposure Duration Application Method	Concentration ($\mu\text{g}/\text{m}^3$)	Concentration (ppb)
Acute - 1 hour ^{b,c}		
Broadcast, non-tarped	110,000	16,000
Bedded, non-tarped	67,000	10,000
Bedded, tarped	77,000	11,000
Broadcast, tarped	40,000	5,900
Bedded, drip, tarped	11,000	1,600
Acute - 8 hour ^c		
Broadcast, non-tarped	44,000	6,500
Bedded, non-tarped	27,000	4,000
Bedded, tarped	31,000	4,600
Broadcast, tarped	16,000	2,400
Bedded, drip, tarped	4,700	700
Acute - 24 hr		
Broadcast, non-tarped	6,500	970
Bedded, non-tarped	5,000	740
Bedded, tarped	7,400	1,100
Broadcast, tarped	4,300	640
Bedded, drip, tarped	1,100	160
Seasonal ^d		
Broadcast, non-tarped	130	19
Bedded, non-tarped	140	21
Bedded, tarped	490	73
Broadcast, tarped	160	24
Bedded, drip, tarped	54	8.0
Annual ^e		
Broadcast, non-tarped	43	6.4
Bedded, non-tarped	47	6.9
Bedded, tarped	160	24
Broadcast, tarped	53	7.9
Bedded, drip, tarped	18	2.7

a Reasonable worst case exposure estimates for bystanders were generated using the Industrial Complex Short Term, Version 3 (ISCST3) air dispersion model and flux data from application site monitoring studies in Arizona (Beard *et al.*, 1996) and California (Rotondoro, 2004) adjusting for the maximum application rate and assuming the bystander was downwind, 10 ft (3.0 m) from the edge of a square, 40-acre field and the breathing zone was 4 ft (1.2 m) above ground (Beauvais, 2009). The exposure estimates were rounded to two significant figures for both $\mu\text{g}/\text{m}^3$ and ppb. Values in bold are the application method with highest exposure estimates for each exposure duration.

b The 1-hr exposure was estimated from the highest 6-hr concentration for the different application methods (using the peak-to-mean ratio: $C_p = C_m(t_p/t_m)^{1/2}$ where C_p is the peak concentration over the peak period of interest, t_p , and C_m is the mean concentration over mean measurement period, t_m).

c The highest day or night 6-hr air concentration for each application method was used for their respective 1-hr and 8-hr exposure estimates.

d Seasonal exposure was estimated by calculating an average 24-hr flux over 2 weeks, then adjusted using a time-scaling factor based on the peak-to-mean theory.

e Annual exposure was assumed 4 months of seasonal exposure per year.

Table 20. Estimated Lifetime Exposure for Bystanders to Chloropicrin Following Soil Fumigation^{a,b}

Application Method	Residential µg/kg/day	Occupational µg/kg/day
Broadcast, non-tarped	10	5.9
Bedded, non-tarped	11	6.4
Bedded, tarped	20	11
Broadcast, tarped	6.4	3.6
Bedded, drip, tarped	2.2	1.2

a Reasonable worst case exposure estimates for bystanders were generated using the Industrial Complex Short Term, Version 3 (ISCST3) air dispersion model and flux data from application site monitoring studies in Arizona (Beard *et al.*, 1996) and California (Rotendro, 2004) adjusting for the maximum application rate and assuming the bystander was downwind, 10 ft (3.0 m) from the edge of a square, 40-acre field and the breathing zone was 4 ft (1.2 m) above ground (Beauvais, 2009).

b Lifetime exposure estimates were calculated from the annual exposure in µg/m³ from Table 19 and multiplied by the breathing rate for adults which was assumed to be 0.28 m³/kg/day. Residential bystanders were assumed to be exposed every year throughout their lifetime. Occupational bystanders were assumed to be exposed for only 40 years in 70-year lifespan.

structures fumigated where chloropicrin is used as a warning agent. Multiple structural fumigations are not anticipated in the same area; therefore, no seasonal or annual exposure estimates were calculated for structural fumigation.

II.B.2.b. Indoor Exposure

Indoor air concentrations of chloropicrin following structural fumigation were measured in two studies conducted by ARB in 2002 and 2004 (ARB, 2003c & 2005a). In both of these studies, two 24-hour samples were collected after completion of aeration. The highest indoor air concentrations were reported with the study conducted in 2004 in the south end of the house following 16.5-hr aeration (ARB, 2005a). This was also the study with the highest off-site air concentrations and could be because this house had the largest fumigation volume (81,000 ft³). Air concentrations were corrected for recovery and the maximum application rate. The 24-hr indoor exposure to chloropicrin from structural fumigation was estimated to be 140 µg/m³ (21 ppb) based on this study. One-hour and 8-hour exposure estimates were not calculated since the shortest sampling interval was 24 hours.

Table 21. Estimated Exposure for Bystanders to Chloropicrin Following Structural Fumigation^a

Exposure Duration	Concentration (µg/m ³)	Concentration (ppb)
Acute - 1 hour ^b	73	11
Acute - 8 hour ^c	16	2.4
Acute - 24 hr ^d	6.2	0.92

a Exposure estimates for bystanders were based on the highest air concentration found during structural fumigation in three studies conducted by ARB (ARB, 2003d, 2005 a&b). The study conducted in Nevada County during the fumigation of a two-story house with a fumigation volume of 81,000 ft³ had the highest air concentration 1.5 m northwest of the house during mechanical ventilation (ARB, 2005a). Exposure estimates were adjusted for recovery and the maximum application rate (Beauvais, 2009).

b The 1-hour exposure was based on the air concentration during the 1.6 hour sample.

c The 8-hour exposure was based on the time-weighted average of the consecutive 1.6 and 4.9-hour concentrations.

d The 24-hour exposure is based on the average of the consecutive 12-hour concentrations.

1 II.B.3. Enclosed Space Fumigation

2 II.B.3.a. Bystander Exposure

3 One chloropicrin product includes directions for its use as an active ingredient in
 4 fumigating empty potato storages and empty grain bins. Therefore, exposure estimates were
 5 calculated for bystanders following enclosed space fumigation (Table 22). There were no
 6 monitoring data available associated for this type of use, so the ARB air monitoring data
 7 following structural fumigation was used to estimate exposure for bystanders following this use
 8 (ARB, 2005a). The air concentrations from the structural fumigation were adjusted for the
 9 maximum application rate (0.3 kg per 1,000 ft³) and an estimated building size of 330,000 ft³.
 10 The annual exposure was calculated assuming only 2 days of exposure per year. Since exposure
 11 were so infrequent no seasonal exposure was calculated. Lifetime exposure was assumed to be
 12 the same as annual exposure, but was converted to mg/kg/day for ease of calculation of the
 13 cancer risk. The estimate lifetime exposure for bystanders from enclosed space fumigation was
 14 0.14 µg/kg/day.

15 **Table 22.** Estimated Exposure for Bystanders to Chloropicrin Following Enclosed Space
 16 Fumigation^a

17 Exposure Duration	Concentration (µg/m ³)	Concentration (ppb)
18 Acute - 1 hour ^b	2,400	360
19 Acute - 8 hour ^c	680	100
20 Acute - 24 hr ^d	210	31
21 Annual ^e	1.2	0.18

22 a Exposure estimates for bystanders were based on air monitoring data from ARB (2005a) following structural fumigation
 23 adjusting for recovery (79%), a maximum application rate of 0.3 kg/1,000 ft³ and an estimated building size of 330,000 ft³.
 24 The study conducted in Nevada County during the fumigation of a two-story house with a fumigation volume of 81,000 ft³
 25 had the highest air concentration 1.5 m northwest of the house during mechanical ventilation (ARB, 2005a). Exposure
 26 estimates were adjusted for recovery and the maximum application rate (Beauvais, 2009).
 27 b The 1-hour exposure was based on the air concentration during the 1.6 hour sample.
 28 c The 8-hour exposure was based on the time-weighted average of the consecutive 1.6 and 4.9-hour concentrations.
 29 d The 24-hour exposure is based on the average of the consecutive 12-hour concentrations.
 30 e Annual exposure was calculated from 24-hr exposure assuming 2 days of exposure per 365 days.

31 III.C. RISK CHARACTERIZATION

32 The risk for non-carcinogenic human health effects is expressed as a margin of exposure
 33 (MOE). The MOE is the ratio of the NOEL from experimental animal studies to the human
 34 exposure dosage.

$$35 \text{ Margin of Exposure} = \frac{\text{NOEL}}{\text{Exposure Dosage}}$$

36 The risk for carcinogenic effects was calculated by multiplying the carcinogenic potency
 37 by the exposure dosage.

$$38 \text{ Carcinogenic Risk} = \text{Carcinogenic Potency} \times \text{Exposure Dosage}$$

1 III.C.1. Soil Fumigation

2 III.C.1.a. Bystander Exposure

3 The acute MOEs for 1-hr exposure to chloropicrin were calculated for adults and children
4 using the BMDL₁₀ for eye irritation (26 ppb) and the worse case 1-hr bystander exposure
5 estimates for the different application methods in Table 19. The 1-hr acute MOE for eye
6 irritation ranged 0.016 to 0.0016 for both children and adults (Table 23). The 1-hr exposure
7 represents 63,000% to 630,000% of the 1-hr RfC for eye irritation. The 8-hr acute MOE for
8 chloropicrin was calculated using the 8-hr HECs of 270 ppb for children and 580 ppb for adults
9 and the worse case 8-hr bystander exposure estimates from Table 19. The 8-hr MOEs ranged
10 from 0.042 to 2.2 for children and from 0.088 to 4.6 for adults. The 8-hr exposure represent
11 between 4,500% and 240,000% of the RfC for children and between 2,200% and 110,000% of
12 the RfC for adults. The 24-hr MOEs were calculated using the 24-hr HECs of 92 ppb for
13 children and 190 ppb for adults and the 24-hr worse case bystander exposure estimates for the
14 different application methods from Table 19. The 24-hr MOEs ranged from 0.084 to 0.56 for
15 children and from 0.18 to 1.2 for adults. The 24-hr exposures represented between 18,000 and
16 120,000% of the RfC for children and between 8,500% and 57,000% of the RfC for adults. The
17 seasonal MOEs for chloropicrin were calculated using the subchronic HECs from the 90-day
18 inhalation study in rats (children: 35 ppb, adults: 73 ppb) and the worse case seasonal bystander
19 exposure estimates for the different application methods from Table 19. The seasonal MOEs for
20 chloropicrin ranged from 0.48 to 4.4 for children and from 1.0 to 9.1 for adults. The seasonal
21 exposure represented between 2,300 and 21,000% of the seasonal RfCs for children and between
22 1,100% and 10,000% of the RfC for adults. The MOEs for annual exposure were calculated
23 using the chronic HECs of 32 ppb for children and 68 ppb for adults and the worse case annual
24 bystander exposure estimates for the different application methods in Table 19. The annual
25 MOEs for bystanders following soil fumigation were slightly larger than the seasonal MOEs,
26 ranging from 1.3 to 12 for children and from 2.8 to 25 for adults. The annual exposure
27 represented between 840% and 7,600% of the chronic RfCs for children and between 390% and
28 3,600% of the RfC for adults.

29 The carcinogenic risk was calculated using the reasonable worse case lifetime exposure
30 estimates in Table 20 and the cancer potency estimates based on lung adenomas and carcinomas
31 in female mice [$1.3 \text{ (mg/kg/day)}^{-1}$ for MLE or $2.2 \text{ (mg/kg/day)}^{-1}$ for 95% UB]. The carcinogenic
32 risk estimates are shown in Table 24. For the residential bystanders, the carcinogenic risk
33 estimates ranged from 2.8×10^{-3} to 2.5×10^{-2} for the maximum likelihood estimate (MLE) and
34 from 4.8×10^{-3} to 4.3×10^{-2} for the 95th percentile upper bound (95% UB). The estimated
35 carcinogenic risk from lifetime exposure for occupational bystanders to chloropicrin following
36 soil fumigation ranged from 1.6×10^{-3} to 1.5×10^{-2} for the MLE and from 2.7×10^{-3} to 2.5×10^{-2}
37 for the 95% UB.

38 MOEs were not calculated for ambient air since it was assumed that exposure in ambient
39 air would be less than bystander exposure at the application site and, therefore, any mitigation
40 needed for application site exposure would also mitigate ambient air exposure.

Table 23. Estimated Margins of Exposure for Potential Bystander Exposure to Chloropicrin Following Soil Fumigation^a

Exposure Scenarios	Children		Adults	
	MOE	% RfC ^b	MOE	% RfC
Acute - 1 hr				
Broadcast, non-tarped	0.0016	630,000	0.0016	630,000
Bedded, non-tarped	0.0026	380,000	0.0026	380,000
Bedded, tarped	0.0023	440,000	0.0023	440,000
Broadcast, tarped	0.0044	230,000	0.0044	230,000
Bedded, drip, tarped	0.016	63,000	0.016	63,000
Acute - 8 hr				
Broadcast, non-tarped	0.042	240,000	0.088	110,000
Bedded, non-tarped	0.068	150,000	0.14	69,000
Bedded, tarped	0.060	170,000	0.13	80,000
Broadcast, tarped	0.49	21,000	1.0	9,300
Bedded, drip, tarped	2.2	4,500	4.6	2,200
Acute - 24 hr				
Broadcast, non-tarped	0.095	110,000	0.20	50,000
Bedded, non-tarped	0.12	81,000	0.26	39,000
Bedded, tarped	0.084	120,000	0.18	57,000
Broadcast, tarped	0.14	70,000	0.30	33,000
Bedded, drip, tarped	0.56	18,000	1.2	8,500
Seasonal				
Broadcast, non-tarped	1.8	5,500	3.8	2,600
Bedded, non-tarped	1.7	5,900	3.5	2,900
Bedded, tarped	0.48	21,000	1.0	10,000
Broadcast, tarped	1.5	6,800	3.1	3,300
Bedded, drip, tarped	4.4	2,300	9.1	1,100
Chronic				
Broadcast, non-tarped	5.0	2,000	11	950
Bedded, non-tarped	4.6	2,200	9.7	1,000
Bedded, tarped	1.3	7,600	2.8	3,600
Broadcast, tarped	4.1	2,500	8.6	1,200
Bedded, drip, tarped	12	840	25	390

a Margin of Exposure (MOE) = NOEL or HEC / Exposure Dosage. NOEL= No-Observed-Effect Level. HEC = Human Equivalent Concentration. Acute 1-hr NOEL = 26 ppb (humans - eye irritation) for children and adults. Acute 8-hr HEC = 270 ppb for children and 580 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Acute 24-hr HEC = 92 ppb for children and 190 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Subchronic HEC = 35 ppb for children and 73 ppb for adults (female rats - rhinitis). Chronic HEC = 32 ppb for children and 68 ppb for adults (female mice - bronchiectasis). Exposure dosages from Table 19 assuming the bystander was downwind, 10 ft (3.0 m) from the edge of a square, 40-acre field and the breathing zone was 4 ft (1.2 m) above ground. Values rounded to two significant figures.

b % RfC = Percentage of Reference Concentration. The 1-hr, 8-hr, 24-hr, seasonal and chronic RfCs for chloropicrin for children are 8.7 ppb, 2.7 ppb, 0.92 ppb, 0.35 ppb and 0.32 ppb, respectively. The respective RfCs for adults are 8.7 ppb, 5.8 ppb, 1.9 ppb, 0.73 ppb and 0.68 ppb. See Table 18 for more details. Values rounded to two significant figures.

Table 24. Estimated Cancer Risk for Bystanders Exposed to Chloropicrin Following Soil Fumigation^a

Application Method	Residential		Occupational	
	MLE ^b	95% UB ^c	MLE	95% UB
Broadcast, non-tarped	1.4×10^{-2}	2.3×10^{-2}	7.7×10^{-3}	1.3×10^{-2}
Bedded, non-tarped	1.5×10^{-2}	2.5×10^{-2}	8.4×10^{-3}	1.4×10^{-2}
Bedded, tarped	2.5×10^{-2}	4.3×10^{-2}	1.5×10^{-2}	2.5×10^{-2}
Broadcast, tarped	8.3×10^{-3}	1.4×10^{-2}	4.7×10^{-3}	8.0×10^{-3}
Bedded, drip, tarped	2.8×10^{-3}	4.8×10^{-3}	1.6×10^{-3}	2.7×10^{-3}

a Carcinogenic Risk = Carcinogenic Potency x Exposure Dosage. The exposure dosage was the lifetime exposure estimates in Table 20. The maximum likelihood estimate for carcinogenic potency was $1.3 \text{ (mg/kg/day)}^{-1}$. The 95% upper bound estimate for carcinogenic potency was $2.2 \text{ (mg/kg/day)}^{-1}$.

b MLE = Maximum Likelihood Estimate

c 95% UB = 95th percentile upper bound

III.C.2. Structural Fumigation

III.C.2.a. Bystander Exposure

The MOEs for 1-hr exposure to chloropicrin for bystanders near structural fumigation were calculated for adults and children using the acute BMDL₁₀ for eye irritation (26 ppb) and the 1-hr exposure estimate (11 ppb) for structural fumigation from Table 21. The 1-hr acute MOE for structural fumigation is 2.4 for both children and adults (Table 25). The 1-hr exposure estimate represents 420% of the 1-hr RfC for chloropicrin. The 8-hr acute MOE for structural fumigation was calculated using the 8-hr HECs of 270 ppb for children and 580 ppb for adults and the 8-hr exposure estimate (2.4 ppb). The 8-hr MOEs were 110 and 240 for children and adults, respectively. The 8-hr exposure represent 87% and 41% of the RfC for children and adults, respectively. The 24-hr MOEs were calculated using the 24-hr HECs of 92 ppb for children and 190 ppb for adults and a 24-hr exposure estimate for structural fumigation (0.92 ppb). The 24-hr MOEs were 100 and 210 for children and adults, respectively. The 24-hr exposures for structural fumigation represented 100% and 48% of the RfC for children and adults, respectively.

III.C.2.b. Indoor Exposure

The 24-hr MOEs for indoor air exposure to chloropicrin were calculated using the 24-hr HEC (92 ppb for children and 190 ppb for adults) and the highest adjusted 24-hr indoor air concentrations (21 ppb). The 24-hr MOEs for indoor air were estimated to be 4.4 (2,300% RfC) for children and 9.0 (1,100% RfC) for adults.

Table 25. Estimated Margins of Exposure for Potential Bystander Exposure to Chloropicrin Following Structural Fumigation^a

Exposure Scenarios	Children		Adults	
	MOE	% RfC ^b	MOE	% RfC
Acute - 1 hr	2.4	420	2.4	420
Acute - 8 hr	110	87	240	41
Acute - 24 hr	100	100	210	48

a Margin of Exposure (MOE) = NOEL or HEC / Exposure Dosage. NOEL= No-Observed-Effect Level. HEC = Human Equivalent Concentration. Acute 1-hr NOEL = 26 ppb (humans, eye irritation) for children and adults. Acute 8-hr HEC = 270 ppb for children and 580 ppb for adults (rabbits, mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Acute 24-hr HEC = 92 ppb for children and 190 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Exposure dosages from Table 21. Values rounded to two significant figures.

b % RfC = Percentage of Reference Concentration. The 1-hr, 8-hr, and 24-hr RfCs for chloropicrin for children are 8.7 ppb, 2.7 ppb, and 0.92 ppb, respectively. The respective RfCs for adults are 8.7 ppb, 5.8 ppb, and 1.9 ppb. See Table 18 for more details. Values rounded to two significant figures.

16 III.C.3. Enclosed Space Fumigation

17 III.C.3.a. Bystander Exposure

18 The MOEs for 1-hr exposure to chloropicrin for bystanders near enclosed space
 19 fumigation were calculated for adults and children using the acute BMDL₁₀ for eye irritation (26
 20 ppb) and the 1-hr exposure estimate (360 ppb) for enclosed space fumigation from Table 22.
 21 The 1-hr acute MOE for enclosed space fumigation is 0.072 for both children and adults (Table
 22 26). The 1-hr exposure estimate represents 14,000% of the 1-hr RfC for chloropicrin. The 8-hr
 23 acute MOE for enclosed space fumigation was calculated using the 8-hr HECs of 270 ppb for
 24 children and 580 ppb for adults and the 8-hr exposure estimate (100 ppb). The 8-hr MOEs were
 25 2.8 and 5.8 for children and adults, respectively. The 8-hr exposure represent 3,600% and
 26 1,700% of the RfC for children and adults, respectively. The 24-hr MOEs were calculated using
 27 the 24-hr HECs of 92 ppb for children and 190 ppb for adults and a 24-hr exposure estimate for
 28 structural fumigation (31 ppb). The 24-hr MOEs were 3.0 and 6.2 for children and adults,
 29 respectively. The 24-hr exposures for structural fumigation represented 3,400% and 1,600% of
 30 the RfC for children and adults, respectively. The MOEs for annual exposure were calculated
 31 using the chronic HECs of 32 ppb for children and 68 ppb for adults and the worse case annual
 32 bystander exposure estimates for enclosed space fumigation in Table 22. The annual MOEs for
 33 chloropicrin were 180 for children and 380 for adults. The annual exposure represented 56% of
 34 the chronic RfCs for children and 26% of the RfC for adults. The carcinogenic risk was
 35 calculated using the lifetime exposure of 0.14 µg/kg/day and the cancer potency estimates based
 36 on lung tumors in female mice [1.3 (mg/kg/day)⁻¹ for MLE or 2.2 (mg/kg/day)⁻¹ for 95% UB].
 37 The carcinogenic risk estimates ranged from 1.9 x 10⁻⁴ (MLE) to 3.2 x 10⁻⁴ (95% UB).

Table 26. Estimated Margins of Exposure for Potential Bystander Exposure to Chloropicrin Following Enclosed Space Fumigation^a

Exposure Scenarios	Children		Adults	
	MOE	% RfC ^b	MOE	% RfC
Acute - 1 hr	0.072	14,000	0.072	14,000
Acute - 8 hr	2.8	3,600	5.8	1,700
Acute - 24 hr	3.0	3,400	6.2	1,600
Annual	180	56	380	26

a Margin of Exposure (MOE) = NOEL or HEC / Exposure Dosage. NOEL= No-Observed-Effect Level. HEC = Human Equivalent Concentration. Acute 1-hr NOEL = 26 ppb (humans - eye irritation) for children and adults. Acute 8-hr HEC = 270 ppb for children and 580 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Acute 24-hr HEC = 92 ppb for children and 190 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Annual HEC = 32 ppb for children and 68 ppb for adults (female mice - bronchiectasis). Exposure dosages from Table 22. Values rounded to two significant figures.

b % RfC = Percentage of Reference Concentration. The 1-hr, 8-hr, and 24-hr RfCs for chloropicrin for children are 8.7 ppb, 2.7 ppb, 0.92 ppb and 0.32 ppb, respectively. The respective RfCs for adults are 8.7 ppb, 5.8 ppb, 1.9 ppb and 0.68 ppb. See Table 18 for more details. Values rounded to two significant figures.

1

IV. RISK APPRAISAL

2 Risk assessment is the process used to evaluate the potential for human exposure and the
3 likelihood that the adverse effects observed in toxicity studies with laboratory animals will occur
4 in humans under the specific exposure conditions. Every risk assessment has inherent
5 limitations on the application of existing data to estimate the potential risk to human health.
6 Therefore, certain assumptions and extrapolations are incorporated into the hazard identification,
7 dose-response assessment, and exposure assessment processes. These, in turn, result in
8 uncertainty in the risk characterization which integrates all the information from the previous
9 three processes. Qualitatively, risk assessments for all chemicals have similar uncertainties.
10 However, the degree or magnitude of the uncertainty can vary depending on the availability and
11 quality of the data, and the types of exposure scenarios being assessed. Specific areas of
12 uncertainty associated with this risk assessment for chloropicrin are delineated in the following
13 discussion.

14 Following the discussion of the uncertainties related to the different components of
15 DPR's risk assessment is a comparison with the endpoints and exposure estimates used in U.S.
16 EPA's risk assessment for chloropicrin. In addition, there is a discussion of the information
17 available for chloropicrin related to Food Quality Protection Act including potential increased
18 pre- and post-natal sensitivity in infants and children, endocrine effects, cumulative toxicity and
19 aggregate exposure. Both the uncertainties in the risk estimates and the information related to
20 FQPA can be used in determining the adequacy of the MOEs for chloropicrin.

IV.A. HAZARD IDENTIFICATION

22 The acute 1-hr MOEs were calculated using the BMDL₁₀ for eye irritation from the
23 human study. Since chloropicrin is used as a warning agent, a certain amount of eye irritation
24 may be considered acceptable. An alternative endpoint from the human study that could be
25 used to evaluate 1-hr exposures is the slight increase in nitric oxide (NO) in expired nasal air
26 which is an early sign of inflammation of the nasal epithelium. The BMDL₁₀ estimate for the
27 increased NO in nasal air was 75 ppb (0.5 mg/m³). The RfC for this endpoint would be 7.5 ppb
28 by dividing by an uncertainty factor of 10 for intraspecies variation. The differences in
29 breathing rate between adults and children were considered unimportant with this endpoint. If
30 this BMDL₁₀ was used to calculate the acute 1-hr MOEs for soil fumigation, they would be
31 approximately 3-fold higher than estimated as shown in Table 27. The 1-hr MOEs for structural
32 fumigation would also increase from 2.4 to 6.8 (i.e., from 420% to 150% of RfC).

33 Other uncertainties involved in selecting the acute 1-hr NOEL for chloropicrin was in the
34 BMD analysis for the human study. An alternative approach to the hybrid method used in the
35 BMD analysis for this study was to convert the continuous data to quantal data. With this
36 approach, only the scores during the plateau period (minutes 31-55 of exposure) were used. The
37 highest average score with exposure to blank air during the plateau over the 4 days of exposure
38 for any subject was 0.87. Therefore, 1.0 seemed like a logical threshold for identifying
39 responders based on their average score over the 4 days during the plateau period. Using this
40 threshold, the number of responders were 0, 6 and 15 at 0, 100 and 150 ppb, respectively. Four
41 of the quantal models had the best fit with identical AIC, X² values, and p-values for X², but they
42 had slightly different BMDL₁₀ estimates. The average of the BMDL₁₀ estimates from these four

Table 27. Estimated Acute One-Hour Margins of Exposure for Potential Bystander Exposure to Chloropicrin Following Soil Fumigation Based on Increased Nitric Oxide in Expired Nasal Air^a

Exposure Scenarios	Children		Adults	
	MOE	% RfC ^b	MOE	% RfC
Acute - 1 hr - ↑ nasal NO Broadcast, non-tarped	0.0046	220,000	0.0046	220,000
Bedded, non-tarped	0.0075	130,000	0.0075	130,000
Bedded, tarped	0.0065	150,000	0.0065	150,000
Broadcast, tarped	0.013	79,000	0.013	79,000
Bedded, drip, tarped	0.046	22,000	0.046	22,000

a Margin of Exposure (MOE) = NOEL or HEC / Exposure Dosage. NOEL= No-Observed-Effect Level. HEC = Human Equivalent Concentration. Acute 1-hr NOEL = 75 ppb (humans, ↑ NO in expired nasal air) for children and adults. Exposure dosages from Table 19. Values rounded to two significant figures.

b % RfC = Percentage of Reference Concentration. The 1-hr RfC based on ↑ NO in expired nasal air is 7.5 ppb for both children and adults.

models was 33 ppb. Since only one subject had an average score greater than 0.5 over the 4 days of exposure during the plateau period, the use of this threshold was also examined. Using this threshold, there were 1, 12 and 15 responders at 0, 100 and 150 ppb, respectively. Only one model, the Log-Logistic model, had the best fit with a BMDL₁₀ of 13 ppb. Haber *et al.* (2005) also did a BMD analysis of these data using an average score of 1.5 during the plateau period as the cutoff. The rationale for the cutoff of 1.5 was based on chloropicrin being used as a warning agent so that a certain amount of mild eye irritation would be acceptable. This resulted in an incidence of 0, 2, and 9 responders at 0, 100 and 150 ppb, respectively. The average BMDL₁₀ for the best fitting models (Gamma, Log-Logistic, Log-Probit and Weibull) was 73 ppb.

Since there was wide inter-individual variation in sensitivity to chloropicrin, another approach considered for converting continuous data to quantal data was setting individual thresholds based on their response during exposure to blank air. All of the subjects were exposed to blank air as well as the two different air concentrations of chloropicrin, so the upper confidence limit (UCL) on a subject's response during the exposure to the blank air was used to define that individual's threshold, rather than using one threshold value for all subjects. The UCL was defined as follows:

$$UCL = mean + \frac{1.645 \times SD}{\sqrt{n}}$$

where the mean is the mean of the four daily averages and SD is the standard deviation of the four daily averages and n is the number of daily averages. Any subject with an overall mean score greater than their UCL during exposure was considered a responder. Using this definition, 22 subjects were responders at 100 ppb and 27 subjects were responders at 150 ppb. Five of the quantal models had the lowest X² values, the highest p-values for X² and identical AIC scores, but they had slightly different BMDL₁₀ estimates. Therefore, the BMDL₁₀ estimates from these 5 models were averaged, resulting in an average BMDL₁₀ of 7.1 ppb.

A single threshold was also considered for converting the continuous nasal NO concentration data to quantal data. The study investigator considered an increase greater than 25% to be clinically significant (Haber *et al.*, 2005). Using this single threshold, there were 2, 4

1 and 7 responders at 0, 100 and 150 ppb, respectively. Three models (gamma multi-hit, log-
2 logistic, and Weibull) had the lowest X^2 values, although only the log-logistic was
3 able to calculate a p-value. The BMDL₁₀ from these three models were averaged resulting in an
4 estimate of 62 ppb.

5 Like eye irritation, there was a large inter-individual variation in the NO expired in nasal
6 air. Therefore, the nasal NO data were also converted to quantal data using the UCL of the
7 differences during exposure to blank air to define individual thresholds. Using this approach,
8 there were 9 responders at 100 ppb and 13 responders at 150 ppb. The model with the best fit
9 appears to be the Gamma model with a BMDL₁₀ of 22.2 ppb. Overall the BMDL₁₀ estimates
10 were higher for nasal NO production (11-53 ppb) than for eye irritation (2-12 ppb), indicating
11 ocular irritation is the more sensitive endpoint.

12 The Office of Environmental Health Hazard Assessment (OEHHA) in the California
13 Protection Agency (Cal/EPA) derived a 1-hour Reference Level Exposure (REL) for
14 chloropicrin using the RD₅₀ study in mice conducted by Kane *et al.* (1974). They did a BMD
15 analysis to derive a BMD₀₅ of 790 ppb (5,300 $\mu\text{g}/\text{m}^3$) for the respiratory depression. Applying
16 Haber's Law to adjust from the 10 minute exposure to a 1-hour exposure, the 1-hr BMD₀₅
17 became 132 ppb. It is interesting to note that OEHHA applied Haber's Law to estimate the 1-hr
18 REL since some think that sensory irritation is more concentration dependent. However, looking
19 at the human study, during the first 30 minutes of exposure the severity of the eye irritation does
20 appear to increase with time. Therefore, this assumption appears to be appropriate for
21 extrapolating from time periods less than an hour up to an hour. OEHHA used an interspecies
22 factor of only 3 due to the greater degree of certainty or precision in estimating a threshold in
23 animals using a BMD analysis instead of the NOAEL approach. However, OEHHA did not
24 think that the increased precision with the BMD analysis reduced the human variability,
25 therefore, a standard intraspecies uncertainty factor of 10 was applied. This resulted in a 1-hr
26 REL for chloropicrin of 4.4 ppb. It is noteworthy that OEHHA's 1-hr REL based on sensory
27 irritation in mice is only slightly lower than DPR's 1-hr RfC, 8.7 ppb, based on sensory irritation
28 in humans.

29 The inhalation developmental toxicity study in rabbits conducted by York (1993) was
30 selected as the definitive study for evaluating acute exposures of 8 and 24 hours. The endpoints
31 observed at the LOEL in this study (maternal: death, nasal discharge, reduced body weights and
32 food consumption, red discoloration of lungs) were more severe than those measured in the
33 human study (eye irritation). The NOEL might have been higher if only a single dose had been
34 administered since most effects, except the nasal discharge were not seen until after more than
35 one dose was administered. Also, the respiratory effects in this study could also be local effects
36 that were concentration dependent and not time dependent, in which case Haber's Law did not
37 apply and the 8-hr and 24-hr NOEL would be same as the 6-hr NOEL. On the other hand, the
38 NOEL and MOEs might have been lower in this study if sensory irritation had been evaluated in
39 the animals. It is interesting to note that the 8-hour RfC based on this study is almost identical
40 to the 1-hour RfC based on the sensory irritation in humans and the 1-hr REL that OEHHA
41 derived based on sensory irritation in mice. If Haber's Law does not apply to the eye irritation,
42 then the 8-hour and 24-hour RfC should be the same as the 1-hour RfC.

43 The 90-day inhalation study in rats was selected as the definitive study for evaluating
44 seasonal exposure to chloropicrin with a critical NOEL of 120 ppb based on BMDL₀₅ for rhinitis

1 in females rats (Chun and Kintigh, 1993). A NOEL of 300 ppb was observed in this study and in
2 the 90-day inhalation study in mice, although the mice appeared to be more sensitive based on
3 more severe effects at the LOEL including reduced body weights and food consumption,
4 increased lung weights and histopathological lesions in the nasal cavity and lungs (Chun and
5 Kintigh, 1993). The lowest BMDL₀₅ values were found in female mice for alveolar
6 histiocytosis (81 ppb) and epithelial hyalin inclusions (84 ppb). However, after converting to an
7 HEC taking species differences in breathing rate into consideration, the HEC for rhinitis in
8 female rats was lower than the HECs for alveolar histiocytosis (44 ppb) and epithelial hyalin
9 inclusions (45 ppb). If these HECs for alveolar histiocytosis or epithelial hyalin inclusions in
10 female mice had been used instead of the one for rhinitis, the subchronic MOEs would be about
11 25-30% higher than calculated. Alternatively, if the observed NOEL of 300 ppb in rats (HEC =
12 87 ppb) was used, subchronic MOEs would be 2.5 times larger than estimated.

13 A similar situation occurred in the selection of the definitive study for evaluating chronic
14 exposure to chloropicrin. A NOEL of 100 ppb was observed in both rats and mice. The lesions
15 were more severe in mice, but if breathing rate was taken into consideration the NOEL in rats
16 was lower. Therefore, DPR performed a BMD analysis on the more sensitive endpoints in the
17 chronic inhalation studies and found the bronchiectasis in female mice to be the most sensitive
18 endpoint with a BMDL₀₅ of 59 ppb. Even with adjusting for breathing rate, the HECs for this
19 endpoint (32 and 68 ppb for children and adults, respectively) were the lowest. If the NOEL had
20 been used instead of the BMCL₀₅, the lowest HECs would have been in rats (29 and 62 ppb for
21 children and adults, respectively). If these HECs had been used the chronic MOEs would have
22 been lower by about 10%.

23 DPR concluded the weight of evidence for carcinogenicity was sufficient due to the
24 positive genotoxicity data and significant increase in adenomas and carcinomas in the lungs of
25 female mice when survival was taken into consideration. If this adjustment for survival was not
26 considered appropriate, the p-value for the Fisher's exact test at the high dose would be just
27 outside the range that is normally considered statistically significant ($p = 0.053$). Due to this
28 borderline statistical significance, an alternative approach might be preferred where the chronic
29 HEC is divided by an additional uncertainty factor of 10 to derive the chronic RfC to cover the
30 limited evidence for carcinogenicity. This would result in a carcinogenicity RfC of 6.2 ppt
31 which is 25 times larger than the carcinogenicity RfC calculated assuming there is no threshold
32 (0.24 ppt).

33 **IV.B. EXPOSURE ASSESSMENT**

34 Most of the uncertainties associated with the ambient and application site air exposure
35 estimates were also discussed in the Exposure Appraisal section of the Exposure Assessment
36 Document for chloropicrin (Beauvais, 2009) and will not be repeated here. One uncertainty that
37 warranted further discussion was the impact of the modeling on the exposure estimates.
38 Modeling was done to estimate a reasonable worst case exposure since the application site
39 monitoring that was done could have underestimated the exposure depending on the
40 environmental conditions and location of samplers. Additional exposure estimates were
41 calculated using the 50th percentile of the application rate (150 lbs/acre) and field size (15 acres)
42 which were summarized in Appendix 3 of the Exposure Assessment Document for chloropicrin
43 (Beauvais, 2009). These air concentrations are shown in Table 28 along with their respective

MOEs for acute exposure. Exposure estimates were also calculated for different distances from the field edge. The air concentrations using both the 50th percentile for application rate and field size and ½-mile buffer zone are shown in Table 29 along with their respective MOEs. Even with a half-mile buffer zone using the 50th percentile for application rate and field size, none of the MOEs were adequate for acute exposure.

Table 28. Estimated Air Concentrations and Margins of Exposure for Bystanders to Chloropicrin Following Soil Fumigation Using the 50th Percentile^a

Exposure Scenario	Air Concentration		Margin of Exposure	
	µg/m ³	ppb	Children	Adults
Acute - 1 hr ^{b,c}				
Broadcast, non-tarped	24,000	3,600	0.0073	0.0073
Bedded, non-tarped	29,000	4,300	0.0060	0.0060
Bedded, tarped	17,000	2,500	0.010	0.010
Broadcast, tarped	9,700	1,400	0.018	0.018
Bedded, drip, tarped	4,600	680	0.038	0.038
Acute - 8 hr ^c				
Broadcast, non-tarped	9,700	1,400	0.19	0.40
Bedded, non-tarped	12,000	1,800	0.15	0.32
Bedded, tarped	6,900	1,000	0.27	0.56
Broadcast, tarped	4,000	590	0.46	0.97
Bedded, drip, tarped	1,900	280	0.97	2.0
Acute - 24 hr				
Broadcast, non-tarped	1,600	240	0.39	0.81
Bedded, non-tarped	2,500	370	0.25	0.52
Bedded, tarped	1,900	280	0.33	0.68
Broadcast, tarped	1,100	160	0.56	1.2
Bedded, drip, tarped	470	70	1.3	2.8

a Margin of Exposure = NOEL or HEC / Exposure Dosage. NOEL= No-Observed-Effect Level. HEC = Human Equivalent Concentration. Acute 1-hr NOEL = 26 ppb (humans - eye irritation) for children and adults. Acute 8-hr HEC = 270 ppb for children and 580 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Acute 24-hr HEC = 92 ppb for children and 190 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Exposure dosages from Appendix 3 of the Exposure Assessment Document using the 50th percentile for application rate (150 lbs/acre) and field size (15 acres) and assuming the bystander was downwind, 10 ft (3.0 m) from the edge of the field and the breathing zone was 4 ft (1.2 m) above ground (Beauvais, 2009). Values rounded to two significant figures.

b The 1-hr exposure was estimated from the highest 6-hr concentration for the different application methods (using the peak-to-mean ratio: $C_p = C_m(t_p/t_m)^{1/2}$ where C_p is the peak concentration over the peak period of interest, t_p , and C_m is the mean concentration over mean measurement period, t_m).

c The highest day or night 6-hr air concentration for each application method was used for their respective 1-hr and 8-hr exposure estimates.

Another reality check is a comparison of the exposure estimates derived from modeling with flux data with the off-site air concentrations from application site monitoring studies. In Table 7 of the Exposure Assessment Document, the highest air concentration for a 6-hr sampling period was 5,322 µg/m³ for broadcast non-tarped application after adjusting for the maximum application rate. This off-site air concentration is almost an order of magnitude lower than the air concentration estimate from the modeling using the flux data from the same study (44,000 µg/m³). However, the field in the broadcast/untarped study was only 8 acres and the modeling

Table 29. Estimated Air Concentrations and Margins of Exposure for Bystanders to Chloropicrin Following Soil Fumigation Using the 50th Percentile and ½-Mile Buffer Zone^a

Exposure Scenario	Air Concentration		Margin of Exposure	
	µg/m ³	ppb	Children	Adults
Acute - 1 hr ^{b,c}				
Broadcast, non-tarped	5,900	880	0.030	0.030
Bedded, non-tarped	7,400	1,100	0.024	0.024
Bedded, tarped	4,200	620	0.042	0.042
Broadcast, tarped	1,500	220	0.12	0.12
Bedded, drip, tarped	720	110	0.24	0.24
Acute - 8 hr ^c				
Broadcast, non-tarped	2,400	360	0.77	1.6
Bedded, non-tarped	3,000	450	0.62	1.3
Bedded, tarped	1,700	250	1.1	2.3
Broadcast, tarped	620	92	3.0	6.3
Bedded, drip, tarped	290	43	6.4	13
Acute - 24 hr				
Broadcast, non-tarped	160	24	3.9	8.1
Bedded, non-tarped	250	37	2.5	5.2
Bedded, tarped	180	27	3.4	7.2
Broadcast, tarped	110	16	5.6	12
Bedded, drip, tarped	45	6.7	14	29

a Margin of Exposure = NOEL or HEC / Exposure Dosage. NOEL= No-Observed-Effect Level. HEC = Human Equivalent Concentration. Acute 1-hr NOEL = 26 ppb (humans - eye irritation) for children and adults. Acute 8-hr HEC = 270 ppb for children and 580 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Acute 24-hr HEC = 92 ppb for children and 190 ppb for adults (rabbits - mortalities, nasal discharge, ↓ body weights & food consumption, red discoloration in lungs in does and skeletal variations in fetuses). Exposure dosages from Appendix 3 of the Exposure Assessment Document using the 50th percentile for application rate (150 lbs/acre) and field size (15 acres) and assuming the bystander was downwind, 2,500 ft (760 m) from the edge of the field and the breathing zone was 4 ft (1.2 m) above ground (Beauvais, 2009). Values rounded to two significant figures.

b The 1-hr exposure was estimated from the highest 6-hr concentration for the different application methods (using the peak-to-mean ratio: $C_p = C_m(t_p/t_m)^{1/2}$ where C_p is the peak concentration over the peak period of interest, t_p , and C_m is the mean concentration over mean measurement period, t_m).

c The highest day or night 6-hr air concentration for each application method was used for their respective 1-hr and 8-hr exposure estimates.

assumed a 40 acre field. Also, the closest sampler in the broadcast/untarped study was 60 ft from the field edge whereas the modeling estimated exposure at 10 ft from the field edge. The off-site air concentrations from the broadcast/untarped study were almost uniform out to 180 ft suggesting that the near field concentration was not likely the maximum off-site concentration during that sampling period. Taking these differences into consideration, the modeled air concentration values may still be higher than the actual air monitoring values by a factor of 2. However, the air modeling also reflects the highest possible downwind air concentration and the samplers may have missed this location. Furthermore, the screening weather conditions in the air modeling may have been more stable than those in the air monitoring study, leading to higher air concentration estimates. Insufficient information was available in the Exposure Assessment Document to readily calculate the 24-hr and 2-wk average air concentrations from the actual off-

1 site air concentrations, but the differences are likely to be smaller since the estimates for these
2 longer periods usually involved averaging the 6-hr samples to derive them.

3 Acute indoor air exposure following structural fumigation with chloropicrin was
4 probably underestimated since only 24-hour samples were collected in the monitoring studies
5 available with this use. One-hour and 8-hour exposures were not estimated since the mean-to-
6 peak ratio could not be applied to indoor air since it assumes a plume and downwind exposure.
7 For this reason, acute indoor air concentrations may be higher for periods shorter than 24 hours.

8 **IV.C. RISK CHARACTERIZATION**

9 Generally, an MOE of at least 100 is considered sufficiently protective of human health
10 when the NOEL for an adverse effect is derived from an animal study. The MOE of 100 allows
11 for humans being 10 times more sensitive than animals and for a 10-fold variation in sensitivity
12 between the lower range of the normal distribution in the overall population and the sensitive
13 subgroup (Dourson *et al.*, 2002). When the NOEL is derived from a human study, an MOE of
14 10 or greater is generally considered sufficiently protective allowing for intraspecies variation in
15 sensitivity. The inter- and intraspecies uncertainty factors may be further divided into
16 toxicokinetic and toxicodynamic components of 3.16 ($10^{0.5}$) each (Renwick and Lazarus, 1998).
17 An argument has been made that the toxicokinetic component of the intraspecies uncertainty
18 factor for sensory irritation could be reduced to one because of the mechanism of action (CMTF,
19 2009). The mechanism of action for chloropicrin with respect to sensory irritation involves the
20 direct interaction of the compound with the free trigeminal nerve endings in the respiratory
21 mucosa. Consequently, toxicokinetics should not play a significant role in the development of
22 this effect. The guidelines of the National Advisory Committee for Acute Exposure Guideline
23 Levels for Hazardous Substances recommends an intraspecies uncertainty factor of 3 when the
24 “response involves a direct acting mechanism of action where metabolic and physiologic
25 differences are unlikely to play a major role” (NAC/AEGL Committee, 2001). An argument was
26 also made to reduce the toxicodynamic component (variation in the interaction of the toxicant
27 with the receptor) to 1 based on the use of a benchmark dose analysis to set the threshold for the
28 response and that the subjects in the study represented the more sensitive human population
29 subgroup (i.e., young adults). There was a large variation in sensitivity among the subjects of
30 this study and this was taken into consideration in the use of the benchmark dose analysis to set
31 the threshold. Since the eye irritation observed was mild and reversible, a benchmark response
32 of 10% was used to set the threshold rather than the default of 5%. However, there is some
33 uncertainty whether the most sensitive individuals were tested in this study. For one, subjects
34 with asthma, allergic rhinitis, respiratory allergies, and chronic sinusitis were purposely excluded
35 from the chloropicrin human sensory irritation study. Shusterman *et al.* (2003) reported that
36 individuals with allergic rhinitis were more sensitive to sensory irritation due to various
37 biochemical mediators, such as, histamine, prostaglandin E₂, and nerve growth factor that are
38 known to augment the sensitivity of airway nerves to physical and chemical stimuli. Secondly,
39 children have rarely been tested for sensory irritation so it is unclear if they are more or less
40 sensitive than young adults. Children appear to be less able to detect odor than young adults
41 and this was attributed to a lack of odor-specific knowledge rather than reduced olfactory nerve
42 sensitivity (Cain *et al.*, 1995). For these reasons, an intraspecies uncertainty factor of at least 3 is
43 still desirable given the uncertainties regarding the toxicodynamic variation.

1 Bystander exposure to chloropicrin following soil fumigation is of concern since all of
2 the MOEs were less than 100 for both children and adults. The acute MOEs are of great concern
3 since they are all less than 1. With the 1-hr exposure, the MOEs are orders of magnitude lower
4 than the benchmark that would be considered adequate based on sensory irritation in the human
5 study (i.e., 3). Even if the intraspecies uncertainty factor had been reduced to 1X, the bystander
6 exposure would still be of concern. The seasonal and chronic MOEs for soil fumigation air were
7 greater than 1 (except for seasonal bedded tarped application), but still less than 100 which is the
8 target MOE for these exposure durations since the NOELs were based on animal studies. All of
9 the bystander exposures meet the criteria for identifying chloropicrin as a toxic air contaminant
10 since the MOEs are not 10-fold greater than the benchmark or target MOE that is considered
11 adequately protective of human health (California Code of Regulations, Title 3, Division 6,
12 Section 6890).

13 The bystander MOEs for chloropicrin following structural fumigation are higher than
14 those for soil fumigation, but the 1-hr bystander MOEs for structural fumigation are still lower
15 than 3, thus the acute exposure for structural fumigation is of concern. The 8-hr and 24-hr
16 bystander MOEs for structural fumigation are greater than 100 and, therefore, these exposure
17 scenarios do not present a health concern. However, none of the acute bystander MOEs for
18 structural fumigation are 10-fold greater than the target MOEs and, therefore, they meet the
19 criteria for listing chloropicrin as a toxic air contaminant. The 24-hr MOEs for indoor air after
20 complete aeration with structural fumigation are of concern since they are less than 100. The
21 indoor air concentrations would also meet the criteria for listing chloropicrin as a toxic air
22 contaminant.

23 Bystander exposure following enclosed space fumigation with chloropicrin is of concern
24 since all of the acute MOEs are less than their target MOE by at least a couple of orders of
25 magnitude. Consequently, off-site air concentrations associated with enclosed space fumigation
26 clearly meet the criteria for listing chloropicrin as a toxic air contaminant.
27

28 A carcinogenic risk level less than 10^{-6} is generally considered negligible. The
29 carcinogenic risk estimates for residential bystanders and occupational bystanders for soil
30 fumigation were significantly greater (10^{-3} to 10^{-2}) than the negligible risk level, and therefore,
31 are of great concern. Since the cancer risk level is not 10-fold below the benchmark that is
32 generally considered negligible (i.e., $< 10^{-7}$), the lifetime exposure to chloropicrin following soil
33 fumigant for both residential and occupational bystanders meet the criteria for listing it as a toxic
34 air contaminant. The lifetime bystander exposure to chloropicrin associated with enclosed space
35 fumigation is also of concern although the cancer risk estimates are less than those associated
36 with soil fumigation, but they are still greater ($\sim 10^{-4}$) than the negligible risk level. For this
37 reason, the lifetime bystander exposure for enclosed space fumigation is also sufficiently high to
38 meet the criteria for listing chloropicrin as a toxic air contaminant.

39 **IV.D. U.S. EPA'S HUMAN HEALTH RISK ASSESSMENT FOR CHLOROPICRIN**

40 U.S. EPA completed a Human Health Risk Assessment for chloropicrin in June 2008
41 (Reaves and Smith, 2008). U.S. EPA evaluated occupational and residential exposure to
42 chloropicrin in the air using inhalation NOELs. U.S. EPA did not evaluate dietary exposure to
43 chloropicrin since no residues are anticipated on food based on its volatility and results from

1 metabolism studies on soil and plants. Therefore, there are no food tolerances for chloropicrin.
2 U.S. EPA evaluated acute (1-24 hours) non-occupational and occupational exposure to
3 chloropicrin using the human sensory irritation study. This study was evaluated by U.S. EPA's
4 Human Studies Review Board (HSRB) which concluded it was conducted in an ethical manner
5 and was scientifically sound. U.S. EPA adopted the benchmark dose analysis of the human
6 study performed by TERA which was sponsored by the Chloropicrin Manufacturers Task Force.
7 The benchmark concentration (BMC) at the 10% response level (BMC_{10}) of 73 ppb was selected
8 as the NOAEL or point of departure. In their analysis, TERA converted the eye irritation scores
9 which were continuous to quantal data by selecting a cut-off for the average score during the
10 plateau period to define adversity. The average score selected was 1.5 assuming that a certain
11 amount of mild irritation was acceptable given its use as a warning agent. This is in contrast to
12 DPR's approach that made no assumption about the adversity of a given average eye irritation
13 score, but instead used the standard deviation of the average scores with exposure to the blank
14 air to define the threshold. Consequently, the BMC_{10} that DPR used to evaluate acute exposure
15 was 26 ppb or approximately 3-fold lower than that used by U.S. EPA. Unlike U.S. EPA, DPR
16 only used the human study to evaluate exposures up to 1-hr. Due to uncertainties about the
17 applicability of Haber's Law to sensory irritation, which is more concentration dependent than
18 time dependent, DPR derived 8-hr and 24-hr NOELs from a developmental toxicity study in
19 rabbits based on maternal effects observed within the first few days of exposure (deaths with red
20 discolored lungs, nasal discharge, and reduced body weights and food consumption) that were
21 not clearly concentration dependent so Haber's Law was applied. The estimated 8-hr and 24-hr
22 NOELs that DPR used were 27 and 9 ppb, respectively. These NOELs were approximately 3-
23 fold and 8-fold lower than those U.S. EPA used to evaluate acute occupational and non-
24 occupational exposure, respectively.

25 Unlike DPR, U.S. EPA did not do a BMD analysis on the subchronic studies. Instead
26 they used the observed NOELs and converted them to HECs using a regional gas dose ratio
27 (RGDR) which adjusts for interspecies differences in not only breathing rate, but also regional
28 surface area, if the effects were local. The RGDR for respiratory effects is basically the ratio of
29 the minute volume to the regional surface area in animals divided by the ratio of the minute
30 volume to the regional surface area in humans. For this purpose, the respiratory tract was
31 divided into three regions: extrathoracic, tracheobronchial and pulmonary. Using the RGDR for
32 extrathoracic effects, U.S. EPA calculated a HEC of 8 ppb for the 90-day mouse inhalation
33 study, which it used to evaluate seasonal non-occupational exposure to chloropicrin. U.S. EPA's
34 HEC for seasonal occupational exposure was 35 ppb assuming exposure was limited to 8
35 hrs/day, 5 days/wk. DPR did not calculate different HECs for occupational and residential
36 exposure, but did calculate different HECs for adults and children based on differences in their
37 breathing rates. DPR's subchronic HEC for children was 35 ppb and for adults was 73 ppb.

38 U.S. EPA assumes that pharmacokinetic differences are taken into consideration in the
39 RGDR adjustment and, consequently, only use an uncertainty factor of 3 for interspecies
40 differences to account for pharmacodynamic differences. DPR has not adopted the use of the
41 RGDR adjustment in the HEC calculation because there are insufficient data and experience for
42 an adjustment of the dose estimate for respiratory effects based on surface area, especially on a
43 regional basis, that would adequately account for the pharmacokinetic differences between
44 species. Instead, DPR prefers to make adjustments for species differences in intake based on
45 their breathing rate and not make any assumption about the concentration of the chemical in
46 different regions of the respiratory tract. For this reason, DPR retains the use of the default

1 uncertainty factor of 10 for interspecies variation to account for both pharmacokinetic and
 2 pharmacodynamic differences. So despite the differences in the subchronic HECs, the
 3 subchronic RfCs for residential exposure are fairly similar between DPR (0.35 ppb - children)
 4 and U.S. EPA (0.27 ppb).

5 A similar situation occurred with the chronic endpoints. U.S. EPA used the chronic
 6 NOEL from the mouse inhalation study and estimated an HEC of 4 ppb for long-term non-
 7 occupational exposure and 15 ppb for long-term occupational exposure. OEHHA also calculated
 8 an HEC for the chronic mouse inhalation study using an RGDR factor, however, OEHHA's
 9 HEC for the chronic mouse study (1.6 ppb) was 2.5-fold lower than U.S. EPA's HEC because
 10 OEHHA used a BMC₀₅ of 42 ppb for this study instead of the observed NOAEL of 100 ppb.
 11 EPA's and OEHHA's HECs for the chronic mouse study are about 8-fold and 20-fold lower,
 12 respectively. However, because DPR applied a larger uncertainty factor to estimate the chronic
 13 RfC, DPR's chronic RfC was only about 3-fold higher than U.S. EPA's chronic RfC and about
 14 7-fold higher than OEHHA's chronic REL. U.S. EPA acknowledged that there may be a
 15 carcinogenic risk with oral exposure to chloropicrin based on the increase in fibroadenomas in
 16 female rats in one study with oral exposure, but they did not think chloropicrin was a carcinogen
 17 by the inhalation exposure based on the inhalation studies which, in their evaluation, did not
 18 indicate an increase in neoplasm incidence. The National Advisory Committee for Acute
 19 Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) apparently also
 20 did not consider chloropicrin carcinogenic by the inhalation route since they did not mention the
 21 increase in adenomas and carcinomas in lungs of female mice in their summary of the inhalation
 22 carcinogenicity studies for chloropicrin (NAC/AEGL Committee, 2008). Table 30 summarizes
 23 the NOELs, endpoints and RfCs that U.S. EPA used in its risk assessment for chloropicrin.

24 **Table 30.** U.S. EPA Critical NOELs and Reference Concentrations

25 Exposure Scenario	26 NOEL	Effects on LOEL	RfC
27 Acute	73 ppb	Ocular irritation in humans	<u>Residential</u> 73 ppb <u>Occupational</u> 73 ppb
28 Seasonal	300 ppb	Nasal and lung damage, increased lung weights in mice	<u>Residential</u> 0.27 ppb <u>Occupational</u> 1.2 ppb
29 Chronic	100 ppb	Nasal discharge, nasal and lung damage, increased lung weight, body weight loss in mice	<u>Residential</u> 133 ppt <u>Occupational</u> 500 ppt

30 Both U.S. EPA and DPR estimated bystander exposure to chloropicrin following soil
 31 fumigation using the ISCST3 model. However, DPR used a deterministic approach with
 32 screening level meteorological conditions to provide a single downwind centerline of off-site air

1 concentrations representing reasonable worst case exposure. U.S. EPA used the PERFUM
2 model, which has the ISCST3 model as the core processor, and applied a variety of
3 meteorological conditions to produce buffer zones in a distributional format. U.S. EPA ran
4 analyses with PERFUM assuming 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 80, 100 and 120 acre
5 fields and 2, 10, 20, 25, 30, 35, 40, 50, 75 and 100% of the maximum application rate. The 2%
6 application rate was selected to evaluate the use of chloropicrin as a warning agent.
7 Meteorological data from six weather stations were used (Ventura, CA, Bakersfield, CA, Flint,
8 MI, Tallahassee, FL, Bradenton, FL, and Yakima, WA). Twelve flux profiles were analyzed by
9 U.S. EPA including broadcast/tarped, broadcast/untarped, bedded/tarped, and bedded/untarped
10 applications in Phoenix (AZ), bedded/tarped applications in Dover (FL), Bainbridge (GA), and
11 Hart (MI) with three different tarps, broadcast/tarped applications in Bradenton (FL) and Yakima
12 (WA), and drip irrigation/tarped applications in Douglas (GA) and Salinas (CA, 2 volatility
13 studies with different tarps). In comparison, DPR limited its exposure estimates to seven flux
14 profiles, including broadcast/tarped, broadcast/untarped, bedded/tarped, and bedded/untarped
15 applications in Phoenix (AZ), broadcast/tarped applications in Bradenton (FL) and Yakima
16 (WA), and a drip irrigation/tarped application in Salinas (CA). Reasonable worst case
17 downwind centerline air concentrations at several application rates were simulated. However, as
18 part of the deterministic approach, the DPR exposure assessment only used air concentration
19 estimates for the maximum application rate at a distance of 3.04 m (10 ft). Since U.S. EPA only
20 reported the size of the buffer zone needed to mitigate the risk and not specific air
21 concentrations, a direct comparison of U.S. EPA's and DPR's exposure estimates was difficult.
22 DPR found the highest 1-hour and 8-hour exposure estimates with the broadcast/non-tarped
23 application and the highest 24-hour exposure estimates with the bedded/tarped application. U.S.
24 EPA only estimated buffer zones for 24-hour exposure periods. U.S. EPA found that the
25 maximum buffer zone distances for a 40 acre field exceeded 1440 meters (the maximum buffer
26 zone distance calculated by PERFUM) using the flux data from the bedded/tarped,
27 bedded/untarped and broadcast/untarped applications in Phoenix, AZ, regardless of the
28 meteorological data used and assuming the maximum application rate. U.S. EPA also calculated
29 both whole field and maximum buffer zone distances while DPR only calculated maximum
30 buffer zone distances. DPR did not calculate whole field buffer zones because it is not possible
31 to know the percentile of protection for any particular whole field buffer zone.

32 To estimate bystander exposure following structural fumigation, U.S. EPA used air
33 concentrations using air monitoring data that ARB performed in 2004 (ARB, 2005a &b). DPR
34 used the highest air concentrations from these same data to estimate exposure for structural
35 fumigation. The highest air concentration U.S. EPA estimated from these data was 0.79 ppb (5.3
36 $\mu\text{g}/\text{m}^3$), however, it is not clear if this represented a 1-hr, 8-hr or 24-hr exposure estimate. DPR
37 estimated the highest 1-hr, 8-hr and 24-hr air concentrations to be 11, 2.4 and 0.92 ppb (73, 16
38 and 6.2 $\mu\text{g}/\text{m}^3$), respectively, after adjusting for recovery and maximum application rate.

39 U.S. EPA also estimated exposures for greenhouse fumigation. The exposures for this
40 use were also estimated using the PERFUM model assuming aeration with no stack. At 25% of
41 the maximum application rate or less, the maximum buffer zone distances were very small with
42 greenhouses up to 50,000 sq. ft. With higher concentrations, the maximum buffer zone distances
43 at the 95th percentile of exposure ranged from 20 to 325 meters with the distances increasing
44 with application rate and area treated. DPR did not estimate greenhouse fumigation so no
45 comparison was possible. On the other hand, DPR estimated bystander exposure following
46 enclosed space fumigation which U.S. EPA did not.

1 U.S. EPA did not specifically evaluate the need for an additional uncertainty factor for
2 infants and children based on the Food Quality and Protection Act since there are no tolerances
3 for chloropicrin. However, they noted that the incident reports for chloropicrin suggest that
4 children and asthmatics respond similarly to other individuals. Furthermore, they also
5 recommended that an intraspecies uncertainty factor of 10 is not warranted. They cited a 2005
6 WHO International Programme on Chemical Safety (IPCS) guidance document on deriving
7 chemical specific adjustment factors which divided the intraspecies uncertainty factor into two
8 components, toxicokinetics and toxicodynamics. Sensory irritation is a local effect so
9 absorption, distribution, metabolism and excretion are not involved. Therefore, they argued that
10 the toxicokinetic component can be reduced to 1X. The toxicodynamic component is defined as
11 the determination and quantification of the sequence of events at the cellular and molecular
12 levels leading to a toxic response. The IPCS guidance document listed three questions to
13 consider in the determination of the adequacy of the experimental data for refinement of the
14 toxicodynamic component: relevance of population, adequacy of concentration-response data
15 and adequacy of number of subjects/samples. U.S. EPA considered the population tested to be
16 the most sensitive, there was a clear dose-response evaluation in the third phase of the human
17 study and the number of subjects tested (127 for all 3 phases) adequate. Consequently, they
18 argued the toxicodynamic component could also be reduced to 1X. Therefore, an MOE of 1
19 defined U.S. EPA's level of concern for acute exposure. DPR recommended an intraspecies
20 uncertainty factor of 10 be used for eye irritation since there appears to be a large variation in
21 sensitivity among the subjects of the human study based on their eye irritation scores.

22 **IV.E. ISSUES RELATED TO THE FOOD QUALITY PROTECTION ACT**

23 The Food Quality Protection Act of 1996 mandated U.S. EPA to “upgrade its risk
24 assessment process as part of the tolerance setting procedures” (U.S. EPA, 1997a and b). The
25 improvements to risk assessment were based on the recommendations from the 1993 National
26 Academy of Sciences report, “Pesticides in the Diets of Infants and Children” (NAS, 1993).
27 The Act required an explicit finding that tolerances are safe for children. U.S. EPA was required
28 to use an extra 10-fold safety factor to take into account potential pre- and post-natal
29 developmental toxicity and the completeness of the data unless U.S. EPA determined, based on
30 reliable data, that a different margin would be safe. In addition, U.S. EPA must consider
31 available information on: 1) aggregate exposure from all non-occupational sources; 2) effects of
32 cumulative exposure to the pesticide and other substances with common mechanisms of toxicity;
33 3) the effects of *in utero* exposure; and 4) the potential for endocrine disrupting effects. U.S.
34 EPA did not recommend an FQPA factor for chloropicrin since there are no food tolerances for
35 chloropicrin and, therefore, FQPA does not apply. However, the issues addressed under FQPA
36 could still be potentially of concern for chloropicrin and warrant further discussion.

37 **IV.E.1. Prenatal and Postnatal Sensitivity**

38 Two developmental toxicity studies (one with rats and another with rabbits) were
39 available for chloropicrin (Schardein, 1993; York, 1993). Both studies were acceptable based on
40 FIFRA guidelines. Fetal effects in rats included reduced fetal body weights and various skeletal
41 variations (reduced ossification of skull bone, less than 13 rib pairs, 14th rudimentary ribs, bent
42 ribs, unossified 5th and 6th sternebrae). Developmental effects in rabbits included increased pre-
43 and post-implantation losses, late-term abortions, reduced fetal body weights, visceral (left

1 carotid arising from the innominate) and skeletal variations (unossified hyoid body and
2 unossified tail). In both studies, the developmental NOEL was equal or greater than the NOEL
3 for maternal effects. Based on these two studies, there is no evidence of increased prenatal
4 sensitivity to chloropicrin.

5 There were two reproductive toxicity studies in rats for chloropicrin, a one-generation
6 range-finding study and a standard two-generation study (Denny, 1996; Schardein, 1994). Only
7 the two-generation study met FIFRA guidelines. No developmental effects were seen in the
8 pups in either study. The only reproductive effect was a reduced number of implantation sites in
9 the range-finding study at 2 ppm which was higher than the top dose in the main study (1.5
10 ppm). The pup/reproductive NOELs were equal to or greater than the parental NOELs in these
11 studies. Based on these reproductive toxicity studies, there is no evidence of increased postnatal
12 sensitivity to chloropicrin. While not required by FIFRA guidelines, the neonates in this study
13 were not exposed directly to chloropicrin vapors until day 28, so theoretically they could have
14 been more sensitive during this developmental period either due to a higher breathing rate, the
15 immaturity of their respiratory system, or immaturity of their metabolic enzymes.

16 Based on the absence of ossification and reduced ossification seen in the two
17 developmental studies, OEHHA concluded that the fetus is impacted by inhalation exposure to
18 chloropicrin (OEHHA, 2009). They note that the octanol/water partition coefficient suggests
19 that it is likely to cross the placenta and be present in breast milk. They suggested a
20 toxicokinetic safety factor of 10 should be applied to protect for this. They also suggest that
21 chloropicrin may impact development by binding with sulfhydryl groups during critical phases
22 of development, leading to possible functional deficits later in life. They note that chloropicrin
23 as a similar mechanism of action to that of arsenic, methylene chloride and a few other
24 chemicals which have been shown to affect critical enzymes during development. This may also
25 be true for chloropicrin, but there is no evidence that this is occurring in fetuses at doses below
26 those which cause maternal or parental toxicity. Furthermore, chloropicrin appears to be a fairly
27 reactive chemical and is most likely reacting primarily with sulfhydryl groups at the site of first
28 contact (i.e, the respiratory tract). For this reason, it seems unlikely that a sufficient amount of
29 chloropicrin would get into the blood stream to affect the developing fetus or nursing pup. Most
30 of the effects seen in the adults were in the respiratory tract, supporting the theory that very little
31 of it reaches the blood stream. In addition, the effects seen in available developmental and
32 reproductive toxicity studies were non-specific signs of delayed development including reduced
33 implantation sites, late-term abortions, reduced pup weights and visceral and skeletal variations.
34 Since these fetal or pup effects were seen at doses that also caused maternal toxicity, it is
35 possible that they are indirect effects from maternal toxicity, such as reduced maternal body
36 weight. There was nothing to suggest any functional losses, either physiological or neurological,
37 although a developmental neurotoxicity study had not been conducted. Generally, DPR and U.S.
38 EPA do not require developmental neurotoxicity studies for chemicals unless there is evidence
39 of neurotoxicity in adults. Furthermore, it has not been DPR's or U.S. EPA's policy to apply
40 additional uncertainty factors for increased pre- and postnatal sensitivity based on a theoretical
41 risk when all the required studies have been submitted and the NOELs for fetal or neonatal
42 effects are equal or greater than the NOELs for maternal or parental toxicity. Although there
43 was no evidence of increased pre- and postnatal sensitivity from the available developmental and
44 reproductive toxicity studies which met FIFRA guidelines, theoretically it is possible that the
45 neonates could be more sensitive to direct exposure to chloropicrin vapors which was not
46 evaluated.

1 IV.E.2. Endocrine Effects

2 The Food Quality Protection Act (FQPA) of 1996 required U.S. EPA to develop a
3 screening program to determine the endocrine disruption potential of pesticides. In 1997, the
4 Risk Assessment Forum of the U.S. EPA published a report that reviewed the current state of
5 science relative to environmental endocrine disruption (U.S. EPA, 1997c). U.S. EPA formed the
6 Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) to develop a
7 strategy for screening and testing of pesticides for their potential to produce endocrine
8 disruption. The EDSTAC members include various stakeholders and scientific experts. This
9 screening and testing process was to be implemented by August of 1999 as required by FQPA.

10 Environmental chemicals can interact with the endocrine system, resulting in cancer,
11 reproductive and/or developmental anomalies (EDSTAC, 1998). It may produce these effects by
12 affecting hormonal production and synthesis, binding directly to hormone receptors or
13 interfering with the breakdown of hormones (U.S. EPA, 1997c). The interim science policy
14 stated in U.S. EPA's 1997 report is that "*the Agency does not consider endocrine disruption to*
15 *be an adverse endpoint per se, but rather to be a mode or mechanism of action leading to other*
16 *outcomes.*" The only possible endocrine related effects seen in the available animal studies for
17 chloropicrin were reduced number of implantation sites, increased pre- and post-implantation
18 losses and later-term abortions observed in the developmental and reproductive toxicity studies
19 (York, 1993; Denny, 1996). However, it is unclear from these studies if any of these effects are
20 mediated through endocrine disruption or some other mechanism. U.S. EPA has stated that once
21 its Endocrine Disruptor Screening Program (EDSP) has been developed and vetted, chloropicrin
22 may be subject to additional screening and/or testing to better characterize its endocrine
23 disruption potential (U.S. EPA, 2008a). It should be noted that U.S. EPA concluded in its
24 human health assessment for chloropicrin that there was no evidence of endocrine disruption
25 from the available data (Reaves and Smith, 2008).

26 IV.E.3. Cumulative Toxicity

27 Chloropicrin kills common root destroying fungi, nematodes, soil insects and other plant
28 pests. Chloropicrin causes sensory and respiratory irritation in animals which may be related to
29 its reaction with thiol groups in proteins. U.S. EPA evaluated the mode of action for
30 chloropicrin and noted that its potential to cause eye irritation was similar to methyl isocyanate
31 (MITC) (U.S. EPA, 2008b). U.S. EPA described the mode of action for chloropicrin as sensory
32 irritation. This may describe the mode of action for the effects in the upper respiratory tract at
33 low concentrations, but obviously the irritation goes beyond the irritation of sensory trigeminal
34 nerves at higher concentrations, especially in the lower respiratory tract. Irritation may still be a
35 key part of its mode of action in the lower respiratory tract. However, there is insufficient
36 information about the mode of action for chloropicrin and other fumigants which also cause
37 sensory and/or respiratory irritation to know if they have similar modes of action.

V. CONCLUSIONS

The risks for potential adverse human health effects with bystander exposure to chloropicrin after soil and structural fumigation were evaluated using margin of exposure (MOE) estimates. The MOEs for acute, subchronic and chronic exposure were calculated using no-observed-effect levels (NOELs) or benchmark dose (BMD) estimates from the available guideline and literature toxicity studies for chloropicrin. In selecting the NOELs/BMDs to evaluate exposure, the greatest weight was given to studies which met FIFRA guidelines. Generally, an MOE greater than 100 is considered sufficiently protective of human health when the NOEL/BMD for an adverse effect is derived from an animal study. The MOE of 100 allows for humans being 10 times more sensitive than animals and for a 10-fold variation in sensitivity between the lower distribution of the overall human population and the sensitive subgroup. When the NOEL/BMD is derived from a human study generally an MOE of 10 is considered sufficiently protective, allowing for intraspecies variation. Since sensory irritation involves a direct-acting mechanism of toxicity where toxicokinetic variation among individuals is not anticipated, a MOE of 3 may be adequate. A carcinogenic risk level less than one in a million or 10^{-6} is generally considered negligible.

The potential health risks from bystander exposure to chloropicrin following soil fumigation are of concern since all of the MOEs were less than 100 for both children and adults based on reasonable worst case exposure estimates. The acute MOEs for soil fumigation are clearly of concern since they are all less than 1. With the 1-hr exposure, the MOEs are orders of magnitude lower than the target MOE of 3. The seasonal and chronic MOEs for soil fumigation were greater than 1 (except for seasonal exposure with bedded tarped application), but they were still less than the target MOE of 100. The carcinogenic risk estimates for residential and occupational bystanders to chloropicrin following soil fumigation were of great concern since they were greater than the negligible risk level by several orders of magnitude.

The off-site air concentrations of chloropicrin following structural fumigation are lower than those following soil fumigation, but the 1-hr exposures are still of concern (i.e., MOEs are less than 3). Although the 8-hr and 24-hr MOEs are greater than or equal to 100, they are less than 1,000. The indoor air concentrations after complete aeration with structural fumigation were also of concern with 24-hr MOEs less than 100. No seasonal, chronic or lifetime exposures were expected for structural fumigation.

The off-site air concentrations of chloropicrin following enclosed space fumigation are great concern since all of the MOEs were less than the target MOEs by at least a couple orders of magnitude. The lifetime exposure for bystanders following enclosed space fumigation with chloropicrin are also of great concern since the cancer risk estimates were a couple orders of magnitude higher than the negligible risk level.

California regulations state that if the air concentrations of a pesticide are not 10-fold lower than the reference concentration that is considered adequately protective of human health, it meets the criteria to be listed as toxic air contaminant. This is equivalent to the MOEs being greater than 30 when the NOEL is for sensory irritation from a human study or 1,000 when the NOEL is from an animal study. For cancer, the risk estimates must be 10-fold below the negligible risk level. Therefore, chloropicrin meets the criteria for listing it as a toxic air contaminant based on all of the bystander exposure scenarios for soil fumigation including

- 1 lifetime, the 1-hr bystander and 24-hr indoor exposure scenarios for structural fumigation, and
- 2 all of the bystander exposure scenarios for enclosed space fumigation including lifetime.

1

VI. REFERENCES

2
3

ACGIH, 1997. Chloropicrin. *In: Documentation of the Threshold Limit Values, 6th Ed.* (CD-ROM). American Conference of Governmental Industrial Hygienists.

4
5

ARB, 1987. ARB monitoring of chloropicrin. Contract A5-169-43. Air Resources Board, California Environmental Protection Agency.

6
7
8
9

ARB, 2003a. Ambient air monitoring for chloropicrin and breakdown products of metam sodium in Kern County - Summer 2001. Project No. P-01-004. Air Resources Board, California Environmental Protection Agency. November 13, 2003.
<http://www.cdpr.ca.gov/docs/emon/pubs/tac/tacpdfs/chlormitc03.pdf>

10
11
12
13

ARB, 2003b. Ambient air Monitoring for chloropicrin and breakdown products of metam sodium in Monterey and Santa Cruz Counties - Fall 2001. Project No. P-01-004. Air Resources Board, California Environmental Protection Agency. November 13, 2003.
http://www.cdpr.ca.gov/docs/emon/pubs/tac/tacpdfs/chlor_metsod04.pdf

14
15
16
17

ARB, 2003c. Air monitoring around a bed fumigation application of chloropicrin - Fall 2001. Project No. P-01-002. Air Resources Board, California Environmental Protection Agency. March 17, 2003.
http://www.cdpr.ca.gov/docs/emon/pubs/tac/tacpdfs/chloropicrin_2001.pdf

18
19
20
21

ARB, 2003d. Report for the air monitoring around a structural application of sulfuryl fluoride - Fall 2002. Project No. P-02-004. Air Resources Board, California Environmental Protection Agency. June 18, 2003.
http://www.cdpr.ca.gov/docs/emon/pubs/tac/tacpdfs/sulfurylf_2002.pdf

22
23
24
25

ARB, 2004. Air monitoring around a bed fumigation of chloropicrin in Santa Cruz County - November 2003. Project No. P-03-001. Air Resources Board, California Environmental Protection Agency. December 1, 2004.
<http://www.cdpr.ca.gov/docs/emon/pubs/tac/tacpdfs/chlorpic03.pdf>

26
27
28
29

ARB, 2005a. Report for the air monitoring around a structural application of sulfuryl fluoride in Grass Valley, CA - Summer 2004. Air Resources Board, California Environmental Protection Agency. June 9, 2005.
http://www.cdpr.ca.gov/docs/emon/pubs/tac/tacpdfs/sf_gv_rpt.pdf

30
31
32
33

ARB, 2005b. Report for the air monitoring around a structural application of sulfuryl fluoride in Loomis, CA - Summer 2004. Air Resources Board, California Environmental Protection Agency. June 9, 2005.
http://www.cdpr.ca.gov/docs/emon/pubs/tac/tacpdfs/sf_lm_rpt.pdf

34
35
36
37

ARB, 2006. Report on air monitoring around a field application of chloropicrin in Santa Barbara County - October 2005. Air Resources Board, California Environmental Protection Agency. August 7, 2006.
http://www.cdpr.ca.gov/docs/emon/pubs/tac/tacpdfs/Chloro_rep06.pdf

- 1 **Auerbach, C., 1950.** SH poisoning and mutation. *Experimentia* 6: 17-18. DPR Vol. 199-038,
2 Rec. No. 90209.
- 3 **Barry, T., 2008.** Memorandum: Screening Level Air Concentration Estimates for Worker
4 Health and Safety Exposure Appraisals. August 21, 2008. Environmental Monitoring
5 Branch, Department of Pesticide Regulation, California Environmental Protection
6 Agency.
- 7 **Beauvais, S., 2009.** Public Exposure to Airborne Chloropicrin in California. HS-1846.
8 Evaluation of Chloropicrin As a Toxic Air Contaminant. Part A. Environmental Fate
9 Review and Exposure Assessment. Public Exposure to Airborne Chloropicrin in
10 California. Worker Health and Safety Branch, Department of Pesticide Regulation,
11 California Environmental Protection Agency. April 20, 2009.
- 12 **Beard, K.K., P.G. Murphy, D.D. Fontaine, and J.T. Weinberg, 1996.** Monitoring of potential
13 worker exposure, field flux, off-site air cocentration during chloropicrin field application.
14 Chloropicrin Manufacturers Task Force. DPR Vol. 199-073, Rec. No.
- 15 **Berghoff, R.S., 1919.** The more common gases: Their effect on the respiratory tract. *Arch. Int.*
16 *Med.* 24: 678-684.
- 17 **Buckley, L.A., X.Z. Jiang, R.A. James, K.T. Morgan, and C.S. Barrow, 1984.** Respiratory
18 tract lesions induced by sensory irritants at the RD₅₀ concentration. *Toxicol. Appl.*
19 *Pharmacol.* 74: 417-429.
- 20 **Burleigh-Flayer, H.D and C.L. Benson (Bushy Run Research Center), 1995.** Chloropicrin:
21 Vapor inhalation oncogenicity study in CD[®] rats. The Chloropicrin Manufacturers Task
22 Force. DPR Vol. 199-067, Rec. No. 139750.
- 23 **Burleigh-Flayer, H.D., W.J. Kintigh, and C.L. Benson (Bushy Run Research Center), 1995.**
24 Chloropicrin: Vapor inhalation oncogenicity study in CD-1[®] mice. The Chloropicrin
25 Manufacturers Task Force. DPR Vol. 199-058, Rec. No. 136552.
- 26 **CMTF, 2009.** Memorandum to DPR: UCSD Human Sensory Irritation Study with Chloropicrin
27 - Background and References. John Butala, Toxicologist, Chloropicrin Manufacturing
28 Task Force.
- 29 **Cain, W.S., J.C. Stevens, C.M. Nickou, A. Giles, I. Johnston, M.R. Garcia-Medina, 1995.**
30 Life-span development of odor identification, learning and olfactory sensitivity.
31 *Perception* 24: 1457-1472.
32
- 33 **Cain, W.S. (Chemosensory Perception Laboratory, U.C. San Diego), 2004.** Human sensory
34 irritation testing for chloropicrin. Chloropicrin Manufacturers Task Force. DPR Vol.
35 199-0113, Rec. No. 215620.
- 36 **Castro, C.E., R. S. Wade and N.O. Belser, 1983.** Biodehalogenation. The metabolism of
37 chloropicrin by *Pseudomonas* sp. *J. Agric. Food Chem.* 31: 1184-1187.
- 38 **Chun, J.S. and W.J. Kintigh (Bushy Run Research Center, Union Carbide Chemicals and**

- 1 **Plastics Co., Inc.), 1993.** Chloropicrin: Ninety-day inhalation toxicology study in rats
2 and mice. Chloropicrin Manufacturers Task Force. DPR Vol. 199-088, Rec. No.
3 183793.
- 4 **Condie, L.W., F.B. Daniel, G.R. Olson, and M. Robinson, 1994.** Ten and ninety-day toxicity
5 studies of chloropicrin in Sprague-Dawley rats. *Drug Chem. Toxicol.* 17(2): 125-137.
- 6 **Cortez, B., 2001.** Notice of Decision to Begin Reevaluation of Pesticide Products Containing
7 Chloropicrin. California Notice 2001-8. Department of Pesticide Regulation, California
8 Environmental Protection Agency, Sacramento, CA. December 1, 2001.
9 <http://www.cdpr.ca.gov/docs/canot/ca01-8.pdf>
- 10 **Crump, K.S., 1995.** Calculation of benchmark doses from continuous data. *Risk Anal.* 15: 79-
11 89.
- 12 **Curren, R.D. (Microbiological Associates, Inc.), 1990.** Unscheduled DNA synthesis in rat
13 primary hepatocytes with a confirmatory assay. Niklor Chemical Co., Inc. DPR Vol.
14 199-046, Rec. No. 88718.
- 15 **Denny, K.H (MPI Research), 1996.** Reproduction range-finding inhalation study in rats -
16 chloropicrin. The Chloropicrin Manufacturer's Task Force. DPR Vol. 199-115, Rec.
17 No. 217717.
- 18 **Dourson, M., G. Charnley and R. Scheuplein, 2002.** Differential sensitivity of children and
19 adults to chemical toxicity. II. Risk and regulation. *Regul. Toxicol. Pharmacol.* 35:
20 448-467.
- 21 **DPR, 2000.** Memorandum: Interim Guidance for Selecting Default Inhalation Rates for
22 Children and Adults. Worker Health and Safety Branch and Medical Toxicology Branch,
23 Department of Pesticide Regulation, California Environmental Protection Agency.
24 December 1, 2000. HSM-00010.
- 25 **Fries, A.A. and C.J. West, 1921.** *Chemical Warfare.* New York, McGraw-Hill Book
26 Company, Inc. pp. 144-149.
- 27 **Garry, V.F., R.L. Nelson, J. Griffith, and M. Harkins, 1990.** Preparation for Human study of
28 pesticide applicators: Sister chromatid exchanges and chromosome aberrations in
29 cultured human lymphocytes exposed to selected fumigants. *Teratogen, Carcinogen.,*
30 *Mutagen.* 10: 21-29.
- 31 **Gart, J.J., D. Krewski, P.N. Lee, R.E. Tarone, and J. Wahrendorf, 1986.** Statistical Methods
32 in Cancer Research, Vol. III - The Design and Analysis of Long-term Animal
33 Experiments. International Agency for Research on Cancer Scientific Publication No.
34 79. Lyon, France. pp. 82-85.
- 35 **Gehring, P.J., R.J. Nolan, P.G. Watanabe, and A.M. Schumann, 1991.** Solvents, fumigants
36 and related compounds. *In: Handbook of Pesticide Toxicology, Vol. 2* (W.J. Hayes, Jr.,
37 and E.R. Laws, Jr., eds.). Academic Press, San Diego. Pp. 637-730.

- 1 **Giknis, M.L. and C.B. Clifford, 2000.** Spontaneous neoplastic lesions in the Crl:CD-1®
2 (ICR)BR mouse. Charles River Laboratories.
3 http://www.criver.com/flex_content_area/documents/rm_rm_r_lesions_crl_cd_icr_br_m
4 [ouse.pdf](http://www.criver.com/flex_content_area/documents/rm_rm_r_lesions_crl_cd_icr_br_m)
- 5 **Giller, S., F. Le Curieux, L. Gauthier, F. Erb, and D. Marzin, 1995.** Genotoxicity assay of
6 chloral hydrate and chloropicrine. *Mut. Res.* 348: 147-152.
- 7 **Goldman, L.R., D. Mengle, D.M. Epstein, D. Fredson, K. Kelly, R.J. Jackson, 1987.** Acute
8 symptoms in persons residing near a field treated with the soil fumigants methyl bromide
9 and chloropicrin. *West. J. Med.* 147: 95-98.
- 10 **Gonmori, K. H. Muto, T. Yamamoto, K. Takahashi, 1987.** A case of homicidal intoxication
11 by chloropicrin. *Am. J. Foren. Med. Pathol.* 8(2): 135-138.
- 12 **Haber, L., E. Hack, and M. Dourson (TERA), 2005.** Use of benchmark concentration
13 modeling and categorical regression to evaluate the effects of acute exposure to
14 chloropicrin vapor. Chloropicrin Manufacturers Task Force. DPR Vol. 199-0118, Rec.
15 No. 219517.
- 16 **Harton, E.E., Jr., and R.R. Rawl, 1976.** Toxicological and skin corrosion testing of selected
17 hazardous materials. Office of Hazardous Materials Operations, Department of
18 Transportation, Washington, D.C. NTIS PB-264 975.
- 19 **Haworth, S., T. Lawlor, K. Mortelmans, W. Speck, and E. Zeiger, 1983.** Salmonella
20 mutagenicity test results for 250 chemicals. *Environ. Mutagen. Suppl.* 1: 3-142.
- 21 **Hoffman, G. (Huntingdon Life Sciences), 1999a.** Chloropicrin: An acute (4-hour) inhalation
22 toxicity study in the rat via whole-body exposure. Chloropicrin Manufacturers Task
23 Force c/o Niklor Chemical Co. DPR Vol. 199-082, Rec. No. 172375.
- 24 **Hoffman, G. (Huntingdon Life Sciences), 1999b.** Chloropicrin: A sensory irritation study in
25 the mouse via head-only exposure. Chloropicrin Manufacturers Task Force c/o Niklor
26 Chemical Co. DPR Vol. 199-081, Rec. No. 172374.
- 27 **Hummel, T., T. Futschik, J. Frasnelli, K.-B. Hüttenbrink, 2003.** Effects of olfactory
28 function, age and gender on trigeminally mediated sensations: a study based on the
29 lateralization of chemosensory stimuli. *Toxicol. Letters* 140-141: 273-280.
- 30 **IPCS, 2005.** Chemical-Specific Adjustment Factors for Interspecies Difference and Human
31 Variability: Guidance Document for Use of Data in Dose-Concentration-Response
32 Assessment. Harmonization Project Document No. 2. International Programme on
33 Chemical Safety, World Health Organization, Geneva, Switzerland.
- 34 **Kane, L.E., C.S. Barrow, and Y. Alarie, 1979.** A short-term test to predict acceptable levels of
35 exposure to airborne sensory irritants. *Amer. Ind. Hyg. Assoc. J.* 40: 207-229
- 36 **Kawai, A., S. Goto, Y. Matsumoto, and H. Matsushita, 1987.** Mutagenicity of aliphatic and
37 aromatic nitro compounds. *Jpn. J. Ind. Health* 29: 34-54.

- 1 **Kjaergaard, S., O.F. Pedersen, and L. Mølhave, 1992.** Sensitivity of the eyes to airborne
2 irritant stimuli influence of individual characteristics. Arch. Environ. Health 47(1) 45-
3 50.
- 4 **Lambert, R.A. and L. Jackson, 1920.** The pathology of chloropicrin poisoning. *In:* Pathology
5 of War Gas Poisoning. New Haven, Yale University Press. pp. 68-87.
- 6 **Maddy, K.T., D.B. Gibbons, D.M. Richmond and A.S. Frederickson, 1983.** A study of the
7 levels of methyl bromide and chloropicrin in the air downwind from a field during and
8 after a preplant soil fumigation (shallow injection) - A preliminary report. HS-1061.
9 Worker Health and Safety Branch, Department of Pesticide Regulation, California
10 Environmental Protection Agency. <http://www.cdpr.ca.gov/docs/whs/pdf/hs1061.pdf>
- 11 **Maddy, K.T., D.B. Gibbons, D.M. Richmond, and A.S. Frerickson, 1984.** Additional
12 monitoring of the concentrations of methyl bromide and chloropicrin in the air downwind
13 from fields during and after preplant soil fumigations (shallow injection). HA-1183.
14 Worker Health and Safety Branch, Department of Pesticide Regulation, Environmental
15 Protection Agency. <http://www.cdpr.ca.gov/docs/whs/pdf/hs1183.pdf>
- 16 **Moriya, M., T. Ohta, K. Watanabe, T. Miyazawa, K. Kato and Y. Shirasu, 1983.** Further
17 mutagenicity studies on pesticides in bacterial reversion assay systems. Mut. Res. 116:
18 185-216. DPR Vol. 199-038, Rec. No. 90207.
- 19 **NAC/AEGL Committee, 2001.** Standing Operating Procedures for Developing Acute
20 Exposure Guideline Levels for Hazardous Chemicals. Subcommittee on Acute Exposure
21 Guideline Levels, Committee on Toxicology, Board on Environmental Studies and
22 Toxicology, Commission on Life Sciences, National Research Council, National
23 Academy of Sciences. National Academy Press, Washington, D.C. p. 90.
24 <http://www.nap.edu/ctalog/10122.html>
- 25 **NAC/AEGL Committee, 2008.** Acute Exposure Guideline Levels (AEGLs) - Chloropicrin
26 (CAS Reg. No. 76-06-2). Interim. National Advisory Committee for Acute Exposure
27 Guideline Levels for Hazardous Substances, National Research Council, National
28 Academy of Sciences. http://www.epa.gov/oppt/aegl/pubs/chloropicrin_interim.pdf
- 29 **NCI, 1978.** Bioassay of chloropicrin for possible carcinogenicity, CAS No. 76-06-2. National
30 Cancer Institute, Bethesda, MD. NTIS No. PB 282 311. DPR Vol. 199-038, Rec. No.
31 90206.
- 32 **NIOSH, 1996.** Chloropicrin: IDLH Documentation. Washington, D.C.: National Institute for
33 Occupational Safety and Health, U.S. Department of Health and Human Services.
34 <http://www.cdc.gov/niosh/idlh/76062.html>
- 35 **OEHHA, 1999.** Air Toxics Hot Spot Program Risk Assessment Guidelines. Part I:
36 Determination of Acute Reference Exposure Levels for Airborne Toxicants. Office of
37 Environmental Health Hazard Assessment, California Environmental Protection Agency.
38 March 1999. pp. C-91 – C-95.
- 39 **OEHHA, 2001.** Chloropicrin. Air Toxics Hot Spot Program Risk Assessment Guidelines. Part

- 1 III. The Determination of Chronic Reference Exposure Levels for Airborne Toxicants.
2 Batch 2B. Environmental Health Hazard Assessment, California Environmental
3 Protection Agency. December 2001. pp. A-21 - A-26.
- 4 **OEHHA, 2005.** Air Toxics Hot Spot Program Risk Assessment Guidelines. Part II. Technical
5 Support Document Describing Available Cancer Potency Factors. Air Toxicology and
6 Epidemiology Section, Office of Environmental Health Hazard Assessment, California
7 Environmental Protection Agency. May 2005.
8 http://www.oehha.ca.gov/air/hot_spots/may2005tsd.html
- 9 **OEHHA, 2009.** Memorandum: Comments on Draft Exposure Assessment Document and Draft
10 Risk Characterization Document for the Pesticide Active Ingredient, Chloropicrin.
11 Office of Health Hazard Assessment, California Environmental Protection Agency.
12 March 23, 2009.
- 13 **Okumura, D.Y., 1988.** Memorandum to S. Segal, U.S. EPA: Final Report on Priority
14 Investigation No. 78-SCR-87. California Department of Food and Agriculture,
15 Sacramento, CA. August 1988.
- 16 **Portier, C.J. and A.J. Bailer, 1989.** Testing for increased carcinogenicity using a survival-
17 adjusted quantal response test. *Fund. Appl. Toxicol.* 12: 731-737.
- 18 **Prentiss, A.M., 1937.** *Chemicals in War: A Treatise on Chemical Warfare.* New York,
19 McGraw-Hill Book Company, Inc. pp. 140, 161-163.
- 20 **Prudhomme, J.C., R. Bhatia, J.M. Nutik, and D.J. Shusterman, 1999.** Chest wall pain and
21 possible rhabdomyolysis after chloropicrin exposure. *J. Occup. Environ. Med.* 41(1):
22 17-22.
- 23 **Putman, D.L. and M.J. Morris (Microbiological Associates, Inc.), 1990.** Chromosome
24 aberrations in Chinese hamster ovary (CHO) cells with confirmatory assay. Niklor
25 Chemical Co., Inc. DPR Vol. 199-041, Rec. No. 86983,
- 26 **Reaves, E. and C. Smith, 2008.** Human health risk assessment - Chloropicrin. U.S.
27 Environmental Protection Agency, Office of Pesticide Programs, Health Effects Division.
28 June 18, 2008. pp. 477. Docket ID: EPA-HQ-OPP-2007-0350-0171.
- 29 **Renwick, A.G. and N.R. Lazarus, 1998.** Human variability and noncancer risk assessment -
30 An analysis of the default uncertainty factor. *Reg. Toxicol. Pharmacol.* 27: 3-20.
- 31 **Rotondaro, A., 2004.** Monitoring of chloropicrin emissions from field and greenhouse drip
32 irrigation applications, and implied worker inhalation exposure from applications of
33 chloropicrin by shank injection, drip irrigation systems and at tree replant sites.
34 Chloropicrin Manufacturers Task Force. DPR Vol. 199-112, Rec. No. 209842.
- 35 **San, R.H.C. and C.I. Sigler (Microbiological Associates, Inc.), 1990.** L5178Y TK+/- mouse
36 lymphoma mutagenesis assay with confirmation. Niklor Chemical Co., Inc. DPR Vol.
37 199-041, Rec. No. 86982.

- 1 **San, R.H.C. and V.O. Wagner (Microbiological Associates, Inc.), 1990.** *Salmonella/*
2 *mammalian-microsome plate incorporation mutagenicity assay (Ames test) with*
3 *confirmatory assay. Niklor Chemical Co., Inc. DPR Vol. 199-046, Rec. No. 88717.*
- 4 **Sariaslani, F.S. and R.G. Stahl, Jr., 1990.** Activation of promutagenic chemicals by
5 *Streptomyces griseus* containing cytochrome P-450_{soy}. *Biochem. Biophys. Res. Comm.*
6 166(2): 743-749.
- 7 **Schardein, J.L., 1993.** Inhalation developmental toxicity study in rats. The Chloropicrin
8 Manufacturer's Task Force. DPR Vol. 199-051, Rec. No. 122503.
- 9 **Schardein, J.L., 1994.** Two generation inhalation reproduction/fertility study in rats. The
10 Chloropicrin Manufacturer's Task Force. DPR Vol. 199-056, Rec. No. 132463
- 11 **Schneider, M., G.B. Quistad and J.E. Casida, 1999.** Glutathione activation of chloropicrin in
12 the *Salmonella* mutagenicity test. *Mut. Res.* 439: 233-238.
- 13 **Selala, M.I., J.J. Janssens, Ph. G. Jorens, L.L. Bossaert, L. Beaucourt, and P.J.C. Schepens,**
14 **1989.** An improperly labeled container with chloropicrin: A farmer's nightmare. *Bull.*
15 *Environ. Contam. Toxicol.* 42: 202-208.
- 16 **Shirasu, Y., M. Moriya, H. Tezuka, S. Teramoto, T. Ohta, and T. Inoue, 1982.** Mutagenicity
17 screening studies on pesticides. *Environmental Mutagens and Carcinogens, Proceedings*
18 *of the 3rd International Conference, Tokyo, Japan, Sept 21-27, 1981. Alan R. Liss, New*
19 *York, N.Y. pp. 331-335.*
- 20 **Shusterman, D., M.A. Murphy, and J. Balmes, 2003.** Differences in nasal irritant sensitivity
21 by age, gender, and allergic rhinitis status. *Int. Arch. Occup. Environ. Health* 76: 577-
22 583.
- 23 **Shusterman, D., E. Matovinovic, and A. Salmon, 2006.** Does Haber's Law apply to sensory
24 irritation? *Inhal. Toxicol.* 18: 457-471.
- 25 **Slauter, R.W. (IRDC), 1995.** Two year oral (gavage) chronic toxicity study of chloropicrin in
26 rats. The Chloropicrin Manufacturers Task Force. DPR Vol. 199-066, Rec. No.138871.
- 27 **Sparks, S.E., G.B. Quistad and J.E. Casida, 1997.** Chloropicrin: Reactions with biological
28 thiols and metabolism in mice. *Chem. Res. Toxicol.* 10: 1001-1007.
- 29 **Sparks, S.E., G.B. Quistad, W. Li, and J.E. Casida, 2000.** Chloropicrin dechlorination in
30 relation to toxic action. *J. Biochem. Mole. Toxicol.* 14: 26-32.
- 31 **TeSlaa, G., M. Kaiser, L. Biederman, and C.M. Stowe, 1986.** Chloropicrin toxicity involving
32 animal and human exposure. *Vet. Hum. Toxicol.* 28(4): 323-324.
- 33 **Underhill, F.P., 1919.** The physiology and experimental treatment of poisoning with the lethal
34 war gases. *Arch. Intern. Med.* 23: 753-770.
- 35 **Underhill, F.P., 1920.** The use of lethal gases. *In: The Lethal War Gases: Physiology and*

- 1 Experimental Treatment. Yale University Press, New Haven, Conn. pp. 1-17, 40-84.
- 2 **U.S. EPA, 1997a.** The Federal Insecticide Fungicide, and Rodenticide Act (FIFRA) and Federal
3 Food, Drug, and Cosmetic Act (FFDCA) as Amended by the Food Quality Protection Act
4 (FQPA) of August 3, 1996. Document no. 730L97001, March 1997. Office of Pesticide
5 Programs, U.S. Environmental Protection Agency, Washington, D.C.
- 6 **U.S. EPA, 1997b.** 1996 Food Quality Protection Act Implementation Plan. March, 1977.
7 Office of Prevention, Pesticides and Toxic Substances (7506C), U.S. Environmental
8 Protection Agency, Washington, D.C. (<http://www.epa.gov/fedrgstr/>)
- 9 **U.S. EPA, 1997c.** Special Report on Environmental Endocrine Disruption: An Effects
10 Assessment and Analysis. Risk Assessment Forum, U.S. Environmental Protection
11 Agency, Washington, D.C.
- 12 **U.S. EPA, 2008a.** Reregistration Eligibility Decision (RED) for Chloropicrin. Office of
13 Pesticide Programs, U.S. Environmental Protection Agency. July 9, 2008. EPA-738-R-
14 08-009. Docket ID: EPA-HQ-OPP-2007-0350-0175.
- 15 **U.S. EPA, 2008b.** Memorandum: Mode of Action, Eye Irritation, and the Intra-Species Factor:
16 Comparison of Chloropicrin and MITC. Health Effects Division, Office of Prevention,
17 Pesticides and Toxic Substances, U.S. Environmental Protection Agency. June 25, 2008.
18 Docket ID: EPA-HQ-OPP-2007-0350-0172.
- 19 **Valencia, R., J.M. Mason, R.C. Woodruff, and S. Zimmering, 1985.** Chemical mutagenesis
20 testing in *Drosophila*. III. Results of 48 coded compounds tested for the National
21 Toxicology Program. Environ. Mutag. 7: 325-348. DPR Vol. 199-038, Rec. No. 90208.
- 22 **Wilhelm, S.N. (Niklor Chemical Co., Chloropicrin Manufacturers Task Force), 1996.**
23 Chloropicrin as a soil fumigant. Products and Services, Agricultural Research Service,
24 U.S. Department of Agriculture. <http://www.ars.usda.gov/is/np/mba/july96/wilhell1.html>
- 25 **Wisler, J.A. (IRDC), 1994.** Evaluation of chloropicrin in a one year oral (capsule) toxicity
26 study in dogs. The Chloropicrin Manufacturers Task Force. DPR Vol. 199-055, Rec.
27 No. 129614.
- 28 **Witschi, H., 1999.** Some notes on the history of Haber's law. Toxicol. Sci. 50: 164-168.
- 29 **Wofford, P., R. Segawa, L. Ross, J. Schreider and F. Spurlock, 2003.** Ambient air
30 monitoring of pesticides in Lompoc, California. Vol. 2: Fumigants. Department of
31 Pesticide Regulation, California Environmental Protection Agency.
32 http://www.cdpr.ca.gov/docs/specproj/lompoc/vol2_fumigants/volume2_march2003.pdf
- 33 **Wysocki, C.J., B.J. Cowart, and T. Radil, 2003.** Nasal trigeminal chemosensitivity across the
34 adult life span. Perception & Psychophysics 65(1): 115-122.
- 35 **York, R.G., 1993.** Inhalation developmental toxicity study in New Zealand White rabbits. The
36 Chloropicrin Manufacturer's Task Force. DPR Vol. 199-051, Rec. No. 122504.

- 1 **Yoshida, M., T. Ikeda, M. Iwasaki, S. Tsuda, and Y. Shirasu, 1987a.** Acute inhalation
2 toxicity of chloropicrin vapor in rats. *J. Pest. Sci.* 12: 237-244.
- 3 **Yoshida, M., T. Ikeda, M. Iwasaki, M. Ikeda, T. Harada, K. Ebino, S. Tsuda, and Y.**
4 **Shirasu, 1987b.** Subchronic inhalation toxicity of chloropicrin vapor in rats. *J. Pest.*
5 *Sci.* 12: 673-681. DPR Vol. 199-038, Rec. No. 90205.
- 6 **Yoshida, M., N. Murao, S. Tsuda, and Y. Shirasu, 1991.** Effects of mode of exposure on
7 acute inhalation toxicity of chloropicrin vapor in rats. *J. Pest. Sci.* 16: 63-69.
- 8 **Zielhuis, R.L. and F.W. van der Kreek, 1979.** The use of a safety factor in setting health
9 based permissible levels for occupational exposure. *Int. Arch. Occup. Environ. Health*
10 42: 191-201.